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This thesis describes the development and synthesis of a range of novel fluorophores 
based on 1,8-naphthalimide, N-heterocyclic carbene (NHC) and phosphine derivatives, 
as well as coordination chemistry with Au(I), Ir(III) and Fe(II). Detailed discussions on the 
characterisation and the photophysical properties are described, with reference to 
applications including bioimaging, diagnostics and therapeutics. 
Chapter 2 describes the synthetic development and spectroscopic analysis of a series of 
NHC-functionalised 1,8-naphthalimide fluorophores, generating ten new ligands that 
were successfully utilised for Au(I) coordination chemistry. The optical properties of the 
compounds were dictated by ligand-centred transitions. Cytotoxicity assessments 
revealed that compounds were the most toxic to LOVO and MCF-7 cell lines. In addition, 
lysosomal localisation was observed in cell imaging studies with MCF-7 cells, as seen 
with structurally related anticancer compounds. 
Chapter 3 describes the synthetic development and spectroscopic analysis of a series of 
aminophosphine and phosphinite fluorophores, generating six new ligands, with some 
successfully utilised for Au(I) coordination chemistry. The photophysical properties were 
explored in detail due to the presence of different fluorescent groups, including 
naphthalene, anthracene, pyrene and anthraquinone. In this chapter, 31P NMR was 
particularly important in confirming the success of the synthetic routes.  
Chapter 4 describes the comparative syntheses of six new phenyl-1H-pyrazoles and their 
corresponding cyclometalated iridium(III) complexes using both batch and, successfully 
applied, flow-microwave methodologies. Isolation of spectroscopically pure species in 
less than 1 hour of reaction time from IrCl3 was observed, along with ligand-dependent, 
tuneable green-yellow luminescence. 
Chapter 5 outlines determination of a successful synthetic route to a series of 
fluorescent electrochemical biosensors that incorporate both a redox active ferrocene 
unit and a naphthalimide moiety, with the intention to be applied as an electrochemical 
detection method for Clostridium Difficile (CDF). Detailed photophysical and 
electrochemical investigations were used to determine suitability for the desired 
application.  
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DNA – deoxyribosenucleic acid 
ctDNA – circulating tumour                                                                                
deoxyribosenucleic acid 
RNA – ribonucleic acid  
HIV – Human Immunodeficiency Virus  
TMRE – Tetramethylrhodium ethyl ester  
HEK – Human Embryonic Kidney 
LOVO – human colon cancer cell line 
HeLa – human cervical cancer cell line  
MCF7 – human breast cancer cell line  
A549 – human lung cancer cell line  
PC3 – human prostate cancer cells  
CDF - Clostridium Difficile 
GFP – green fluorescent protein  
DAPI - 4',6-diamidino-2-phenylindole 
CX1- human colon carcinoma cell line 
LX1 – human lung carcinoma cell line 
Bel7402 – human hepatoceullular 
carcinoma cells 
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HT29 – human colon carcinoma cells 
HepG2 – human liver cancer cell line 
ICB2 – site of topoisomerase II alpha 
promotor 
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Chapter 1 - Introduction 
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1.1 Luminescence  
Luminescence is defined as the emission of light from any substance.1 This light comes 
from the emission of photons by a molecule as it relaxes from its excited state (ES) to 
ground state (GS). This can be achieved via a number of pathways, as described by the 
Jablonski energy level diagram in Figure 1.2. Many different types of luminescence are 
possible: electroluminescence, chemiluminescence, bioluminescence, 
radioluminescence and photoluminescence.2,3 The work described herein concentrates 
on photoluminescence and its applications. 
1.1.1 Photoluminescence 
Each type of luminescence initially requires the promotion of an electron to excited 
energy levels.4 For photoluminescence, absorption of light by a molecule is required in 
order for electrons to occupy excited state energy levels,3,5 because the energy gap is 
too great to be exceeded thermally. Excitation is likely to be from the ground singlet 
state (S0) to the first excited singlet energy level (S1). This is defined by the Franck-
Condon principle (Figure 1.1), which describes that: i) nuclei are much larger than 
electrons; and ii) a shift of internuclear separation occurs if the bonding character is 
different in the ground and excited states (i.e. increased antibonding character). For 
these reasons, the Franck-Condon principle states that electronic transitions must be 
vertical1 because the transition is so rapid (10-15 s) that the nuclei do not have sufficient 
time to react, instead they remain in a stationary framework.  
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Figure 1.1: Illustration of the Franck-Condon Principle 
The Jablonski energy level diagram (Figure 1.2) describes the processes that occur 
between the absorption and emission of light via photoluminescence, the transitions in 
which are shown as vertical lines to demonstrate the instantaneous nature of light 
absorption, as described above. Energy levels marked with an S represent singlet 
electronic states, whereas those marked with a T represent triplet electronic states.1 
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Figure 1.2: Jablonski energy level diagram 
Upon light absorption, a luminophore is excited from the ground state level S0 to a 
higher energy vibrational level of S1. The higher energy excited state is relatively 
unstable, therefore deactivation is favourable and can occur via several processes.2
Firstly, molecules can quickly relax to the lowest vibrational level of S1 through non-
radiative internal conversion (IC) where energy is lost in the form of heat, usually 
occurring within 10-12 s or less. This process usually occurs before emission, and then 
emission usually occurs from the lowest vibrational state of S1  (i.e. after reaching 
thermal equilibrium).1,3 In addition, it is observed that the wavelength at which 
luminescence emission occurs is generally independent of excitation wavelength due to 
the speed of IC, known as Kasha’s rule.1
Following IC, the electron can undergo one of two processes. One of these is 
fluorescence, which occurs from the lowest energy vibration state of S1 back to an 
excited vibrational ground state in level S0, and occurs for most organic fluorophores.5
During fluorescence, overall electron spin is conserved and therefore allowed according 
to selection rules rules.4 This results in an efficient process with decay rates in the region 
of 10-8 s,1,2,6 which leads to lifetimes below 10 ns.   
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Another option following IC is intersystem crossing (ISC), where molecules residing in 
the S1 state undergo spin conversion to the T1 state in a non-radiative process. In the 
absence of spin-orbit coupling or an external magnetic field the singlet and triplet states 
are close in energy, with the triplet state usually lower in energy than the singlet state.3
ISC is spectroscopically spin forbidden, but facilitated by heavy atoms,1 and is a kinetic 
process occurring via collisions.6 After ISC, further energy can be lost by the emission of 
a photon to allow the electron to relax from the T1 state to S0.1 This process is known as 
phosphorescence and is also a spin forbidden process and therefore lifetimes are longer 
than fluorescence (ms-s). Furthermore, the additional energy loss results in a lower 
energy of phosphorescence emission when compared to fluorescence emission. Due to 
the aforementioned heavy atom facilitation of ICS, most emissive transition metal 
complexes undergo spin change and exhibit phosphorescence. 4
1.1.2 Measuring Photophysical Characteristics  
Important photophysical properties of luminescent compounds are measured using two 
main techniques: steady state and time resolved measurements.1 The most common of 
these, steady state measurements, are performed via constant illumination of a sample. 
This process allows a steady excited state to be reached, thus resulting in constant 
emission. On the other hand, time-resolved measurements require exceptionally short 
timeframes and therefore involve more sophisticated equipment. The technique 
involves exposure of a sample to a pulse of light that must be shorter than the decay 
time to allow the decay profile to be recorded. The nature of these two techniques 
renders steady state measurements an average of time-resolved measurements for the 
period of the decay, therefore combination of the two can give information on several 
significant parameters. 
1.1.2.1 Quantum Yield (Φ)
An extremely important photophysical parameter is quantum yield, which describes the 
ratio of the number of emitted photons relative to the number of absorbed photons.1,3,5
It describes the efficiency of the radiative decay process and takes into account the 
radiative decay rate (Г) and the rate of non-radiative decay (knr), as explained by 
Equation 1.7 High Φ values give rise to the brightest emission, for example values 
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approaching unity can be seen in rhodamine species where Г is much greater than knr. 
However, due to quenching (see Section 1.1.2.3) it is impossible to reach perfect unity.1
 =     ℎ   ℎ        (1)
 =  ГГ +           (2)
Quantum yields can be calculated experimentally by comparison with a standard such 
as [Ru(bpy)3][PF6]2 (denoted by subscript R) by using Equation 3, where S is the area 
below the emission spectrum, A is the absorbance at the excitation wavelength and n is 
the refractive index of the solvent.8
 =    22             (3)
1.1.2.2 Lifetime (τ)
Different systems have varying emissive characteristics which are dominated by the 
length of the luminescence lifetime. Measurement of luminescent lifetimes allows a 
distinction to be made between fluorescence and phosphorescence, as well as 
determining the time available for the ES to interact with the environment. The lifetime 
(τ) is defined as the average time molecules spend in the excited state before returning 
to the ground state, as described by Equation 4.1,5
Ʈ = 1Г +            (4)
Despite being useful for probe applications, long lifetimes can be a disadvantage 
because the ES is more accessible to quenching deactivation pathways. Lifetimes can 
also offer an additional contrast parameter for cellular imaging techniques such as 
fluorescence lifetime imaging microscopy (FLIM).5
1.1.2.3 Quenching  
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As well as non-radiative processes, the luminescence lifetime of a compound is affected 
by quenching. Quenching is defined as a decrease in emission intensity through a variety 
of processes, and is most common when in solution. The most common form of 
quenching is collisional, otherwise known as dynamic, and involves the ES being 
deactivated following contact with another molecule and hence is accelerated by 
diffusion effects in solution.5 The most frequently encountered quenching species is 
molecular oxygen and therefore it is common practise to remove dissolved oxygen to 
obtain luminescent spectra. Although often debated, the most probable cause of O2
quenching is paramagnetic O2 causing ISC,1 which can also be facilitated by halogens. In 
these cases, once ISC has occurred the long-lived triplet state is completely quenched 
before phosphorescence can occur.  
Collisional quenching is defined by the Stern-Volmer equation (Equation 5):1
0
 = 1 +  [] = 1 +  0[]          (5)
In this equation, K is the Stern-Volmer quenching constant and informs on the sensitivity 
of the fluorophore to collisional quenching. F and F0 are the fluorescence intensity with 
and without the quencher, respectively. [Q] refers to the concentration of the quencher, 
τ0 is the unquenched lifetime and kq is the bimolecular quenching constant.  
There are several other quenching mechanisms in addition to collisional quenching. One 
example is static quenching, which involves the formation of non-emissive complexes of 
luminophores with a quencher.5 Amines can demonstrate this form of quenching as they 
are able to form ES charge transfer complexes for which the exciplex is quenched in 
polar solvents. Amines are also able to quench fluorophores via photoinduced electron 
transfer (PeT).  Another quenching mechanism is resonance energy transfer (RET), also 
referred to as Förster RET (FRET).1,5 This mechanism is defined as non-radiative transfer 
of energy between an excited donor and acceptor molecule; hence it only occurs when 
there is sufficient overlap of the absorption profiles of the donor and the acceptor.9
As discussed above, quenching mechanisms can be problematic with regards to 
luminescent properties, but can also lead to a variety of important applications, for 
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example on-off fluorescent probes or in photodynamic therapy. These can be used for 
a number of processes:1 i) diffusion membrane probes; ii) DNA and protein binding 
probes; and iii) quenching of fluorescence due to specific binding events, for example 
binding to metal ions.  
1.1.2.4 Stokes’ Shift  
It can be seen from the Jablonski energy level diagram (Figure 1.2) that the energy of 
emission is generally less than that of absorption. In 1852 Sir G. G. Stokes noted this as 
the emission wavelength is always longer than that of the excitation. Stokes’ shift is 
therefore defined as the difference between the wavelength/frequency of the absorbed 
and emitted photons.4 The emission energy is always lower than the excitation due to 
the energy lost by IC and thermalisation of excess vibrational energy.1 The Stokes’ shift 
is an essential property for consideration in the application of a ligand as a fluorophore, 
as large value shifts are able to reduce the self-quenching of luminescence by the 
molecule. Organic fluorophores tend to have small to moderate Stokes’ shifts due to 
their tendency for spin conservation. However ES changes in geometry can give rise to 
larger values.4 In addition, large shifts allow distinction between fluorescence and 
autofluorescence in cellular imaging applications, where autofluoresence describes the 
intrinsic fluorescence of natural cellular objects.4 An optical filter of FLIM techniques can 
be employed to selectively filter out autofluorescence of luminophores with large 
Stokes’ shifts.5
1.1.2.5 Environmental Considerations 
There are several environmental factors that can affect the emission wavelength of a 
luminophore, for example other fluorophores, solvent molecules, ions and pH.5 Shifts in 
the wavelength can be described as either bathochromic or hypsochromic, and changes 
in intensity are referred to as hyperchromic or hypochromic (Figure 1.3).1 Controlling 
the nature of a fluorophore can give rise to desirable applications, for example 
hyperchromic and bathochromic shifts are desirable for biological systems and hence 
ideal for cell imaging applications.10
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Figure 1.3: Shifts of absorption and emission spectra 
Absorption and emission spectra of samples in solution are highly dependent on the 
nature of the solvent. This is due to the fact that irradiation by light leads to the 
redistribution of electron density within a molecule.1 This changes the interactions 
between the solute and any molecules that are solvating the excited molecules. For 
these reasons, the dipole moment of the luminophore can change during excitation, 
which is common in samples that show charge transfer (CT) character.11 Perturbation of 
the emission band is known as solvatochromism, where the extent depends on a 
number of factors: i) solvent nature; ii) nature of the luminophore; and iii) type of 
transition that occurs.1 When the ES is more polar in nature and can therefore be 
stabilised by solvent reorientation around the molecule, the result is lowering the 
energy of ES resulting in a bathochromic shift. This type of shift is described as positive 
solvatochromism and can make a significant contribution to the Stokes’ shift. When the 
GS is more polar than the excited state, negative solvatochromism occurs.   
In addition to the previously mentioned environmental factors, photobleaching can also 
reduce the emission intensity. This is a frequently encountered problem for fluorescence 
imaging techniques and occurs when an irreversible chemical change is induced after 
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excitation. Increasing the sensitivity of the imaging technique and designing a low 
illumination level fluorophore can reduce the amount of photobleaching.5,12
1.1.2.6 Organic Luminophores and their Substituents 
There is a huge variety of organic luminophores based on aromatic species that can be 
conjugated, substituted and functionalised. The unsaturated nature of aromatic species 
means they possess strong π-π* absorptions3 and commonly exhibit fluorescence from 
the lowest lying π* ES and/or intra-ligand charge transfer (ICT). Larger bathochromic 
shifts and emission intensities are observed with highly conjugated molecules,3 in 
addition to the introduction of vibronic structures due to rigidity.13 Although organic 
luminophores usually exhibit fluorescence emission, there are rare examples where 
triplet emission is possible but often readily quenched.  
The nature of the substituents on the aromatic unit can have a significant effect on the 
luminescent behaviour of a luminophore due to the effect on electron density.3,14
Electron donating groups, such as alcohols or amines, cause a shift in the absorption and 
emission spectra, in addition to an increase in the molar absorption coefficients. 
Furthermore, electron donating groups can cause spectra to become broad and pH 
sensitive due to a significant l-π* contribution – which is essentially an ICT process. On 
the other hand, electron withdrawing groups such as carbonyls or imides give rise to low 
lying n- π* ES. This results in lower extinction coefficients and quantum yields.3 The 
quantum yield will be highly dependent on solvent when the n-π* ES lies close in energy 
to the π-π*.15 It is also possible for organic compounds to aggregate and form excimers, 
which often exhibit bathochromic and hyperchromic shift16 combined with a broadening 
of emission profiles.17 There are numerous examples of organic fluorophores based on 
1,8-naphthalimide derivatives, which are discussed in Section 1.4. 
1.1.3 Luminescent Probes 
There has been extensive research into the applications of optical probes for 
biochemical and medicinal studies,18 for example to sense either: i) biological conditions 
(pH,19 O2 levels18) or biological processes; or ii) specific species of biological interest 
(such as Zn(II),20  Cu(II)19,21 and sugars22). There are three main requirements that must 
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be met in order for a luminophore to become an effective luminescent probe: i) obvious 
change in the photophysical properties upon the sensing event; ii) a high affinity and 
selectivity for the chosen analyte; and iii) easy delivery to the subject matter.1,23 With 
rational design, fluorescent probes can exhibit high sensitivity, resolution and good 
acquisition times, in addition to their use at relatively low concentrations.24 Due to 
advances in biological imaging technologies (see section 1.3), they are also capable of 
imaging at intracellular level in real time, with excellent spatial resolution.23,25
1.2 Coordination Chemistry  
Coordination chemistry is the study of coordination compounds or complexes, which 
are defined according to IUPAC recommendations as: “an ion or neutral molecule that is 
composed of a central atom, usually that of a metal, to which is attached a surrounding 
array or other atoms or groups of atoms, each of which is called a ligand”.26 Coordination 
chemistry was first developed in the 19th century when Werner, for example, disbanded 
the link between metal oxidation state and coordination number and began use of the 
term coordination compounds.27 Today, coordination compounds are the subject of a 
vast amount of varied research. In particular, there is a rich array of coordination 
compounds that exhibit extremely interesting spectroscopic properties.  
1.2.1 d-Block Metal Complexes 
As discussed above, most organic fluorophores possess a singlet excited state that is 
short lived, giving rise to small Stokes’ shifts. Luminescent coordination compounds 
containing d-block metals typically emit from triplet excited states, and are thus suitable 
for sensing and imaging properties due to a number of inherent properties.  
1.2.2 Crystal Field Theory  
Metal complexes are made up of a number of ligands, each of which forms coordinative 
dative bonds to a metal ion.28 Crystal field theory describes a ligand lone pair modelled 
as a point negative charge (or as the partial charge of an electric dipole) that repels 
electrons in the d-orbitals of the central metal ion.29 Thus, the formation of bonds occurs 
through the donation of a lone pair of electrons for σ- and π-donors, which are 
complemented by a π-acceptor component.28 The theory focuses on how the nature of 
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a ligand affects the resultant splitting of d-orbitals into groups with non-degenerate 
energies, thus helping to rationalise the optical spectra, thermodynamic stability and 
magnetic properties of complexes.29 For example, in 6-coordinate, octahedral 
complexes (Oh), the five d orbitals split into two non-degenerate energies where three 
non-bonding orbitals with t2g symmetry lie at lower energies and correspond to dxy, dxz
and dyz, whilst the two eg symmetric anti-bonding orbitals, dx2-y2 and dz2 orbitals lie at 
higher energy.  
Rationalisation of the stability of a complex uses the crystal field splitting energy (Δ), 
which is dependent on the principle quantum number, charge of the metal and the 
nature of the ligand.30 With octahedral complexes, for example, this is denoted as Δo. 
The partial filling of the aforementioned t2g and eg orbitals allows for electronic 
transitions to occur when the irraditation energy is equal to Δo. With careful ligand 
design, the photophysical properties of a complex can be controlled due to the 
dependant nature of Δ on the nature of the ligand. The Spectrochemical Series (Figure 
1.4) represents the effects that different ligand types have on the perturbation of the d 
orbitals , and ranks them in order of their effect on Δ.28 The general trend is as follows: 
Figure 1.4: Spectrochemical Series 
In addition, polydentate ligands, for example bipyridine (bpy) and 1,10-phenanthroline 
(phen), donate electron density from more than one site.28 They are often preferred 
because they increase the thermodynamic stability of a coordination complex; this is 
known as the chelate effect, which was first described by Curtis in 1964.31 These types 
of ligands are further explored in Chapter 4.  The increase in thermodynamic stability 
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can be related to the Gibbs free energy of a system, where a lower ΔG leads to a higher 
stability, as denoted in Equation 6.29
 =   −            (6)
The entropic contribution towards increased disorder is favourable for polydentate 
ligands, as moving from a MX6 complex to ML3 complex (where X is a mondentate ligand 
and L is a bidentate ligand), for example, results in an increase in molar equivalents of 
the reaction products. The enthalpic contribution originates from breaking each of the 
coordinative bonds in order to fully dissociate a polydentate ligand.  
1.3 Diagnostic Medicine – Medical Imaging 
Coordination compounds and organic luminophores have been applied for a variety of 
medical imaging techniques. The last few decades of the twentieth century saw huge 
development and commercialization of a range of new medical imaging technologies. In 
part, this acceleration is attributed to advances in understanding the fundamentals of 
the physical phenomena on which the imaging technologies are based.32 Medical 
imaging is reliant upon detecting the differences between the compositions of different 
tissues within the body, using an external source.33 Classical forms of imaging are known 
as anatomical imaging which involves the detection of internal structural consequences 
from outside the body. In recent years, molecular imaging has emerged as a successful 
technique, and involves the detection of the biological or physical abnormalities 
underlying the disease.34 A key difference between these two imaging techniques is that 
molecular imaging always requires a probe that must be specific to the molecular event 
to be detected, thus chemistry plays a crucial role in the development of new 
approaches. There are many imaging modalities that are currently available to the 
clinician; examples include Positron Emission Tomography (PET), Magnetic Resonance 
Imaging (MRI), Computed Tomography (CT), X-Ray and fluorescence microscopy. 
Specifically, there has been a remarkable growth in the use of fluorescence spectroscopy 
during the past 20 years.1 One protocol is by no means an isolated or independent mode 
of imaging,35 and each technique has distinct advantages and disadvantages.  
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1.3.1 Fluorescence Microscopy 
Fluorescence microscopy is a powerful, highly sensitive36 imaging technique that utilises 
fluorescent probes for biological or medicinal applications.2,5 In rare cases, the 
technique utilises the intrinsic fluorescence of a biological sample upon excitation, 
rather than a fluorescent probe.4,37 Its use in the screening of chemical and biochemical 
analytes has become a quickly advancing area over the past few decades.32 It has 
become an ideal microscopy technique for the assessment of biological specimens 
because it provides a technique for specific detection of non-emissive cells, with 
advantages including increased contrast and signal-to-noise ratio when compared to 
standard microscopy techniques.4,19 In addition, fluorescence microscopy offers high 
nanometer resolution (ca. half of the emission wavelength),2,5,38 non-invasive character 
and requires a relatively low concentration of probe. The high degree of sensitivity is 
due to the detection of emitted light as opposed to reflected light used for normal 
spectroscopy, thus allowing visualisation at molecular level for a relatively low cost.38
The technique is used in industry for inspection of surfaces and coatings, but in a 
biological context it dynamically notifies on the localisation and uptake of molecules 
within cells.36,39
Despite its advantages, the technique is inherently limited due to the requirement for 
both excitation and emission wavelengths to be tissue compatible, thus confining its use 
to largely imaging at a cellular or thin tissue level, as opposed to being a whole-body 
technique.40 In addition, tissue compatible wavelengths are generally in the near-IR 
region and have poor penetration through tissue.4
1.3.2 Confocal Fluorescence Microscopy (CFM) 
There has been substantial improvements in fluorescence microscopy techniques due 
to advances in technologies such as probe chemistry, confocal optics, multiphoton 
excitation, detectors and genetically expressed fluorophores such as green fluorescent 
protein (GFP).41 Confocal fluorescence microscopy has helped to address the problems 
associated with the traditional technique as it limits photon detection to light that is 
emitted from the focal point by actively supressing signal coming from out-of-focus 
planes,42 thus giving rise to a significant increase in the contrast and resolution. This 
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technique allowed the introduction of optical sectioning and gave rise to three-
dimensional microscopic reconstructions of biological tissue.2 The confocal principle was 
first discovered in 1957 by Martin Minsky and the first commercial instrument was 
created in 1982.2 The modern microscope utilises either the output of photomultiplier 
tubes or a digital charge-coupled device (CCD) camera to build up the image, which is 
then directly processed in a computer imaging system and displayed on a high-
resolution video monitor.43 In addition to CFM, advances have been made in two-photon 
microscopy, which involves the excitation of a chromophore by two photons 
simultaneously. The success of this technique relies on a very high concentration of 
photons, a property that only occurs at the focal point, thus giving rise to focused, 
sectioned images.40 The technique has been described as the ‘optical magic wand’ due 
to the avoidance of the photo damage and photobleaching.40 As mentioned above, the 
development of genetically encoded fluorophores such as GFP are said to have 
revolutionised fluorescence microscopy.40 The protein is naturally occurring in the 
bioluminescent jellyfish Aequorea Victoria and absorbs blue light and emits green.41 It 
has provided a basis for the synthesis for a wide number of variants, giving rise to a wide 
choice for the microscopist. Besides GPF and two-photon, the past decade has seen 
advancement in other fields of fluorescence microscopy, such as total internal 
fluorescence (TIRF), which monitors the movement of single molecules in very thin 
samples;44 as well as imaging deconvolution and analysis, which has had a profound 
impact in cytogenetics.45 Other recent developments have been focused around 
quantum dots and fluorescent nano-crystals.37
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The basic structure of CFM equipment is displayed in Figure 1.5.46 The excitation 
photons firstly pass through a pinhole before focusing through an objective lens onto a 
precise location in one focal plane. The emission is then passed through a second 
pinhole to reject any out-of-focus light.2,36,38 This gives rise to 2D optical slices (z-stacks) 
that are collected and reconstructed to form a false-colour, 3D image.4,5,36
Importantly, CFM can perform multi-channel detection via a master beam splitter that 
reflects selected wavelengths. The selected wavelengths are split using dichromic 
mirrors and distinguished using different detectors. This ability gives rise to the 
detection of specific staining and co-localisation experiments, which are extensively 
explored in Chapter 2. Co-localisation studies work by using two fluorescent probes 
simultaneously, where one is hypothesised to localise in a certain cellular substructure, 
and another with different emissive properties that is known to target the same 
substructure.5 Following this, the degree of co-localisation can be determined by 
overlaying the corresponding images, thus concluding the target of the new probe.38
Figure 1.5: Illustration of CFM46
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A more recently developed technique, known as super-resolution fluorescence 
microscopy, encompasses a variety of sub-techniques based on tailored illumination, 
non-linear optical (NLO) devices and the accurate localisation of single molecule 
probes.47 The Nobel Prize in 2014 was won by Betzig, Moerner and Hell for development 
of some of the techniques, including stimulated emission depletion (STED) microscopy 
and single molecule microscopy.47,48
1.3.3 Luminescent Probes for Cell Imaging  
Fluorescent probes must possess a number of requirements for biological applications, 
including: i) bright emission at tissue compatible wavelengths; ii) tissue and laser 
compatible excitation wavelengths; iii) a low tendency of photobleaching; and iv) a 
method of differentiating from autofluorescence via large Stokes’ shifts or long 
lifetimes.5,36,38 In addition, probes must exhibit good membrane permeability, solubility 
in aqueous media and low toxicity. It is possible for probes to target specific cell 
substructures according to their design, for example Golgi apparatus and endoplasmic 
reticulum require lipids or inhibitors of protein movement, and the nucleus requires 
DNA binding properties.5
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Figure 1.6: Acriflavine (left) and DAPI (right)
Bommer used an acriflavine dye as the probe for the first fluorescent imaging of a fixed 
tissue sample in 1929 (Figure 1.6).2 Today, most probes are organic structures with fused 
aromatic or heterocyclic rings, for example 4',6-diamidino-2-phenylindole (DAPI), a 
nuclear fluorescent stain (Figure 1.6).4 Inorganic species have also been applied to cell 
imaging applications due to their desirable photophysical properties and tunable nature. 
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1.4 1,8-Naphthalimides 
Naphthalimides are a class of polycyclic imides containing a π-deficient flat aromatic or 
heteroaromatic ring system (Figure 1.7). In general, they are characterised by the 
presence of a planar aromatic chromophore and one or two flexible basic side chains 
which promote DNA affinity through electrostatic or hydrophobic interactions.49 1,8-
Naphthalimide derivatives make up an extremely important family of fluorescent 
compounds with multiple applications, such as DNA targeting, anticancer and cellular 
imaging.50 In particular, they are a category of compounds which exhibit high levels of 
anti-tumour activities centred around their effective intercalation into DNA and other 
effects such as apoptosis induction.49 Many derivatives in the literature focus on mono- 
or bis-naphthalimide structures, where substituents include amines, polyamine 
conjugates, heterocycles, oligonucleotides, peptides and metal complexes. They are 
ideal candidates as probes because they have rich photophysical properties that are 
dependent on the nature and the substitution pattern of the aryl ring.  
N OO
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Figure 1.7: General structure of a 1,8-naphthalimide 
In addition to their photophysical properties, the prevalence of 1,8-naphthalimides in 
recent literature is partly due to their ease of synthesis from the corresponding 1,8-
naphthalic anhydride.51 This is able to react with a range of amines, which can in turn be 
followed by substitution of the aryl ring, most commonly at the 2- or 4-position to give 
compounds of high purity and with high yields.50 These synthetic protocols give rise to a 
vast array of possibilities, which means it is possible to control electronic properties, 
spectroscopic properties and photochemical behaviour via the use of specific moieties.  
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It is this type of tuneable behaviour that allows these compounds to be exploited as dual 
therapeutic and fluorescent imaging agents.  
1.4.1 1,8-Naphthalimides as anticancer agents 
The discovery of novel and effective anti-cancer drugs is a primary focus amongst 
researchers as clinically used drugs exhibit poor pharmacokinetics, dangerous side 
effects and drug resistance.49 As discussed above, naphthalimides are highly active 
anticancer drugs based upon effective intercalation with DNA, which can be investigated 
in terms of structural modifications and structure activity relationships (SAR).  
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Figure 1.8: Amonafide (left) and Mitonafide (right)
1,8-Naphthalimides as DNA-binding agents were originally established by Brana et al.52
Some derivatives have entered into phase III and phase II clinical trials, including 
amonafide and mitonafide (Figure 1.8). Clinical trials have shown that both show high 
anti-tumour activity and have desirable IC50 values (concentration of a drug required to 
inhibit a biological process by 50%) against HeLa cell lines.53 Both are able to bind to DNA 
through intercalation into minor grooves, thus inhibiting topoisomerase activity by 
affecting the breakage-rejoining step.54 Amonafide is commercially known as 
Quinamed®, a dichloride salt of amonafide developed by ChemGenex Pharmaceuticals 
as a treatment for acute myeloid leukaemia which has reached phase III clinical trials.55
It has been found by SAR studies that the presence of a basic terminal group in the side 
chain has a significant effect on the anticancer activity, hence a large number of these 
types of compounds have been synthesised.53  It has also been observed that if there is 
a nitro-substituted analogue present, there will be a higher anticancer activity in the 3-
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substituted position in comparison to the 4-. It is thought that this is due to the ease of 
co-planar orientation and hence more effective stacking interactions between the 3-
nitro-1,8-naphthalimides and DNA.56
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Figure 1.9: Derivatives by Wang et al.57
DNA binders showing high anticancer activity against leukaemia have also been 
developed by Zee-Cheng and Cheng. The structures were reported as N-
(dialkylaminoethyl)-derivatives of 3,6-dinitro and 3,6-diamino-1,8-naphthalimides, 
again with low IC50 values.58 Following this, a series of 3-amino-6-nitro-1,8-
naphthalimide derivatives showed high cytotoxicity against human colon carcinoma 
(CX1) and lung carcinoma cell lines (LX1).59 In recent work, Wang et al. reported the ct-
DNA binding properties of naphthalimide derivatives containing hydroxyl-alkylamines at 
the 4-position (Figure 1.9).57 Spectral changes in the UV-Vis and emission profiles 
suggested intercalation of the compounds into the base pairs of DNA, where an increase 
in the fluorescence intensity in the presence of ct-DNA was observed. In addition, the 
derivatives were found to be more cytotoxic than cis-platin in Bel-7402 and HL-60 cell 
lines, where anti-cancer activities increased with increasing length of the side chain.  
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1.4.2 Bis-naphthalimide anticancer agents 
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Figure 1.10: Elifinide 
Bis-naphthalimides describe a class of compounds where two 1,8-naphthalimides are 
connected by a polyamine spacer in order to exploit the DNA binding and anti-tumour 
activity and were initially developed by Brana and co-workers,60 for example elifinide
(Figure 1.10) shows high activity against a range of human xenograft models such as 
lung, colon, and melanoma.61 It is able to unwind and change the viscosity of closed 
circular plasmid DNA by binding along the major groove, and shows a preferential DNA 
interaction for alternating purine-pyrimidine dinucleotide steps.62 This goes against the 
trend that the nitro/amino substituted derivatives display better antitumour activity.63
Within this family of structures comes an efficient DNA binder incorporating a 
phenanthrene chromophore (Figure 1.11) that displayed excellent L1210 activity with a 
significant IC50.64 A noteworthy extension to the bis-naphthalimide derivatives comes 
from Gunnlaugsson et al., which involved the inclusion of a Troger’s base linker for DNA 
targeting. Compounds were designed to ensure that the terminal nitrogen atom in the 
side chain is protonated at physiological pH, meaning that water solubility is enhanced 
and electrostatic interactions with the negatively charged phosphate backbone of DNA 
are favoured.65  In this research, binding with specifically high affinity to calf thymus DNA 
was observed. In addition, rapid uptake into leukaemia cells was observed with nuclear 
localisation, as monitored by commercially available co-stains.  
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Figure 1.11: Phenanthrene derivative64
Ethidium bromide displacement assay has been used to study the interaction between 
naphthimidobenzamide derivatives (Figure 1.12) and various DNA sequences.66 Binding 
was 350 times stronger to G-C repeats than to A-T and A-A repeating oligomers. The 
contact of the ligand with a specific DNA sequence showed p300 gene expression and 
significant anti-cancer activity in human solid xenografts was observed. This research 
interestingly concluded that DNA binding agents can be sequence specific and may be 
used as a possible control mechanism for transcription of tumour related genes.  
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Figure 1.12:Naphthalimidobenzamide derivative66
1.4.3 Naphthalimide-Metal Complex Conjugates 
Transition metal complexes of 1,8-naphthalimides have also received a considerable 
amount of interest in the past couple of decades for developing cancer and 
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chemotherapeutic agents.67,68 Cis-platin is a well-known chemotherapeutic that has 
encountered frequent problems, mainly due to cellular resistance. Perez et al. have 
developed novel Pt-bis-naphthalimide complexes (Figure 1.13) to enhance DNA binding 
and cytotoxicity in an attempt overcome the issues associated with cis-platin,69 through 
intercalation of the bis-naphthalimide unit in addition to the platination of DNA bases.  
N
N
Pt
N
NClCl
O
O
O
O
Figure 1.13: Naphthalimide-Pt conjugate bby Perez et al.69
The antiproliferative activity of gold(I)-complexes has also been explored during 
development of gold(I)-phosphine complexes bearing a thio-naphthalimide ligand 
(Figure 1.14),70 where compounds exhibited growth inhibitory effects in MCF-7 breast 
cancer and HT-29 colon carcinoma cells. In comparison to the free naphthalimide 
analogue, there was increased cellular uptake and accumulation of gold in the nucleus 
of tumour cells due to the presence of a thiol moiety.   
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Figure 1.14: Gold(I)-phosphine naphthalimide derivative70
Ruthenium has also been investigated extensively in this field, namely by Gunnlaugsson 
et al. for use as potential DNA-binders and photocleaving agents. Flexible and rigid 
linkers have been used in the development of Ru(II) polypyridyl complexes with 1,8-
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naphthalimide derivatives. One example includes the use of an aromatic linker as shown 
by Quinn and Gunnlaugsson, which was shown to possess control over the relative 
orientation of the chromophores, thus placing the naphthalimide in close proximity to a 
metal centre.71 Complexes exhibit hypochromism and a red shift in the MLCT band when 
DNA is present, and cause DNA cleavage under irradiation in aerated solution.  
In more recent work, “3d-metal scorpionates” incorporating 1,8-naphthalimide 
chromophores have been developed and are shown to exhibit moderately high affinity 
for ct-DNA.50 As well as this, the Co(II) and Cu(II) derivatives have been found to induce 
DNA cleavage and to exhibit significantly higher cytotoxicity against HeLa cervical cancer 
cells when exposed to UV radiation.  
Finally, two series of naphthalimide based Ru(II)-arene complexes showed that the 
presence of the intercalating naphthalimide moiety enhanced the cytotoxicity of the 
unit with cancer cells.72 Findings reported that the intercalation mechanism of the 
naphthalimide unit within DNA along with the binding of the Ru(II)-arene unit with 
proteins led to the increased in anti-cancer selectivity for the complexes over model 
healthy cells, as well as cells with cis-platin acquired drug resistance.  
1.4.4 Other uses of 1,8-naphthalimides  
1,8-Naphthalimide derivatives can also be used as selective fluorescence sensors, for 
example in biochemistry and environmental research. It has been seen that using 1,8-
naphthalimide units in fluorescent probes for detecting metal ions offers significant 
advantages over traditional detection methods, due to their increased sensitivity, 
simplicity and response time.73,74 An example of this is provided by Wang et al.75 who 
synthesised a naphthalimide-rhodamine B derivative which was suitable for use as a 
fluorescence turn-on chemodosimeter for Sn4+. Chemodosimeters detect an analyte via
a highly selective chemical reaction between a dosimeter molecule and target analyte.76
In this case, the ring opening reaction of rhodamine and a fluorescence resonance 
energy transfer process caused a marked colour change and an enhancement in 
fluorescence in the presence of Sn4+, Cu2+ and Cr3+. As well as this, the structure has been 
useful as a fluorescent probe for Sn4+ in biological systems and can behave as an aid to 
investigate the physiological functions of tin or pathogenesis in the human body.  
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Figure 1.15:Fluorescence sensor for Zn2+ detection 
The fluorescent sensing of Zn2+ is also biologically relevant due to the ions involvement 
in Alzheimer’s disease, epilepsy, ischemic stroke and infantile diarrhoea.73,77,74 A novel 
1,8-naphthalimide compound has been designed for the sensitive turn-on fluorescence 
detection of Zn2+ in aqueous media and intracellular fluid (Figure 1.15).78 The compound 
was selective for the Zn2+ in comparison to other metals, and a 13-fold increase in 
fluorescence was seen in the presence of the ion. A similar turn-on fluorescence sensor 
for Zn2+ has been developed that exhibits nucleus envelope penetrability in in situ
imaging of HeLa and HepG2 cells.79 In other recent work, Lui et al. have synthesised a 4-
amino-1,8-naphthalimide-PeT-based fluorescent sensor.80 The compound incorporated 
glutamic acid and iminodiacetic acid functionalities (Figure 1.16), the latter of which acts 
as a receptor for the highly selective detection of Zn2+. A characteristic emission band 
was seen for the fluorescent probe at ~550 nm and was effectively utilised to image Zn2+
in living cells.  
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Figure 1.16:Fluorescence sensor for Zn2+ detection by Lui et al. 
Silver ions have also been investigated in a similar way due to their ability to deactivate 
sulfhydryl enzymes and bind with amine, carboxyl and imidazole groups of several 
metabolites. Xu et al. have developed a naphthalimide based fluorescent probe (Figure 
1.17) that contained a new receptor and acted as a turn-on fluorescence sensor with 
outstanding selectivity towards Ag+ in comparison to other metal ions.81 A sensor for the 
live cell imaging of copper has also been developed, incorporating a tetrathia-azacrown 
into a naphthalimide-based structure.82
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Figure 1.17:Fluorescence probe for Ag+ by Xu et al. 
As well as the sensing of metals, 1,8-naphthalimide derivatives can be used for the 
sensing of simple molecules, for example nitrous oxide (NO). This is important because 
it acts as a messenger in cardiovascular and nervous systems, and is also utilised in 
human immune responses. An example of fluorescent NO sensing comes from Hu et al. 
who synthesised a new copper(II) complex with a naphthalimide-containing ligand.83
The complex demonstrated an approximate 8-fold increase in fluorescence where the 
detection limit of NO was 1nM in aqueous solution. The probe was shown to be specific 
for NO over other species such as ClO-, NO2-, NO3-, H2O2, and 1O2, all of which are 
biologically relevant reactive species. Other biologically important species include 
phosphates, due to their role in cellular ATP hydrolysis, DNA and RNA polymerization, 
and many enzyme controlled reactions. For this reason a zinc(II) complex incorporating 
1,8-naphthalimide with two dipicolylamino arms has been developed as a novel 
fluorescence sensor to monitor intracellular phosphate.84
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Figure 1.18: Lysosome specific, pH sensitive ‘off-on’ fluorescent probe85
A 1,8-naphthalimide-derived probe has also been developed for H2S detection in bovine 
serum and live cell imaging, as well as having the ability to detect intracellular H2S in 
lysosomes.86 In related work, a pH sensitive ‘off-on’ fluorescent probe has been 
developed for lysosome imaging (Figure 1.18).85 The probe was shown to have 
advantageous specificity for lysosomes over other organelles, and was based on a 4-
acylated 1,8-naphthalimide fluorophore. In addition, the compound displayed intrinsic 
high signal to noise ratio in cell imaging, broad Stokes’ shift and practical fluorescence 
quantum yield. 
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2.1 Introduction 
2.1.1 Chemical Properties of Gold  
Gold as a metal has been encountered since early civilisation, when it was associated 
with power, beauty and the cultural elite.1 Initially, the understanding of the chemistry 
of gold was limited to its concentration, recovery and purification. However, over time, 
gold chemistry has advanced to become an extremely important branch of science with 
applications in various fields.2  Gold has only one naturally occurring isotope, and is the 
most electronegative of all metals.3 Gold’s most commonly studied species are of 
oxidation state +1. However +3, 0 and -1 are also known.1
Gold(I) has an electronic configuration of 5d106s0, where 10 electrons in a closed set of 
5d orbitals explains the relative stability of these compounds.1 The post-lanthanide 
position of gold means a large number of protons are contained in its atomic nuclei and 
a very high effective nuclear charge is observed. For this reason, electrons are treated 
with a relativistic approach, as their movement reaches velocities approaching the 
speed of light. This effect (particularly for s electrons) causes the orbital radius to be 
contracted and the distance from the nucleus to be reduced, thus giving rise to a number 
of properties: i) the colour of gold arising from a transition from the filled 5d band to the 
Fermi level (2.4 eV); ii) shorter covalent bond lengths involving gold atoms; and iii) the 
closed 5d shell is no longer chemically inert and can interact with other gold atoms in 
molecules or clusters. 
2.1.2 Au(I) Coordination Chemistry and Ligand Design 
The chemistry of Au(I) compounds is by far the most studied and numerous 
mononuclear, dinuclear and polynuclear derivatives have been reported with 
interesting photochemical and photophysical properties.4 Due to the small difference in 
energy between the s and d orbitals; linear, two-coordinate complexes dominate.1
Trigonal three-coordination and tetrahedral four-coordination complexes have also 
been reported, but to a far lesser extent.5 Au(I) is a soft cation, thus has a high affinity 
for sulfur, phosphine, arsenic, alkynyl and selenium donors;3,6 numerous Au(I) 
complexes exist with such ligands. 
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Au(I) forms kinetically stable complexes due to its d10 configuration. However, ligand 
exchange is a major contributing factor in the biological activity and behaviour of Au(I) 
complexes. For example, solution calorimetry studies of a [AuCl(L)] (L = phosphine or 
phosphite) system showed that the electronic parameters of the ligand dominates. In 
this case, bond dissociation enthalpies for tertiary phosphines were estimated at 58-
65±5 kcal mol-1.7 As well as this, factors such as protein binding, excretion pathways, and 
toxicity can be modulated by tuning the amphiphilic nature of Au(I) bound ligands.8,9
2.1.3 N-Heterocyclic Carbenes 
Carbenes are an interesting class of carbon-containing compounds comprising a divalent 
carbon atom with a six-electron valence shell.10 For this reason, free carbenes were 
normally very reactive and traditionally used as highly reactive transient intermediates, 
for example in cyclopropanation. Despite this, free carbenes have been stabilised using 
favourable interactions with phosphorus and silicon substituents,11 well as through 
incorporation into a nitrogen heterocycle.12 N-heterocyclic carbenes (NHCs) were first 
isolated and characterised in 1991, and have since developed into an extremely 
powerful group of compounds for organic and inorganic chemistry.10 In this context, 
synthesis of the first isolable NHC, 1,3-di(adamantyl)imidazole-2-ylidene (IAd) (Figure 
2.1), led to a significant increase in the experimental and theoretical studies with a vast 
library of novel NHCs being developed. Specifically, NHCs have been found to be 
excellent ligands for transition metals, and thus have found multiple applications, for 
example as catalysts.10 In addition, these carbenes are currently recognised as a useful 
alternative to tackle the limitations associated with phosphine ligands in 
organometallics and catalysis.13,14
N N
Figure 2.1: IAd 
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The broad definition of an NHC is a heterocyclic species containing a carbene carbon and 
at least one nitrogen atom within the ring structure.15,16 They are also known as 
Arduengo carbenes, and form Fischer-type complexes with transition metals.16 The 
carbene centre shows a remarkable level of stability due to the electronic and steric 
effects of the structural features. NHCs containing bulky substituents adjacent to the 
carbene atom increase the kinetic stability by sterically disfavouring dimerization (the 
Wanzlick equilibrium).10 In addition, the steric impact of the N-substituents is affected 
by minor alterations to the NHC architecture, thus giving rise to huge changes of the 
electronic donor properties of the carbene groups with relation to a coordinated 
metal.17,18 They have also been described as amongst the most powerful neutral organic 
bases, where their strength is comparable to DBU and pentacyclic vinamidines.19,20
The electronic stabilization provided by the nitrogen atoms is also a factor in explaining 
the stability of NHCs. NHCs such as IAd have a singlet-ground state electronic 
configuration with the HOMO and the LUMO best described as a formally sp2-hybridised 
lone pair and an unoccupied p-orbital at the C2 carbon.10 The adjacent σ-electron 
withdrawing orbital and π-electron donating nitrogen atoms stabilise this arrangement 
both inductively and mesomerically. In addition, the cyclic nature of NHCs give rise to a 
bent, sp2-like arrangement for the carbene carbon, further favouring the singlet state. 
The ground state structure described is supported by the C-N bond lengths that are 
observed in IAd (1.37 Å), which fall between those of its corresponding C2-saturated 
analogue and imidazolium salt. This suggests that the C2-nitrogen bonds possess partial 
double bond character.  
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Scheme 2.1: Preparation of imidazolium precursors16
The main method of generating NHCs is through imidazolylidenes and 
imidazolidinylidenes, while other methods exist, but are rarely employed. In this vein, 
there are various routes available to prepare imidazolium precursors (Scheme 2.1).21
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Perhaps the most simple is a one-pot synthesis, that utilises a primary amine and 
formaldehyde.22 The corresponding Schiff base is formed via coupling between the 
amine and glyoxal under acidic conditions, followed by condensation with formaldehyde 
to form the imidazolium salt (Scheme 2.1). For more sterically demanding syntheses, 
Glorius et al. provide an alternative approach using silver triflate and chloromethyl 
pivalate. For unsymmetrical imidazolium salts, an alternative route has been developed 
involving the stepwise alkylation of an imidazolium anion generated from the reaction 
of imidazole with potassium.21
As discussed above, NHCs form a range of organometallic complexes with a wide variety 
of metals. It is generally accepted that NHCs bind strongly to metals via σ-bonding, while 
the back bonding can usually be considered to be negligible.16 This is not observed, 
however, for Group 11 metals, where the π-back bonding component becomes 
significant.23 NHCs have been compared to phosphines in metal complexes, where both 
act as monodentate two-electron donor ligands.16 For example, NHCs have been shown 
to be more electron donating than most basic phosphines when studied with a variety 
of nickel(0) complexes.24 NHCs have also formed metal complexes with alkali metals. For 
example, the 4,5-dimethyl-1,3-diisopropylimidazolium salt is deprotonated with lithium, 
sodium and potassium hexamethyldisilazide forming the corresponding carbene alkali 
metal complexes.25 In addition, complexes have been formed with alkaline earth 
metals26, group 13 metals27, rare earth metals15,28, and transition metals.29 In contrast,  
the carbene chemistry of complexes with groups 14, 15 and 16 metals is extremely 
underdeveloped.16
2.1.4 Therapeutic Activity of Gold  
The use of gold-based compounds in medicinal chemistry is referred to as 
chrysotherapy.30–32 The most common variety of Au(I) coordination complexes used in 
a clinical setting are those incorporating thiolate or phosphine ligands.5 Amongst the 
most widely utilised are auranofin, sodium aurothiomalate (Figure 2.2), and sodium 
aurothioglucose, all of which have been applied for the treatment of inflammatory 
autoimmune conditions such as rheumatoid arthritis.33,34 Auranofin is also under 
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investigation as a treatment to reduce the viral reservoir of HIV that lies latent in the 
body’s T-cells.35
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Figure 2.2: Sodium aurothiomalate (left) and auranofin (right) 
The mechanism of biological action of such clinical treatments is extremely difficult to 
unravel,36,37 although it is thought to be related to the inhibition of cathepsin B activity 
via targeting of lysosomal cysteine proteases.38,39 Another hypothesis is that Au(I) 
complexes deactivate singlet O2 through the inhibition of the enzyme thioredoxin 
reductase (TrxR), thus interrupting oxidative stress regulation in cells.39,40–42 As well as 
being involved in many other metabolic pathways, it is the antioxidant capability of TrxR 
that is thought to be associated with protecting cells from oxidative stress.43 In addition, 
elevated levels of TrxR have been reported in a range of cancer cell lines. Furthermore, 
recent work has observed the inhibition of the selenium-glutathione peroxidase 
enzyme, highlighting the thio- and selenophilic nature of Au(I).44,45 As well as focused 
studies on developing treatments for rheumatoid arthritis, a variety of Au(I) complexes 
have been assessed in terms of their anti-tumour properties.46,47
In summary, mechanistic studies to date define three major classes of gold compounds 
according to their mode of action with biological targets:5 i) prodrugs that are able to 
coordinate tightly to biomolecules’ side chains; ii) ‘big cations’ capable of crossing 
membranes and binding non-covalently to biomolecules; and iii) compounds that react 
with biomolecules through redox chemistry to cause oxidative damage. 
2.1.5 Au(I) Complexes as Anti-Cancer Agents 
As previously introduced, gold compounds are an important class of metallodrugs with 
great scope for cancer treatment.5 Over the last two decades, there have been several 
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reports suggesting that a variety of Au(I) complexes possess relevant antiproliterative 
properties in vitro against selected human tumour cell lines.  
Preliminary research into the mode of action of Au(I) compounds for anti-cancer 
applications focused on DNA and RNA targets, as these biomolecules are considered to 
be important targets for similar platinum based drugs. However, weak interactions were 
observed between anti-arthritic gold(I) drugs and DNA, suggesting that different cellular 
processes may be involved in their cytotoxic mechanism.48 Alternatively, relevant 
alterations observed on mitochondrial functions are observed following Au(I) complex 
treatment, which can be explained by the action of Au(I) compounds on TrxR.5 In relation 
to this, expression levels of the cytosolic thioredoxin isoform Trx1 are increased in 
several human carcinomas,49,50 and linked to tumour aggressiveness, and to inhibition 
of apoptosis.51,52 For these reasons, much research focuses on the thioredoxin system 
as a potential target for new anti-cancer drugs. Auranofin acts as a specific inhibitor of 
both cytosolic53 and mitochondrial TrxR54–56 due to its reaction with thiol and/or selenol 
groups. As well as other structural analogues, it is also found to induce, in the presence 
of Ca2+ ions, mitochondrial swelling and mitochondrial membrane potential decrease, 
and stimulation of respiration which results in the overall release of cytochrome C into 
the cytoplasm.8,55 The process described is, importantly, involved in the formation of 
apoptosomes and therefore the induction of apoptosis.     
In this context, the ability of auranofin to inhibit TrxR and induce apoptosis has been 
confirmed in cis-platin resistant human ovarian cancer cells.57 In addition, structural 
analogues of auranofin have been shown to display significant cytotoxicity against B16 
melanoma and P388 leukemia cell lines.58 The importance of nature of the ancillary 
tertiary phosphine was a key conclusion in this work. Some were found to induce 
additional potency to the complex, for example for a given thiolate ligand, triethyl 
derivatives were generally more cytotoxic than triphenyl. In addition, Tiekink 
summarised a number of studies evaluating the cytotoxicity of a large range of Au(I) 
complexes.37 This work assessed the structure-property relationships with tetrahedral 
Au(I) complexes. Examples from this work include complexes with charged and/or 
bidentate thiols, chiral phosphines and thiols labelled with biologically active groups. In 
addition, gold phosphine compounds incorporating a variable number of coordinating 
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phosphorus atoms were seen to show increased cytotoxic potency in murine tumour 
cell lines as the number of gold-coordinated phosphorus atoms increases.59,60
There are also numerous examples of Au(I)-NHC complexes with anti-tumour 
applications. For examples of these, see Section 2.1.7. 
2.1.6 Luminescent Monometallic Au(I) Complexes and Fluorescence Bioimaging 
The development of organometallic Au(I) compounds has allowed investigations into 
luminescent complexes to be carried out, where photophysical properties are dictated 
by the nature of the coordinated ligand.6 There are no ligand field excited states 
available due to the 5d frontier orbitals being full. However, low energy metal centred 
transitions (5d-6s/6p at ca. 250 nm) are accessible.61 The ability of Au(I) to be both 
oxidising and reducing means LMCT transitions can also occur, most commonly with π-
acceptor ligands such as phosphines. In addition, coordinatively unsaturated Au(I) 
complexes are able to aggregate through metallophilic interactions, which perturbs 
excited states with ligand-centred and/or CT character, as well as introduce new excited 
states due to aurophilic interactions.6
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Figure 2.3: Example of luminescent Au(I) complex62
An example of this is provided by Castineiras et al., who generated supramolecular Au(I) 
architectures based on 2-pyridineformamide thiosemicarbazone ligands (Figure 2.3), 
resulting in a luminescent species whose absorption spectra were dominated by ligand 
centred n-π* transitions ca. 392 nm.62 Corresponding solid-state emission peaks were 
assigned to ligand-centred fluorescence in all cases, which were perturbed to different 
degrees by the presence of Au(I) and the presence of any weak Au…Au interactions. 
Related compounds with thiocarbamoyl-pyrazoline ligands also showed absorption at 
300-350 nm attributed to a LMCT transition (Figure 2.4).63 This series of cytotoxic 
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mercapto-pteridine ligands also show overlapping ligand-centred and S-to-Au LMCT 
transitions, as well as displaying visible luminescence assigned to the fluorophore. A 
simple heteroleptic species, [Au(PPh3)(C5H5N)]+, was first reported by Schmidbaur in 
2004.64 Following this, related species based on [Au(Py)2]+ (Py = 4-subsituted pyridine) 
showed solid-state luminescence properties which were highly dependant upon the 
nature of the intermolecular Au(I)…Au(I) interactions.65 In addition, naphthalimide based 
ligands have been studied and form a variety of complexes of the type [Au(PR3)(L)]+.66,67
The compounds showed metal-perturbed ligand-centred fluorescence in all cases, as 
suggested by literature precedent.  
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Figure 2.4:Example of luminescent Au(I) complex63
Due to the difficulties associated with understanding the biological action of Au(I) drugs, 
cellular imaging techniques have been commonly employed to elucidate the cellular 
uptake and intracellular distribution of Au(I) complexes.6 This is still a challenging area 
of research, and can be embodied into two strategies: i) the functionalisation of Au(I) 
compounds with fluorescent labels compatible with CFM; and ii) the use of analytical 
techniques that allow elemental isotopic composition to be mapped.  Unfortunately, the 
latter of the two is associated with destructive methods with low resolution, such as ICP-
MS and SR-XRF. An example of the former identifies alkyne-coordinated Au(I) complexes 
which selectively target TrxR.67 In addition, fluorescent alkynyl-functionalised 
anthraquinone ligands and their associated mono- and dimetallic Au(I) complexes have 
been applied to cellular imaging studies (Figure 2.5).68 In this research, CFM showed 
good cellular uptake in MCF cells for all complexes (> 80 %).  
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Figure 2.5: Examples of CFM images of MCF-7 cells. Cells incubated with  
anthraquinone species by Balasingham et al.68
The Ott group also presented linear Au(I) complexes incorporating an ancillary 
phosphine and a thiolated fluorophoric ligand of the form [Au(PR3)(S-Nap))] (S-Nap = 4-
mercapto-1,8-naphthalic anhydride or N-(N’,N’-dimethylaminoethyl)-1,8-
naphthalimide-4-sulfide).69 CFM of MCF-7 cells showed localisation in cell nuclei, with 
supporting cytotoxicity studies giving IC50 values of 1.1-3.7 μM, comparable with those 
of auranofin (1.1 μM) and cisplatin (2.0 μM). It is also noteworthy that the free 1,8-
naphthalimide ligands showed cytotoxicity, with IC50 values of 1.9-4.6 μM. 
Au(I) complexes incorporating NHCs have also been applied to cellular imaging studies. 
For examples of these, see Section 2.1.7.  
2.1.7 Au(I)-NHC Complexes 
As well as extensive investigation of Au(I) complexes incorporating phosphine and 
thiolate ligands, a variety of research has been carried out into complexes incorporating 
NHCs.70 Au(I)-NHCs have been known for over a quarter of a century, where initial 
synthetic methods used oxidative addition reactions. However, alternative methods 
were discovered after isolation by Burini et al. in 1989 (Figure 2.6).71 Over the past 
decade, the use of NHCs as ligands for Au(I) have developed rapidly, and applications 
have been found to include antimitochondrial, anti-tumour,72,73 antimicrobial,74  and 
catalytic activity.75
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Figure 2.6: Example of complex by Burini et al.71
There are several methods that have been adopted to synthesise Au(I)-NHC 
compounds:70 i) cleavage of electron rich olefins; ii) transfer of carbene from group 6 
carbonyl complexes; iii) reaction of azolium salts of NHCs with a Au(I) source; iv) 
protonation or alkylation of gold azolyl compounds; and v) transmetallation between 
Ag(I)-NHCs and Au(I) pre-cursors. For the last of these examples, [Au(tht)Cl] (tht = 
tetrahydrothiophene) has been commonly employed as a reagent in the 
transmetallation step.  
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Scheme 2.2:Synthesis and structure of complexes by Baker et al. showing anti-mitochondrial activity76
The biological activity of Au(I)-NHC complexes is an extremely important application, 
where pioneering research by the groups of Baker and Berners-Price have found NHCs 
to be a viable alternative to more common phosphine ligands.77,78 Steric control and 
electronic influences can be relatively easily controlled by tuning the nature of the 
precursor imidazolium salt. Lipophilicity of the complexes can also be controlled in this 
way, which is a significant consideration for biological applications. For example, NHC 
complexes have been shown to exhibit anti-tumour activity via TrxR inhibition,79 where 
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more focused studies have suggested that mitochondria are targeted. Similarly, 
homoleptic cationic Au(I) complexes of the nature [Au(NHC)2]+ have been investigated 
as anti-mitochondrial agents (Scheme 2.2).76 In this case, the lipophilicity was controlled 
by the alkyl group on the ligand, where the most lipophilic species gave rise to the 
greatest mitochondrial swelling and permeability. Fine-tuning of the ligand architecture 
was also applied in research by Hickley et al., who designed lipophilic, cationic Au(I)-NHC 
complexes that selectively induce apoptosis in cancer cells and show selective targeting 
of mitochondrial selenoproteins, such as TrxR.80 In addition, a complex of the form 
[Au(NHC)2]+ (NHC = bis-(N-methyl-N´(2-hydroxy-2-phenyl)ethyl)-imidazole-2-ylidine)) 
was found to be the most active anti-tumour compound in a range of Ag(I)- and Au(I)-
NHCs.81 In particular, the lipophilic, cationic compound exhibited lower IC50 values than 
its Ag(I) counterpart (1.0 and 2.6 μM on MCF-7 and ZR-75-1 breast cancer cells, 
respectively), thus suggesting the importance of gold for the increased anti-tumour 
activity. In the same study, it was found that the activity is attributed to the upregulation 
on p53 and p21WAF1/Cip1 expression, dependant on the transcription factor Sp1. In other 
research, Visbal et al. found that lung and pancreatic cancer cells were more sensitive 
to acridine-based Au(I)-NHC compounds than their analogous Ag(I) compounds, where 
apoptosis was found to be the main cell death pathway (Figure 2.7).82 Fluorescence cell 
microscopy found that complexes were mainly localised in the lysosomes and showed 
some nuclear and nucleolar staining. It is also noteworthy that the emission wavelengths 
of the compounds lay in the range of 470 to 530 nm.82,83
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Figure 2.7: Example of complex from Visbal et al.82
Bis-chelated bidentate phosphine and NHC Au(I) complexes have also been shown to 
selectively induce apoptosis in MDA-MB-468 human breast adenocarcinoma cells rather 
than in human normal breast cells.84 In this case, it was found that apoptosis was 
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induced via the mitochondrial pathway by inhibition of both Trx and TrxR. Another 
phosphine gold compound, μ-[1,2-bis(diphenylphosphino) ethane] bis[(1-thio-β-D-
glucopyranosato-S)gold(I)], displayed IC50 values between 4-11 μM towards a selection 
of cisplatin-sensitive cell lines,85 as well as similar cytotoxicity in cis-platin resistant cell 
lines.86
As discussed above, Au(I)-NHC complexes have also found use for cell imaging 
applications. An aforementioned range of dimetallic, water-soluble, cyclophane-bridged 
Au(I)-NHC complexes showed good uptake with RAW264.8 cells, with lysosomal 
localisation and mild toxicity (IC50 = 52 μM).76 In addition, fluorescent Au(I) complexes 
incorporating anthracenyl NHC ligands have been observed to lead to oxidation of the 
thioredoxin system, as well as enabling visualisation of cellular distribution due to the 
anthracene fluorophore.87 This specific example demonstrates that Au(I) complexes 
have dual opportunities to act as both cellular imaging and therapeutic agents. In related 
work, attachment of coumarin fluorophores to the NHC ligand framework of a series of 
Au(I) complexes showed TrxR inhibition, as well as nuclear compartment targeting 
studied by CFM.88
Figure 2.8: Example of Au(I)-NHC-naphthalimide complex showing antitumour activity89
Naphthalimide moieties have also been incorporated into Au(I)-NHC complexes to add 
an element of DNA binding, as they are well known to intercalate (Figure 2.8).89 In this 
case, cytotoxic activity in MCF-7 cells was observed, as well as strong effects on cell 
metabolism, including respiration, cell independence and extracellular acidification. It is 
worth noting that the photophysical properties include λmax = 252 and 345 nm in water 
48
(235 and 336 in DCM) from UV-vis measurements, and luminescence investigations 
found λem = 395 or 450 (365 and 282 in DCM). In addition, effective inhibition of TrxR 
was confirmed as the most probable factor for cytotoxicity. The addition of the Au(I)-
NHC partial structure resulted in enhanced interaction with DNA; therefore, it was 
concluded that the conjugation with naphthalimides may provide a method for design 
of bioorganic anti-cancer agents with multiple modes of action. In this vein, the 
combination of TrxR inhibition (redox-metabolism) with DNA intercalation (DNA-
metabolism) is of particular interest as both mechanisms are associated with cancer 
research but are not directly linked to one another. In broader terms, this research was 
extremely important due to the ability of naphthalimide groups to act as active drugs in 
their own right. The addition of an organometallic Au(I)-NHC, whose chemical biology 
has been studied intensively, could allow scientists to modify the properties of existing 
bioactive agents or work towards drug targeting. 
49
2.2 Aims 
Gold-based compounds have been successfully utilised for medicinal purposes.30–32
Most commonly, gold has been applied for the treatment of autoimmune conditions 
such as rheumatoid arthritis. However gold has also been utilised for anti-cancer 
applications.33,34 A detailed understanding of the mechanisms of biological action 
informs the rational design of new therapeutics, but unravelling the biological action of 
such species is challenging.36,37 One such technique involves the functionalisation of 
Au(I) complexes with fluorescent labels compatible with confocal fluorescence 
microscopy.   
This project aimed to develop the synthetic protocol of a range of NHC-functionalised 
naphthalimide ligands that are suitable for coordination to Au(I). Once synthesised, all 
ligands and complexes would be spectroscopically and analytically characterised. It was 
an aim to investigate the species in terms of their biocompatibility and cytotoxicity 
against MCF-7 cells. It was thought that the tunable nature of the naphthalimide moiety 
would give rise to excellent control over the physical and photophysical properties of 
the final compounds. Therefore, the broad aim was to develop a range of imaging agents 
with potential therapeutic action. 
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2.3 Results and Discussion 
2.3.1 Synthesis of Ligands and Complexes 
The ligands were synthesised in three steps from commercially available 4-chloro-
naphthalic anhydride (Scheme 2.3).90 Firstly, the R1 group, comprising ethoxyethanol, 
propyl, benzyl, octyl, methoxyethyl or glycine ethyl ester was added at the diimide 
position to give Cl1-6 respectively. In this step, ethanol was used as a solvent and the 
reagents were heated at reflux under nitrogen for 24 hours. In the case of Cl6, the amine 
was in the form of a hydrochloride salt; hence an excess of triethylamine was added in 
this reaction step. 
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Scheme 2.3: Synthesis of ligands and complexes. i) R1-NH2, EtOH, reflux, ii) R2-NHCH2CH2NH2, DMSO, 100 
°C, iii) NH4PF6, HC(OEt)3, 100 °C and iv) [AuCl(tht)], CH3OH, reflux  
 Secondly, Cl1-6 were then reacted with either N-ethylethylenediamine or N-
phenylethylenediamine in DMSO to give the proligands Pro1-10. In this step, R2 (ethyl or 
phenyl) was introduced via an SNAr mechanism.91 During this step, any unreacted 
amines were washed away with water. In the case where R2 is an ethyl substituent, it is 
noteworthy that preferential reaction at the less hindered primary amine was observed 
in all but one case (see Section 2.3.2), to give the desired products in good yields. 
51
Subsequent ring closure using triethylorthoformate (both as reagent and solvent) in the 
presence of ammonium hexafluorophosphate yielded the cationic dihydroimidazolium 
based ligands L1-10 as their hexafluorophosphate salts, which were all shown to be 
soluble in acetone. During this step excess triethylorthoformate, as well as any soluble 
intermediates, were removed using diethyl ether and subsequent drying in vacuo. It is 
worth noting that during the course of this work, a literature report showed that 
imidazole can react with a 4-bromo-1,8-naphthalimide derivative to give an unsaturated 
system that can subsequently act as an NHC donor to Ir(III).92
The corresponding gold complexes were prepared using [AuCl(tht)] (tht = 
tetrahydrothiophene) as the Au(I) source and reacting with the dihydroimidazolium 
ligands in methanol, in the presence of a base, potassium tert-butoxide. Due to the light 
sensitivity of Au(I) compounds, tin foil was used to eliminate any light during the 
reaction. Intermediates and/or side products were removed by precipitation with the 
minimum of dichloromethane and diethyl ether. 
2.3.2 Further Attempted Syntheses 
An example was observed where preferential reaction at the less hindered amine to 
form the proligand did not occur. Instead, a mixture of products was formed upon the 
attempted SNAr addition of N-ethylethylenediamine, where R1 was a glycine ethyl ester. 
Despite a number of repeated attempts, the mixture was consistently observed and was 
attributed to two isomeric forms of the product, shown in Figure 2.9.  
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Figure 2.9:Mixture of products formed upon attempted SNAr 
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This was confirmed by the 1H NMR spectrum, which showed multiple additional peaks 
in the aromatic region, as well as two singlets corresponding to the protons adjacent to 
the imine nitrogen in glycine ethyl ester (Figure 2.10). Uniquely, this amine reactivity 
was only observed for the ethyl ester protected glycine ligand variant.  
Figure 2.10: 1H NMR spectrum for product mixture shown in Figure 2.9
Using ethylethylene diamine as a reagent for the second step in Scheme 2.3 was also 
unsuccessful when R1 was a methoxyethyl moiety. In this case, the spectroscopic 
characterisation, including 1H NMR and mass spectrometry, was unclear and 
inconclusive. In addition, [AuCl(L5)] could not be synthesised in sufficient quantities to 
allow unequivocal characterisation, despite several repeated attempts. It is currently 
unclear why this was the case and warrants further investigation.
2.3.3 Spectroscopic Characterisation 
Pro1-10 showed good solubility in a range of organic solvents, allowing characterisation 
in the solution state via 1H NMR spectroscopy. In all cases, 1H NMR spectra for Pro1-10
provided confirmation of substitution at the 4-position of the naphthalimide ring. In 
most cases a characteristic NH resonance was noted at ca. 6-6.5 ppm as a broad triplet, 
1.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.5
f1 (ppm)
-20
0
20
40
60
80
100
120
140
160
180
200
220
240
260
280
300
320
340
360
53
which was assigned to the naphthalimide bound amine. For example, the 1H NMR 
spectra of Pro3 is shown in Figure 2.11. In addition to the NH peak, two upfield triplets 
are observed associated with the presence of two terminal CH3 groups.  
Figure 2.11: 1H NMR spectrum of Pro3 
Upon cyclisation to form L1-10, the corresponding 1H NMR spectra show subtle changes 
in the chemical shifts of the dihydroimidazolium ethyl backbone; in most cases these 
were observed as two triplets at ca. 4.5-4.0 ppm. The NH resonance at 6.0-6.5 ppm had 
also disappeared, consistent with cyclisation. In addition, formation of L1-10 gives rise to 
an additional downfield singlet at 9-9.5 ppm corresponding to the carbene CH (Figure 
2.12), consistent with literature examples.93 Due to their charged nature as a PF6- salt, 
L1-10 all showed good solubility in acetone, allowing characterization in the solution state 
using 1H, 13C{1H}, HRMS, UV-vis and luminescence spectroscopy, as well as IR in the solid 
state. IR spectra of L1-10 showed ν(C=O) at ca. 1650 cm-1 and confirmed absorbances 
consistent with the formation of the salts with ν(PF6-) ca. 830 cm-1. 
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Figure 2.12: 1H NMR spectrum comparison of Pro3 (top) and L3 (bottom) 
In all cases, the proposed molecular formula for the target ligands was supported by 
HMRS (ES+), each showing the expected [M]+ peak, as well as [M + NH3]+ in the case of 
L10 (Figure 2.13). 
Figure 2.13: HRMS of L10
The gold complexes were also characterised by a range of spectroscopic and analytical 
techniques. 1H NMR spectra provided evidence of coordination to Au(I) through changes 
in the resonances associated with the coordinated NHC unit. For example, in [AuCl(L1)] 
the ethyl backbone of the NHC ligand resolves to give two doublet of doublets between 
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3.99-3.86 ppm. This implies a greater rigidity in the NHC backbone and represents an 
upfield shift relative to L1. In addition, the 1H NMR spectrum of each of the complexes 
displays the removal of the singlet at 9-9.5 ppm associated with the loss of the CH proton 
upon coordination to Au(I). 
In all cases, 13C{1H} NMR spectra revealed resonances that correlated with the presence 
of the different R1 and R2 groups. In addition, two carbonyl resonances (consistent with 
the unsymmetrical nature of the naphthalimide unit) ca. 162-165 ppm were observed 
together with a further downfield signal ca. 192-195 ppm. This latter observation was 
assigned to the coordinated carbene carbon and is thus diagnostic of the formation of 
the complex and consistent with the proposed coordination mode of these ligands with 
Au(I). An example of these observations is provided by [AuCl(L7)], shown in Figure 2.14. 
Figure 2.14: 13C{1H} NMR of [AuCl(L7)] 
HRMS data were obtained for the neutral gold complexes, often correlating with the 
formation of a cationic complex fragment through loss of a chloride ligand, or addition 
of a cationic moiety such as Na+ or NH4+. All spectra were consistent with retention of 
the Au-NHC unit. Similarly to the ligands, IR spectra were primarily obtained to confirm 
the presence of the ligand via ν(C=O) ca. 1600-1650 cm-1. 
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2.3.4 X-ray Crystallographic Structural Studies 
In addition to solution state characterisation, confirmation of the solid-state structures 
was provided through X-ray crystallographic studies on one ligand and one complex, L3
and [AuCl(L3)]. Crystals suitable for X-ray diffraction were obtained by room 
temperature vapour diffusion of diethyl ether into concentrated acetone (L3) or 
acetonitrile ([AuCl(L3)]) solutions. Data collection, refinement and structure solution was 
conducted by Dr Peter Horton at the UK National Crystallography Service, Southampton. 
Data collection parameters are shown in Table 2.1, together with supporting bond 
length and bond angle data in Table 2.2. The resultant structures of L3 and [AuCl(L3)] are 
shown in Figure 2.15. 
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Figure 2.15: Structural representation of L3  (top) and [AuCl(L3)] (bottom) 
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Sample L3 Sample [AuCl(L3)]
Empirical formula C20H22F6N3O2P Formula C20H21AuClN3O2
Formula weight 481.37 Dcalc./ g cm-3 1.924
Temperature 100(2) K μ/mm-1 7.659
Wavelength 0.71073 Å Formula Weight 567.81
Crystal system Monoclinic Colour light yellow
Space group P21/n Shape plate
Unit cell dimensions a = 15.6423(13) Å Size/mm3 0.150×0.080×0.020
b = 8.2135(6) Å T/K 100(2)
c = 16.7365(13) Å
α = 90° 
β = 104.089(9)° 
γ = 90°
Crystal System triclinic
Volume 2085.6(3) Å3 Space Group P-1
Z 4 a/Å 9.1088(4)
Density (calculated) 1.533 Mg / m3 b/Å 10.0395(5)
Absorption 
coefficient
0.208 mm−1 c/Å 12.2613(5)
F(000) 992 α/° 67.610(4)
Crystal Needle; Orange β/° 72.865(4)
Crystal size 0.110 × 0.020 × 0.010 
mm3
γ /° 76.132(4)
θ range for data 
collection
2.509 − 25.025° V/Å3 980.36(8)
Index ranges −18 ≤ h ≤ 18, −9 ≤ k ≤ 9, 
−19 ≤ l ≤ 19
Z 2
Reflections 
collected
16606 Z' 1
Independent 
reflections
3671 [Rint = 0.0750] Wavelength/Å 0.71075
Completeness to θ = 
25.025°
99.9 % Radiation type MoK
Absorption 
correction
Semi−empirical from 
equivalents
ϴmin/° 2.217
Max. and min. 
transmission
1.00000 and 0.75532 ϴmax/° 27.521
Refinement method Full-matrix least-squares 
on F2
Measured Refl. 4483
Data / restraints / 
parameters
3671 / 111 / 355 Independent Refl. 4483
Goodness-of-fit on 
F2
1.112 Reflections Used 4327
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Table 2.1: Data collection parameters for the X-ray structures
These structures revealed the anticipated formulations for the ligand and complex, and 
demonstrate retention of the NHC ethyl backbone, as well as the addition of a Au-Cl 
unit. As expected, the C-N bond lengths in the NHC are extended upon coordination to 
Au(I) (Table 2.2). In addition, C-N bond lengths in the NHC unit are shorter than those in 
the naphthalimide unit, and both are comparable to previous literature examples.10
Ligand Bond Length (Å) Complex Bond Length (Å)
N3-C16 1.295(7) N2-C1 1.366(11)
N2-C16 1.322(7) N1-C1 1.331(11)
C16-H16 0.9500 C1-Au 1.983 (8)
Au-Cl 2.299(2)
Table 2.2: Key bond lengths for L3
2.3.5 Photophysical Properties
The photophysical properties of L1-10 and [AuCl(L1-10)] were investigated via UV-vis., 
steady state luminescence, luminescence lifetimes and quantum yields, measured in 
aerated solutions of acetone in each case. The solution state absorption properties of 
the ligands are shown in Figure 2.16. The photophysical properties are summarised in 
Table 2.3. 
Final R indices [F2 > 
2σ(F2)]
R1 = 0.0931, wR2 = 
0.2376
Rint .
R indices (all data) R1 = 0.1327, wR2 = 
0.2586
Parameters 247
Largest diff. peak 
and hole
0.995 and −0.350 e Å−3 Restraints 222
Largest Peak 4.851
Deepest Hole -3.221
GooF 1.196
wR2 (all data) 0.1323
wR2 0.1315
R1 (all data) 0.0494
R1 0.0481
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Figure 2.16: A comparison of the absorption spectra for the ligands
Figure 2.17: UV-vis spectra of Au(I) complexes
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Compound λabsa / nm λemb / nm τobs / ns QY
L1 344, 426 504 7.3 (80%), 2.4 (20%) 4%
L2 342, 429 507 8.7 28%
L3 344, 426 502 9.1 4%
L4 344, 351, 432 503 7.2 4%
L5 344, 428 502 8.4 31%
L6 343, 435 504 8.8 17%
L7 344, 427 501 4.7 5%
L8 345, 433 503 9.0 (92%), 2.6 (8%) 12%
L9 344, 423 502 8.4 4%
L10 345, 432 505 7.8 (91%), 4.0 (9%) 3%
[AuCl(L1)] 344, 351, 436 507 7.8 (45%), 0.9 (55%) 2%
[AuCl(L2)] 349, 433 487 7.2 (78%), 2.8 (22%) 9%
[AuCl(L3)] 345, 351, 439 500 1.1 (76%), 0.2 (24%) 1%
[AuCl(L4)] 354, 352 504 6.9 (33%), 0.06 (67%) 1%
[AuCl(L6)] 343, 436 503 8.3 (82%), 2.6 (18%) 2%
[AuCl(L7)] 345, 351, 439 499 4.3 (9%), 1.0 (91%) 1%
[AuCl(L8)] 344, 351, 441 504 0.4 (21%), 0.01 (79%) 11%
[AuCl(L9)] 344, 350, 443 508 7.8 (89%), 0.6 (11%) 1%
[AuCl(L10)] 344, 351, 444 500 7.3 (68%), 0.1 (32% 1%
Table 2.3:Photophysical properties of ligands and complexes; a measurements obtained in aerated 10-5
M acetone solutions; b λex = 405 nm; c [Ru(bpy)3](PF6)2 as reference of 0.016 in aerated MeCN
The absorption spectra of the ligands were characterised by shorter wavelength peaks 
(<300 nm) which are assigned to π→π* transitions associated with the naphthalimide 
chromophore and phenyl substituents. Between 300-450 nm the spectra also revealed 
weaker features which are assigned to a combination of different n→π* transitions 
including an intramolecular charge transfer (ICT) that arises from the N donor to imide 
transition. It is notable that the wavelength position of the ICT band appears relatively 
insensitive, firstly to the nature of the imide (R1) substituent, and secondly, the R2 group 
on the dihydroimidazolium group. In the cases of L3, L4, L7 and L10, the ICT band is 
hypochromically shifted and almost diminished upon coordination to form the Au(I) 
complexes. A clear example of this is shown in Figure 2.18, which compares L4 with 
[AuCl(L4)]. When compared to other 4-amino-substituted 1,8-naphthalimides,94,95 the 
intensity of the ICT bands in these ligands is relatively diminished and hypsochromically 
shifted. This is attributed to the cationic nature of the dihydroimidazolium moiety, which 
may modulate the overall donor ability of the nitrogen atom at the 4-position of the 
naphthalimide. 
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Figure 2.18: Comparative absorption profiles of L4 and [AuCl(L4)] 
The absorption spectra of the complexes were dominated by the ligand-centred 
transitions highlighted above, with minor perturbations to the π→π* region of the 
spectra due to the coordination of the AuCl unit. However, in the cases of [AuCl(L3)], 
[AuCl(L4)], [AuCl(L7)] and [AuCl(L10)], the ICT band is hypochromically shifted, as 
previously mentioned.  
Luminescence spectra were also obtained on all ligands and complexes using aerated 
acetone solutions (Table 2.3). Using an excitation wavelength of 405 nm the ligands 
revealed a broad emission peak ranging from 501 to 507 nm, as well as a shoulder at 
420-470 nm (Figure 2.19), which is in most cases associated with the presence of a 
phenyl substituent at R2. A wavelength of 405 nm was chosen due to its compatibility 
with both microscopy instruments and the ICT emitting state. Upon coordination, it can 
be seen that the intensity of the lower wavelength peak has increased in the majority of 
cases (Figure 2.20). This is in agreement with the observed lifetime values, which suggest 
two emitting states due to their data best fitting a double exponential algorithm for each 
of the complexes. In the case of [AuCl(L7)], the aforementioned peak is of a higher 
intensity than that at 499 nm. In addition, the broad emission peak is relatively 
unaffected by coordination, and ranges from 499 to 508 nm for the complexes, in 
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agreement with previous reports.82 However, in the case of [AuCl(L2)], the peak is
hypsochromically shifted upon coordination to 487 nm.  
Figure 2.19: Emission spectra of the ligands
Figure 2.20: Emission spectra of the complexes
The aerated, solution state quantum yields were also obtained together with the 
luminescence lifetimes (Table 2.3). Luminescence lifetimes ranged from 4.7 to 9.0 ns for 
the ligands, and 0.1 to 8.3 ns for the complexes; all are indicative of fluorescence. The 
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lifetime data for the ligands best fit a single exponential decay, thus indicating single 
component emission, except for in the cases of L1, L8 and L10. As previously mentioned, 
each of the complexes exhibits a dual component emission. Quantum yields ranged from 
4 to 31 % for the ligands and 1 to 11 % for the complexes, where both are generally 
consistent with previous examples.6,39
2.3.6 Cytotoxicity studies 
Cytotoxicity assessments, using the MTT assay, were obtained for both series of ligands 
and complexes (Table 2.4). Data were recorded for four cancer cell lines: LOVO, A549, 
PC3 and MCF7, the latter for correlation with imaging studies. 
Compound LOVO A549 PC3 MCF7
L1 30.07(3.19) 33.62(5.09) 56.40(3.08) 68.35(3.95)
L2 73.36(2.36) >100 98.1(3.91) 66.83(2.85)
L3 42.75(8.66) 56.83(4.06) 71.27(2.89) 61.21(3.02)
L4 51.81(5.34) 75.68(1.10) 72.82(3.03) 56.38(2.84)
L5 7.27(1.19) 47.10(0.55) 8.58(0.03) 7.12(0.36)
L6 >100 >100 >100 >100
L7 5.22(2.49) 53.95(1.41) 42.00(5.69) 9.98(4.77)
L8 >100 >100 >100 33.23(5.84)
L9 >100 91.02(3.70) 77.42(3.39) 58.86(6.42)
L10 >100 >100 >100 >100
[AuCl(L1)] 68.94(2.29) >100 >100 84.21(11.38)
[AuCl(L2)] 91.64(3.20) >100 >100 62.88(5.58)
[AuCl(L3)] >100 >100 >100 48.58(10.58)
[AuCl(L4)] 41.54(2.88) >100 >100 27.79(11.89)
[AuCl(L6)] 49.10(7.97) >100 >100 46.21(13.01)
[AuCl(L7)] 50.92(6.20) >100 46.63(0.71) 41.75(9.34)
[AuCl(L8)] 40.99(11.08) >100 >100 4.82(0.77)
[AuCl(L9)] 17.08(6.58) >100 >100 76.99(11.58)
[AuCl(L10)] 52.14(1.81) >100 >100 83.94(5.88)
Table 2.4: Cytotoxicity data for ligands and complexes with a variety of cell lines 
For the ligands, L6 and L10 were the least toxic with IC50 values >100 µM for each cell 
type. In contrast, closely related L5 was the most toxic with strong activity against LOVO, 
PC3 and MCF7s. From the pairs of ligands, it appeared that the ethyl variants (R1 = Et) 
were generally more toxic than the phenyl analogues. Most of the complexes were 
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inactive against A549 and PC3 cell lines and the data revealed a general trend where the 
majority of complexes were less toxic than their corresponding ligands for the LOVO, 
A549 and PC3 cell lines. An example of an exception to this observation is [AuCl(L9)], 
which showed significant potency against the LOVO cell line (IC50 = 17.08 µM). This 
general trend was not observed for the MCF7 cell line, where cytotoxicity was enhanced 
in comparison to the ligand in the cases of [AuCl(L2)], [AuCl(L3)], [AuCl(L4)], [AuCl(L6)], 
[AuCl(L8)] and [AuCl(L10)]. The most noteworthy example of this observation was that 
[AuCl(L8)], which showed significant and selective potency against MCF7 (IC50 = 4.82 
µM) which was comparable with cisplatin.5 In addition, within the series of complexes it 
was generally the phenyl variants (R1 = Ph) that demonstrated the greater 
antiproliferative activity for a given cell line. 
The MCF7 data were of most interest to us as this was the cell line to be used in the 
confocal fluorescence microscopy studies. One ligand/complex pairing was selected to 
allow comparison of their imaging potential. Thus, L3 and [AuCl(L3)] were chosen for 
imaging studies as they possessed intermediate lipophilicity and both showed only 
moderate toxicity to MCF7s.  
2.3.7 Bioimaging Studies  
Confocal fluorescence microscopy was performed using MCF7 cells. MCF-7 cells were 
grown on circular glass coverslips for 5-7 days in RPMI-1640 medium, supplemented 
with 5% foetal calf serum (heat inactivated) and 100 U/ml penicillin/streptomycin 
solution, until around 70-90% confluent. For experiments, culture medium was replaced 
with 1 ml fresh RPMI-1640 and cells were incubated with the following concentrations 
of commercially-derived (all from Molecular Probes) or in-house fluorescent 
compounds: 200 nM TMRE (stains mitochondria), 1:1000 dilution of LipidTOX red (stains 
lipid droplets),  1:5000 dilution of LysoTracker red (stains lysosomes), 5 uM of the Golgi 
Apparatus Marker, 1 uM of ERTracker red (stains endoplasmic reticulum) and 100 ug/ml 
of L3 and [AuCl(L3)]. All compounds were incubated for 30 minutes at 37 °C, then washed 
in warmed PBS before imaging. In all cases, an excitation wavelength of 405 nm was 
used together with dual detection wavelengths suitable for both the probe (L3 and 
[AuCl(L3)])  and the co-localisation agents.  
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Figure 2.21: Preliminary CFM images of L3 with MCF-7 cells 
For L3 uptake into the cells was very fast and very bright images were obtained (Figure 
2.21). For [AuCl(L3)], the speed of uptake was similar and images were less bright, yet 
satisfactory. In both cases, preliminary studies found that there were many areas of the 
cell that appeared to be stained: mitochondria; nuclear membranes; Golgi apparatus; 
endoplasmic reticulum and lysosomes. Co-localisation was observed to some extent 
with LysoTracker Red. However none was observed for the mitochondria. At this stage, 
further studies with alternate concentrations were carried out due to the non-distinct 
nature of the localisation. It is thought that lysosomal staining might indicate that cells 
were incubated with too much of the probes.
Figure 2.22: CFM images of L3 with MCF-7 cells; representative images of colocalisation studies with 
(from left to right) an ER stain, Golgi stain and lysosomal stain 
.  
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Figure 2.23:CFM images of [AuCl(L3)] with MCF-7 cells; representative images of colocalisation studies 
with (from left to right) an ER stain, Golgi stain and lysosomal stain 
In consecutive studies, more distinct localisation was observed for both the ligand and 
the complex at a 10 ng/ml concentration (1:10000 dilution when compared to initial 
studies). In this case, colocalisation with Lysotracker Red was exclusively confirmed, as 
can be seen in Figures 2.22 and 2.23. Lysosomes and their roles have been of interest in 
the context of cancer for decades.96 For example, one literature example showed 
lysosomal localisation of acridine-based Au(I) compounds that were seen to be cytotoxic 
towards lung and pancreatic cancer cells.82 In addition, studies have demonstrated that 
mammary gland cell death during involution (the natural degradation of mammary 
tissues after lactation ceases) involves lysosomal activity.97,98 Involution is a commonly 
used model of breast tissue cell death, a large area of research in breast cancer studies. 
These studies highlight lysosomes as an important target for breast cancer therapies 
that could induce cell death. Overall, the imaging studies presented clear evidence of 
the biocompatible utility of L3 and [AuCl(L3)] towards cell imaging using confocal 
fluorescence microscopy. 
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2.4 Conclusions 
This chapter has described the synthetic development and spectroscopic analysis of a 
series of NHC-functionalised 1,8-naphthalimide fluorophores, generating ten new 
ligands that were successfully utilised for Au(I) coordination chemistry, with the 
exception of L5. Confirmation of the solid-state structures was provided through X-ray 
crystallographic studies on one ligand and one complex, L3 and [AuCl(L3)], where an 
expected linear coordination mode was observed in the latter case. The optical 
properties of the fluorophores were dictated by ligand-centred transitions that provide 
visible absorption and emission characteristics, the latter associated with lifetimes up to 
ca. 9 ns and quantum yields between 1 and 31%.  Cytotoxicity assessments revealed that 
all compounds were the most toxic to LOVO and MCF-7 cell lines, where the majority of 
cases for MCF-7 cells showed the complexes had enhanced cytotoxicity when compared 
to the corresponding ligands. A noteworthy example of this was for [AuCl(L8)], whose 
IC50 value was comparable to that of cisplatin (IC50 = 4.8 and 5.3 μM, respectively). 
Cellular imaging studies were conducted on MCF-7 cells for one pair of fluorophores, L3
and [AuCl(L3)]. Both showed good uptake and bright staining. However preliminary 
studies showed that localisation was not specific to a particular group of organelles. 
Upon a reduction in concentration of the ligand and complex, lysosomal colocalisation 
was confirmed in both cases via the use of LysoTracker Red. As lysosomes have been 
shown to be an important target for breast cancer therapies that could induce cell death, 
the observed colocalistion is of particular significance in cancer research.  
The photophysical properties of 1,8-naphthalimides are further explored in Chapter 5, 
where they are designed for an electrochemical biosensing application.
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2.5 Experimental  
2.5.1 General Experimental Considerations 
All reagents and solvents were commercially available and were used without further 
purification if not stated otherwise. Petroleum ether refers to the 40-60 °C fraction. For 
the measurement of 1H and 13C NMR spectra a Bruker Fourier300 (250, 300 MHz), 
400 UltraShieldTM (400 MHz) or AscendTM500 (500 MHz) was used. The obtained 
chemical shifts δ are reported in ppm and are referenced to the residual solvent signal. 
Spin-spin coupling constants J are given in Hz.   
Low-resolution mass spectra were obtained by the staff at Cardiff University. High-
resolution mass spectra were carried out at the EPSRC National Mass Spectrometry 
Facility at Swansea University. High resolution mass spectral (HRMS) data were obtained 
on a Waters MALDI-TOF mx at Cardiff University or on a Thermo Scientific LTQ Orbitrap 
XL by the EPSRC UK National Mass Spectrometry Facility at Swansea University. IR 
spectra were obtained from a Shimadzu IR-Affinity-1S FTIR. UV-Vis studies were 
performed on a Jasco V-570 spectrophotometer as acetone solutions (2.5 or 5 × 10-5 M). 
Photophysical data were obtained on a JobinYvon–Horiba Fluorolog spectrometer fitted 
with a JY TBX picosecond photodetection module as acetone solutions. Emission spectra 
were uncorrected and excitation spectra were instrument corrected. The pulsed source 
was a Nano-LED configured for 459 nm output operating at 1 MHz. Luminescence 
lifetime profiles were obtained using the JobinYvon–Horiba FluoroHub single photon 
counting module and the data fits yielded the lifetime values using the provided DAS6 
deconvolution software. Quantum yield measurements were obtained on aerated 
acetone solutions of the complexes using [Ru(bpy)3](PF6)2 in aerated MeCN as a 
standard (Φ = 0.016). [23]
2.5.2 X-ray Diffraction  
For both samples, Single plate-shaped crystals were recrystallised from ether. A suitable 
crystal was selected and mounted on a MITIGEN holder in perfluoroether oil on a Rigaku 
FRE+ equipped with VHF Varimax confocal mirrors and an AFC12 goniometer and HyPix 
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6000 detector diffractometer. The crystal was kept at T = 100(2) K during data collection. 
Using Olex2,99 the structure was solved with the ShelXT100 structure solution program, 
using the Intrinsic Phasing solution method. The model was refined with version 2014/7 
of ShelXL101 using Least Squares minimisation. All non-hydrogen atoms were refined 
anisotropically. Hydrogen atom positions were calculated geometrically and refined 
using the riding model. 
2.5.3 Ligand Synthesis 
Ethoxyethanol 
Synthesis of Cl1 94
4-chloro-1,8-naphthalic anhydride (2.5 g, 10.8 mmol) and 2-(2-aminoethoxy)ethanol 
(2.15 ml, 21.6 mmol) were heated at reflux in EtOH for 24 hours under a nitrogen 
atmosphere. The solution was cooled to room temperature at stored at -20 °C for 24 
hours. The resulting precipitate was filtered to yield Cl1 as an orange solid. 1H NMR (400 
MHz, CDCl3) δH 8.61 (d, 1H, 3JHH = 7.3 Hz), 8.55 (d, 1H, 3JHH = 8.5 Hz), 8.45 (d, 1H, 3JHH = 
7.9 Hz), 7.81 (d, 1H, 3JHH = 7.9 Hz), 7.76 (d, 1H, 3JHH =7.9 Hz), 4.48 (t, 2H, 3JHH = 5.6 Hz), 
3.79 (t, 2H, 3JHH = 5.6 Hz), 3.66-3.58 (m, 4H) ppm. IR (solid. Vmax)/cm-1: 3455, 2869, 1700, 
1651, 1588, 1574, 1505, 1370, 1341, 1235, 1119, 104, 1022, 558, 855, 780, 750, 729, 
667. HRMS ES- found m/z 320.0687, calculated m/z 320.0684 for [C16H14ClNO4H]+.
Synthesis of Pro1
Cl1 (502 mg, 1.6 mmol) and N-ethylethylenediamine (0.64 ml, 6.3 mmol) were heated 
for 48 hours at 100 °C in DMSO under a nitrogen atmosphere. The solution was cooled 
and water (15 ml) added. The solution was neutralised using 1 M HCl and then extracted 
into DCM. The organic phase was washed with water, dried over MgSO4, and the solvent 
removed to yield Pro1 as an orange solid (yield: 125 mg, 22%). 1H NMR (400 MHz, CDCl3): 
δH 8.51 (d, 1H, 3JHH = 7.2 Hz), 8.30 (d, 1H, 3JHH = 8.4 Hz), 8.09 (d, 1H, 3JHH = 8.5 Hz), 7.48 
(app. t, 1H, 3JHH = 7.7 Hz), 6.51 (d, 1H, 3JHH = 8.4 Hz), 6.35 (br. t, 1H), 4.36 (t, 2H, 3JHH = 5.2 
Hz), 3.81 (t, 2H, 3JHH = 8.1 Hz), 3.70-3.60 (m, 4H), 3.35 (t, 2H, 3JHH = 5.8 Hz), 3.02 (t, 2H, 
3JHH = 5.8 Hz), 2.69 (q, 2H, 3JHH = 7.1 Hz), 1.13 (t, 3H, 3JHH = 7.1 Hz). HRMS found m/z
372.1919, calcd m/z 372.1918 for [C20H26N3O4]+. 
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Synthesis of L1
Pro1 (100 mg, 0.27 mmol) and NH4PF6 (49 mg, 0.30 mmol) were heated at 100 °C in 
HC(OEt)3 for 3 hrs under a nitrogen atmosphere. The solution was cooled and the solvent 
decanted to leave an orange coloured oil. Et2O (2 x 10 ml) was then added and slowly 
decanted and the remaining oil dried in vacuo to yield L1 as an orange oil (77 mg, 54%). 
1H NMR (300 MHz, (CD3)2CO): δH 8.97 (s, 1H), 8.59 (dd, 1H, JHH = 8.5, 3.4 Hz), 8.55 – 8.46 
(m, 2H), 8.00 (dd, 1H, JHH = 7.5, 2.3 Hz), 7.95 – 7.86 (m, 1H), 4.80 (t, 2H, 3JHH = 9.9 Hz), 
4.50 (t, 2H, 3JHH = 10.5 Hz), 4.24 (t, 2H, 3JHH = 6.2 Hz), 3.90 (q, 2H, 3JHH = 7.3 Hz), 3.73 – 
3.66 (m, 2H), 3.58 – 3.52 (m, 2H), 2.03 – 1.99 (m, 2H), 1.47 (t, 3H, 3JHH = 7.3 Hz). 13C{1H} 
NMR (101 MHz, (CD3)2CO): δC 158.15, 138.59, 131.65, 130.78, 128.74, 128.43, 127.07, 
124.09, 123.39, 72.43, 70.15, 69.62, 67.34, 61.06, 53.04, 49.31, 44.12, 39.24, 39.12, 
14.61, 12.00. UV/Vis ((CH3)2CO): λmax / nm (ε / M-1cm-1) = 426 (4960), 344 (10920). HRMS 
found m/z 382.1752, calcd m/z 382.1761 for [C21H24N3O4]+. IR (solid) ν / cm-1: 2978, 
2947, 2875, 1697, 1651, 1581, 1503, 1462, 1450, 1346, 1157, 1123, 1090, 1057, 825, 
783, 754, 739, 556, 422, 405, 392. 
Synthesis of Pro2
As for Pro1, but using Cl1 (502 mg, 1.6 mmol) and N-phenylethylenediamine (0.82 ml, 6.2 
mmol). The product Pro2 was isolated as a yellow solid (yield: 260 mg, 66 %). 1H NMR 
(400 MHz, CDCl3): δH 8.37 (d, 1H, 3JHH = 7.3 Hz), 8.28 (d, 1H, 3JHH = 8.7 Hz), 8.09 (d, 1H, 
3JHH = 8.3 Hz), 7.44 (app. t, 1H, 3JHH = 7.4 Hz), 7.30 (t, 2H, 3JHH = 7.6 Hz), 7.01 – 6.93 (m, 
2H), 6.54 (d, 1H, 3JHH = 8.3 Hz), 6.11 (s, 1H), 4.38 (t, 2H, 3JHH = 4.9 Hz), 3.87 (t, 2H, 3JHH = 
4.7 Hz), 3.77 – 3.62 (overlapping m, 8H). 
Synthesis of L2
As for L1, but using Pro2 (198 mg, 0.47 mmol) and NH4PF6 (82 mg, 0.52 mmol). The 
product L2 was yielded as a yellow powder (yield: 129 mg, 64 %). 1H NMR (400 MHz, 
(CD3)2CO): δH 9.85 (s, 1H), 8.85 (d, 1H, 3JHH = 8.5 Hz), 8.77 – 8.62 (m, 2H), 8.30 (d, 1H, 3JHH
= 7.8 Hz), 8.06 (dd, 1H, JHH = 15.5, 7.9 Hz), 7.72 (d, 2H, 3JHH = 7.7 Hz), 7.63 (d, 2H, 3JHH = 
7.5 Hz), 7.56 – 7.43 (m, 1H), 5.23 – 4.98 (m, 4H), 4.37 (t, 2H, 3JHH = 6.2 Hz), 3.89 – 3.71 
(overlapping m, 6H). 13C{1H} NMR (101 MHz, (CD3)2CO): δC 164.16, 163.68, 157.17, 
138.78, 137.02, 132.68, 131.59, 130.92, 130.54, 129.88, 129.68, 129.57, 128.87, 128.02, 
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125.92, 124.93, 124.27, 119.78, 73.32, 71.03, 68.20, 61.92, 54.57, 50.84, 40.16. UV/Vis 
((CH3)2CO): λmax / nm (ε / M-1cm-1) 429 (1000), 342 (9700). HRMS ES- found m/z 430.1756, 
calcd m/z 430.1761 for [C25H24N3O4]+. IR (solid) ν / cm-1: 3010, 2932, 2810, 1699, 1654, 
1626, 1581, 1492, 1379, 1348, 1269, 1234, 1142, 1128, 1097, 1057, 829, 785, 754, 736, 
689, 556, 410. 
Propyl  
Synthesis of Cl2
4-Chloro-1,8-naphthalic anhydride (3 g, 12.9 mmol) and propylamine (1.9 ml, 25.8 
mmol) were heated at reflux in EtOH for 24 hours under a nitrogen atmosphere. The 
solution was cooled to room temperature and stored at -20 °C for 24 hours. The resulting 
precipitate was filtered to yield Cl2 as a bright yellow solid (2.74 g, 78 %). 1H NMR (400 
MHz, CDCl3): δH 8.59 (d, 1H, 3JHH = 7.3 Hz), 8.53 (d, 1H, 3JHH = 8.5 Hz), 8.42 (d, 1H, 3JHH = 
7.9 Hz), 7.82-7.73 (m, 2H), 4.08 (t, 2H, 3JHH = 7.6 Hz), 1.70 (app. sext., 2H, 3JHH = 7.5 Hz), 
0.95 (t, 3H, 3JHH = 7.4 Hz) ppm.  
Synthesis of Pro3
As for Pro1, but using Cl2 (491 mg, 1.8 mmol) and N-ethylethylenediamine (0.76 ml, 7.2 
mmol). The product was obtained as an orange solid Pro3 (573 mg, 98 %). 1H NMR (500 
MHz, CDCl3): δH 8.51 (d, 1H, 3JHH = 7.3 Hz), 8.38 (d, 1H, 3JHH = 8.4 Hz), 8.14 (d, 1H, 3JHH = 
8.4 Hz), 7.55 (app. t, 1H, 3JHH = 8.2 Hz), 6.61 (d, 1H, 3JHH = 8.4 Hz), 6.29 (br. t, 1H), 4.08 – 
4.03 (m, 2H), 3.41 – 3.36 (m, 2H), 3.06 – 3.01 (m, 2H), 2.69 (q, 2H, 3JHH =  7.1 Hz), 1.69 (q, 
2H, 3JHH = 7.5 Hz), 1.12 (t, 3H, 3JHH = 5.1 Hz), 0.94 (t, 3H, 3JHH = 7.4 Hz) ppm. HRMS found 
m/z 326.1866, calcd m/z 326.1863 for [C29H24N3O2]+. 
Synthesis of L3
As for L1, but using Pro3 (346 mg, 1.1 mmol) and NH4PF6 (190 mg, 1.2 mmol). The product 
L3 was obtained as an orange oil (254 mg, 50 %). 1H NMR (400 MHz, (CD3)2CO): δH 8.94 
(s, 1H), 8.58-8.47 (m, 3H), 7.97 (d, 1H, 3JHH = 7.8 Hz) 7.88 (app. t, 1H, 3JHH = 7.9 Hz), 4.65 
(t, 2H, 3JHH = 10.0 Hz), 4.45 (t, 2H, 3JHH = 11.1 Hz), 3.82 (q, 2H, 3JHH = 7.3 Hz), 1.66-1.52 (m, 
2H), 1.07-0.96 (m, 3H), 0.85 (t, 3H, 3JHH = 7.5 Hz) ppm. 13C{1H} NMR (101 MHz, (CD3)2CO): 
δC 164.03, 163.54, 158.98, 139.33, 132.40, 131.53, 129.79, 129.56, 129.29, 127.90, 
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125.02, 124.20, 124.17, 53.90, 50.14, 44.96, 42.42, 21.91, 12.85, 11.69. UV/Vis 
((CH3)2CO): λmax / nm (ε / M-1cm-1) = 426 (2520), 344 (11980). HRMS found m/z 336.1709, 
calcd m/z 336.1707 for [C20H22N3O2]+. IR (solid) ν / cm-1: 3381, 3089, 2968, 1697, 1651, 
1591, 1514, 1443, 1429, 1408, 1389, 1350, 1269, 1234, 1201, 1155, 1086, 1069, 962, 
891, 876, 825, 789, 760, 738, 556, 463, 434, 409. 
Synthesis of Pro4
As for Pro1, but using Cl2 (767 mg, 2.8 mmol) and N-phenylethylenediamine (1.5 ml, 11.2 
mmol). The product Pro4 was yielded as an orange solid (yield: 1.00 g, 97 %). 1H NMR 
(400 MHz, (CD3)2CO): δH 8.42 (d, 1H, 3JHH =  8.5 Hz), 8.35 (d, 1H, 3JHH =  7.2 Hz), 8.21 (d, 
1H, 3JHH =  8.5 Hz), 7.52 (app. t, 1H, 3JHH =  8.2 Hz), 6.98 (app. t, 2H, 3JHH =  8.2 Hz), 6.76 
(d, 1H, 3JHH =  8.5 Hz), 6.58 (d, 2H, 3JHH =  8.0 Hz), 6.48 (br. t, 1H), 5.15 (br. t, 1H, NH), 3.93 
(t, 2H, 3JHH =  7.5 Hz), 3.62 (t, 2H, 3JHH =  5.8 Hz), 3.47 (t, 2H, 3JHH =  6.0 Hz), 1.58 (q, 2H, 
3JHH =  7.5 Hz), 0.81 (t, 3H, 3JHH =  7.5 Hz).  
Synthesis of L4
As for L1, but using Pro4 (750 mg, 2.0 mmol) and NH4PF6 (360 mg, 2.2 mmol). The product 
L4 was obtained as a yellow solid (yield: 860 mg, 81 %). 1H NMR (400 MHz, (CD3)2CO): δH 
9.87 (s, 1H), 8.86 (d, 2H, 3JHH = 8.5 Hz), 8.71 (overlapping d, 2H), 8.31 (d, 1H, 3JHH = 7.8 
Hz), 8.06 (app. t, 1H, 3JHH = 7.9 Hz), 7.73 (d, 2H, 3JHH = 7.6 Hz), 7.62 (app. t, 2H, 3JHH = 7.5 
Hz), 7.50 (app. t, 1H, 3JHH = 7.4 Hz), 5.17-5.08 (m, 4H), 4.12 (t, 2H, 3JHH = 7.5 Hz), 1.78 (q, 
2H, 3JHH = 7.5 Hz), 1.00 (t, 3H, 3JHH = 7.4 Hz) ppm. 13C{1H} NMR (101 MHz, (CD3)2CO): δC
164.07, 163.58, 157.18, 138.69, 137.04, 132.60, 131.48, 130.94, 130.78, 129.91, 129.55, 
128.89, 128.04, 125.94, 125.11, 124.42, 119.80, 119.59, 119.27, 54.60, 50.86, 42.51, 
21.95, 11.70. UV/Vis ((CH3)2CO): λmax / nm (ε / M-1cm-1) = 432 (620), 351 (14320), 344 
(0.599). HRMS found m/z 384.1700, calcd m/z 384.1707 for [C24H22N3O2]+. IR (solid) ν / 
cm-1: 2974, 1699, 1651, 1626, 1585, 1494, 1391, 1364, 1350, 1271, 1236, 1072, 8423, 
829, 787, 758, 689, 557, 469, 434. 
Benzyl 
Synthesis of Cl3
74
4-Chloro-1-8-naphthalic anhydride (1.00 g, 4.3 mmol) and benzylamine (1 ml, 9.2 mmol) 
were heated at reflux in EtOH for 24 hours under a nitrogen atmosphere. The solution 
was cooled to room temperature and stored at -20 °C for 24 hours. The resulting 
precipitate was filtered to yield Cl3 as a bright yellow solid (1.2 g 88.0 %). 1H NMR (500 
MHz, CDCl3): δH 8.61 (d, 1H, 3JHH = 7.3 Hz), 8.53 (d, 1H, 3JHH = 8.5 Hz), 8.45 (d, 1H, 3JHH = 
7.8 Hz), 7.77 (dd, 2H, JHH = 17.4, 8.2 Hz), 7.49 (d, 2H, 3JHH = 7.6 Hz), 7.26 (app. t, 1H, 3JHH
= 7.4 Hz), 7.23 – 7.16 (m, 2H), 5.32 (s, 2H).
Synthesis of Pro5 
As for Pro1, but using Cl3 (500 mg, 1.6 mmol) and N-ethylethylenediamine (0.65 ml, 6.2 
mmol). The product Pro5 was obtained as an orange solid (574 mg, 94 %). 1H NMR (300 
MHz, CDCl3) δ 8.41 (d, 1H, J = 7.3 Hz), 8.29 (d, 1H, J = 8.4 Hz), 7.97 (d, 1H, J = 8.3 Hz), 7.52 
– 7.37 (m, 3H), 7.25 – 7.10 (m, 3H), 6.48 (d, 1H, J = 8.4 Hz), 6.25 (br. t, 1H), 5.28 (s, 2H), 
3.27 (dd, 2H, J = 10.3, 5.0 Hz), 2.97 (t, 2H, J = 5.7 Hz), 2.65 (q, 2H, J = 7.1 Hz), 1.09 (t, 3H, 
J = 7.1 Hz).
Synthesis of L5 
As for L1, but using Pro5 (LG361) (389 mg, 1.0 mmol) and ammonium 
hexafluorophosphate (187 mg, 1.15 mmol). The product L5 was obtained as an orange 
oil (371 mg, 67%). 1H NMR (300 MHz, Acetone) δ 9.00 (s, 1H), 8.63 (d, 1H, J = 8.5 Hz), 
8.54 (overlapping d. 2H), 8.01 (d, 1H, J = 7.8 Hz), 7.94 (t, 1H, J = 7.9 Hz), 7.44 (d, 2H, J = 
7.3 Hz), 7.33 – 7.20 (m, 3H), 5.25 (s, 2H), 4.82 (t, 2H, J = 10.4 Hz), 4.53 (t, 2H, J = 10.5 Hz), 
3.94 (q, 2H, J = 7.2 Hz), 1.52 (t, 3H, J = 7.4 Hz). 13C{1H} NMR (126 MHz, (CD3)2CO): δC
163.26, 162.75, 158.03, 138.67, 137.52, 131.84, 130.96, 128.95, 128.49, 128.31, 128.23, 
127.24, 127.03, 124.11, 123.14, 123.07, 53.00, 49.27, 44.12, 43.23, 35.19, 23.58, 20.56, 
11.97. UV/Vis ((CH3)2CO): λmax / nm (ε / M-1cm-1): 428 (3700), 344 (14560). HRMS found 
m/z 384.1718, calcd m/z 384.1712 for [C24H22N3O2]+. IR (solid) ν / cm-1: 2372, 2341, 1699, 
1651, 1582, 1549, 1497, 1454, 1423, 1381, 1346, 1290, 1234, 1182, 1155, 1072, 1028, 
970, 876, 827, 783, 754, 734, 702, 665, 613, 583, 556, 469, 407. 
Synthesis of Pro6
As for Pro1, but using Cl3 NS103 (513 mg, mmol) and N-phenylethylenediamine (0.83ml, 
mmol) were heated in DMSO (6 ml) at reflux under nitrogen for 48 hours. The product 
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was cooled giving an orange precipitate. Water (6 ml) was added to form yellow 
precipitate. The reaction solution was neutralised with hydrochloric acid (3 ml, 0.1 M) 
and filtered to give a yellow product. Product re-precipitated using dichloromethane 
and Et2O and filtered to give yellow product Pro6 (yield: 551 mg, 87 %). 1H NMR (400 
MHz, CDCl3): δH 8.51 (d, 1H, 3JHH = 6.6 Hz), 8.41 (d, 1H, 3JHH = 8.3 Hz), 7.88 (d, 1H, 3JHH = 
8.3 Hz), 7.56 (d, 2H, 3JHH = 7.1 Hz), 7.54 – 7.48 (m, 1H), 7.30 (app. t, 2H, 3JHH = 7.3 Hz), 
7.23 (d, 3H, 3JHH = 7.4 Hz), 6.81 (app. t, 1H, 3JHH = 7.4 Hz), 6.76 (d, 2H, 3JHH = 7.6 Hz), 6.66 
(d, 1H, 3JHH = 8.4 Hz), 5.57 (br. t, 1H), 5.35 (s, 2H), 3.61 (overlapping s, 4H).
Synthesis of L6
As for L1, but using Pro6 (346 mg, 0.87 mmol) and NH4PF6 (156 mg, 0.97 mmol). The 
product L6 was obtained as a yellow powder (yield: 322 mg, 85 %). 1H NMR (400 MHz, 
(CD3)2CO): δH 9.87 (s, 1H), 8.86 (d, 1H, 3JHH = 8.5 Hz), 8.74 – 8.68 (m, 2H), 8.30 (d, 1H, 3JHH
= 7.6 Hz), 8.06 (app. t, 1H, 3JHH =  7.7 Hz), 7.72 (d, 2H, 3JHH = 8.4 Hz), 7.62 (app. t, 2H, 3JHH
= 8.2 Hz), 7.48 (d, 3H, 3JHH = 6.7 Hz), 7.36 – 7.24 (m, 3H), 5.35 (s, 2H), 5.15 – 5.09 (m, 4H). 
13C{1H} NMR (101 MHz, (CD3)2CO): δC 164.16, 163.67, 157.20, 138.91, 138.41, 137.02, 
132.89, 131.78, 130.94, 130.15, 129.96, 129.82, 129.62, 129.22, 129.16, 128.90, 128.17, 
128.07, 125.94, 125.18, 124.95, 124.29, 119.77, 54.59, 50.85, 44.18. UV/Vis ((CH3)2CO): 
λmax / nm (ε / M-1cm-1)  435 (400), 343 (5700). HRMS found m/z 432.1701, calcd m/z
432.1707 for [C28H22N3O2]+. IR (solid) ν / cm-1: 1699, 1655, 1637, 1589, 1495, 1452, 1387, 
1350, 1337, 1290, 1277, 1232, 1182, 959, 881, 839, 825, 791, 756, 748, 700, 689, 557, 
472. 
Octanyl 
Synthesis of Cl4
4-Chloro-1,8-naphthalic anhydride (3 g, 12.9 mmol) and octylamine (4.26 ml, 25.8 mmol) 
were heated at reflux in EtOH for 24 hours under a nitrogen atmosphere. The solution 
was cooled to room temperature and stored at -20 °C for 24 hours and the resulting 
precipitate filtered.  The crude product was dissolved in DCM (30 ml) and washed with 
0.1 M HCl (30 ml), followed by H2O (30 ml) and brine (30 ml). The collected organic phase 
was dried over MgSO4, and the solvent removed to yield Cl4 as a yellow solid (3.78 g, 85 
%). 1H NMR (400 MHz, CDCl3): δH 8.60 (d, 1H, 3JHH = 7.3 Hz), 8.53 (d, 1H, 3JHH = 8.5 Hz), 
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8.45 (d, 1H, 3JHH = 7.9 Hz), 7.82-7.75 (m, 2H), 4.11-4.05 (m, 2H), 1.69-1.50 (m, 2H), 1.47-
1.12 (overlapping m, 10H), 0.80 (t, 3H, 3JHH = 6.7 Hz).
Synthesis of Pro7
As for Pro1, but using Cl4 (600 mg, 1.7 mmol) and N-ethylethylenediamine (0.71 ml, 7.0 
mmol). The product was obtained Pro7 as an orange solid (582 mg, 84 %). 1H NMR (400 
MHz, CDCl3): δH 8.60 (d, 1H, 3JHH = 6.5 Hz), 8.37 (d, 1H, 3JHH = 8.4 Hz), 8.15 (d, 1H, 3JHH = 
8.2 Hz), 7.55 (app. t, 1H, 3JHH = 7.6 Hz), 6.59 (d, 1H, 3JHH = 8.4 Hz), 6.32 (br. t, 1H), 4.07 (t, 
2H, 3JHH = 7.6 Hz), 3.40 (q, 2H, 3JHH = 4.9 Hz), 3.05 (t, 2H, 3JHH = 5.4 Hz), 2.71 (q, 2H, 3JHH = 
7.1 Hz), 1.66 (m, 2H), 1.40-1.11 (overlapping m, 13H), 0.78 (t, 3H, 3JHH = 7.0 Hz). HRMS 
found m/z 396.2644, calcd m/z 396.2646 for [C24H34N3O2]+. 
Synthesis of L7
As for L1, but using Pro7 (476 mg, 1.2 mmol) and NH4PF6 (217 mg, 1.3 mmol). The product 
L7 was obtained as a yellow solid (496 mg, 74 %). 1H NMR (500 MHz, (CD3)2CO): δH 9.06 
(s, 1H), 8.69 – 8.58 (m, 3H), 8.08 (d, 1H, 3JHH = 7.8 Hz), 7.99 (dd, 1H, JHH = 8.5, 7.3 Hz), 
4.86 (t, 2H, 3JHH = 10.0 Hz), 4.57 (t, 2H, 3JHH = 11.0 Hz), 4.13 – 4.09 (m, 2H), 3.95 (q, 2H, 
3JHH = 7.2 Hz), 2.87 (d, 3H, 3JHH = 15.7 Hz), 1.70 (dt, 2H, 3JHH = 15.0, 7.5 Hz), 1.51 (t, 2H, 
3JHH = 7.3 Hz), 1.33 – 1.24 (m, 8H), 0.87 (t, 3H, 3JHH = 6.9 Hz) ppm. 13C{1H} NMR (101 MHz, 
(CD3)2CO): δH 163.95, 163.45, 158.88, 139.29, 132.38, 131.50, 129.72 (two overlapping 
environments), 129.53, 129.29, 127.86, 124.99, 124.13, 53.88, 50.13, 44.96, 40.90, 
32.51, 30.00, 29.91, 28.62, 27.75, 23.26, 14.33, 12.82. UV/Vis ((CH3)2CO): λmax / nm (ε / 
M-1cm-1) = 427 (1820), 344 (13620). HRMS found m/z 406.2482, calcd m/z 406.2489 for 
[C25H32N3O2]+. IR (solid) ν / cm-1: 2959, 2924, 2855, 1703, 1651, 1589, 1508, 1391, 1354, 
1254, 1232, 1155, 1093, 827, 785, 754, 555, 416. 
Synthesis of Pro8
As for Pro1, but using Cl4 (503 mg, 1.4 mmol) and N-phenylethylenediamine (0.76 ml, 5.8 
mmol. The product Pro8 was isolated as a yellow solid (yield: 601 mg, 65 %). 1H NMR 
(400 MHz, CDCl3): δH 8.55 (d, 1H, 3JHH = 6.6 Hz), 8.43 (d, 1H, 3JHH = 8.4 Hz), 8.03 (d, 1H, 
3JHH = 8.5 Hz), 7.61 – 7.55 (m, 1H), 7.25 – 7.19 (m, 2H), 6.83 (app. t, 1H, 3JHH = 7.4 Hz), 
6.78 (d, 2H, 3JHH = 8.5 Hz), 6.72 (d, 1H, 3JHH = 8.4 Hz), 5.70 (br. s, 1H), 4.17 – 4.09 (m, 2H), 
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3.65 (t, 4H, 3JHH = 4.3 Hz), 1.72 (dd, 2H, JHH = 15.2, 7.3 Hz), 1.46 – 1.20 (m, 10H), 0.86 (t, 
3H, 3JHH = 6.8 Hz). 
Synthesis of L8
As for L1, but using Pro8 (497 mg, 1.1 mmol) and NH4PF6 (200 mg, 1.2 mmol). The product 
L8 was obtained as a yellow solid (yield: 274 mg, 54 %). 1H NMR (400 MHz, (CD3)2CO): δH
9.85 (s, 1H), 8.84 (d, 1H, 3JHH = 8.6 Hz), 8.70 (dd, 2H, 3JHH = 7.6, 2.6 Hz), 8.29 (d, 1H, 3JHH
= 7.8 Hz), 8.08 – 8.03 (m, 1H), 7.72 (d, 2H, 3JHH = 7.7 Hz), 7.62 (app. t, 2H, 3JHH = 8.0 Hz), 
7.49 (app. t, 1H, 3JHH = 7.4 Hz), 5.18 – 5.07 (m, 4H), 4.14 (t, 2H, 3JHH = 7.2 Hz), 1.77 – 1.66 
(m, 2H), 1.45 – 1.24 (m, 10H), 0.87 (t, 3H, 3JHH = 6.9 Hz). 13C{1H} NMR (101 MHz, 
(CD3)2CO): δC 164.01, 163.52, 157.13, 138.68, 137.02, 132.58, 131.47, 130.91, 129.83, 
129.56, 128.86, 128.00, 125.92, 125.03, 124.35, 119.79, 54.56, 50.83, 40.98, 32.54, 
30.47, 30.28, 30.08, 29.94, 28.65, 27.77, 23.29, 14.34. UV/Vis ((CH3)2CO): λmax / nm (ε / 
M-1cm-1) 433 (200), 345 (7200). HRMS found m/z 454.2478, calcd m/z 454.2489 for 
[C29H32N3O2]+. IR (solid) ν / cm-1: 2922, 2850, 1708, 1697, 1653, 1536, 1589, 1492, 1390, 
1352, 1267, 1232, 1095, 831, 785, 754, 734, 686, 557, 464, 405.  
Methoxyethylamine  
Synthesis of Cl5 
4-chloro-1,8-naphthalic anhydride (2 g, 8.9 mmol) and 2-methoxyethylamine (1.53 ml, 
17.8 mmol) were heated at reflux in EtOH (40 ml) for 24 hours under a nitrogen 
atmosphere. The solution was cooled and the product precipitated and filtered to yield 
Cl5 as a yellow solid. 1H NMR (400 MHz, CDCl3) δH 8.61 (d, 1H, 3JHH = 7.3 Hz), 8.55 (d, 1H, 
3JHH = 8.5 Hz), 8.46 (d, 1H, 3JHH = 7.9 Hz) 7.82-7.74 (m, 2H), 4.39 (t, 2H, 3JHH = 5.8 Hz), 3.68 
(t, 2H, 3JHH = 5.8 Hz), 3.32 (s, 3H) ppm.  HRMS found m/z 290.0579, calculated m/z
290.0578 for [C15H12ClNO3 + H]+.
Synthesis of Pro9 
As for Pro1, but using Cl5 (754 mg, 2.6 mmol) and N-phenylethylenediamine (1.36 ml, 
10.4 mmol). The product Pro9  was yielded as a light orange solid (776 mg, 77%). 1H NMR 
(400 MHz, CDCl3) δH 8.49 (d, 1H, 3JHH = 7.4 Hz), 8.39 (d, 1H, 3JHH = 8.4 Hz), 7.94 (d, 1H, 3JHH
= 9.3 Hz), 7.51 (t, 1H), 7.16 (s, 1H), 6.75 (t, 1H, 3JHH = 7.8 Hz), 6.70 – 6.64 (m, 1H), 5.59 (s, 
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1H), 4.36 (t, 1H, 3JHH = 6.0 Hz), 3.67 (t, 1H,  3JHH = 5.9 Hz), 3.59 (d, 1H, 3JHH = 6.1 Hz) ppm. 
HRMS found m/z 390.1812, calculated m/z 390.1812 for [C23H23N3O3 + H]+.
Synthesis of L9 
As for L1, but using Pro9 (442 mg, 1.3 mmol) and ammonium hexafluorophosphate (234 
mg, 1.4 mmol). The product L9 was yielded as an orange solid (319 mg, 45%). 1H NMR 
(500 MHz, Acetone) δ 9.84 (s, 1H), 8.85 (dd, 1H, 3JHH = 8.5, 1.0 Hz), 8.72 – 8.67 (m, 2H), 
8.29 (d, 1H, 3JHH = 7.8 Hz), 8.05 (dd, 1H, 3JHH = 8.5, 7.3 Hz), 7.75 – 7.70 (m, 2H), 7.62 (dd, 
2H, 3JHH = 8.5, 7.6 Hz,), 7.49 (t, 1H, 3JHH = 7.4 Hz), 5.17 – 5.05 (m, 4H), 4.36 (t, 2H, 3JHH = 
6.2 Hz), 3.67 (t, 2H, 3JHH = 6.2 Hz), 3.32 (s, 3H). 13C NMR (101 MHz, Acetone) δ 164.09, 
163.60, 157.17, 138.79, 137.03, 132.69, 131.59, 130.93, 129.90, 129.68, 129.58, 128.90, 
128.05, 125.95, 124.95, 124.28, 119.82, 69.70, 58.63, 54.59, 50.87, 39.87. UV/Vis 
((CH3)2CO) : λmax/nm (ε/M-1 cm-1) = 423 (800), 344 (13480). HRMS found m/z 400.1658, 
calculated m/z 400.1656 for [C24H22N3O3]+. IR (solid. Vmax)/cm-1: 3107, 2983, 2951, 1699, 
1655, 1628, 1585, 1514, 1479, 1450, 1406, 1393, 1375, 1269, 1236, 1182, 1105, 1056, 
954, 825, 786, 756, 736, 688, 557, 468. 
Glycine ethyl ester 
Synthesis of Cl6
4-chloro-1,8-naphthalic anhydride (1 g, 4.3 mmol), glycine ethyl ester hydrochloride (1.2 
g, 8.6 mmol) and triethylamine (3 ml, 40 mmol) were heated at reflux in ethanol (30 ml) 
under nitrogen for 24 hours. The solution was cooled and the resulting precipitate 
filtered and dried in vacuo to give Cl6 as an orange solid (1.0 g, 73 %). 1H NMR (400 MHz, 
CDCl3) δH 8.63 (d, 1H, 3JHH = 7.3 Hz), 8.57 (d, 1H, 3JHH = 8.5 Hz), 8.45 (d, 1H, 3JHH = 7.9 Hz), 
7.82 (d, 1H, 3JHH = 7.9 Hz), 7.78 (d, 1H, 3JHH = 7.8 Hz), 4.86 (s, 2H), 4.18 (q, 2H, 3JHH =7.1 
Hz), 1.23 (t, 3H, 3JHH =7.1 Hz). IR (solid. Vmax)/cm-1: 3055, 2984, 1748, 1705, 1667, 1620, 
1591, 1574, 1397, 1375, 1352, 1339, 1317, 1265, 1236, 1206, 1181, 1128, 1051, 1020, 
980, 941, 853, 783, 731, 700, 662.
Synthesis of Pro10 
As for Pro1, but using Cl6 (354 mg, 1.1mmol) and N-phenylethylenediamine (0.58 ml, 4.5 
mmol). The product Pro10 was yielded as an orange solid (86.2%). 1H NMR (400 MHz, 
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CDCl3) δH 8.17-8.08 (m, 2H), 7.95 (d, 1H, 3JHH = 8.5 Hz), 7.24-7.12 (m, 2H), 6.70 (d, 3H, 
3JHH = 7.8 Hz), 6.41 (d, 1H, 3JHH = 8.5 Hz), 6.08 (s, 1H), 4.86 (s, 2H), 4.06 (q, 2H, 3JHH = 7.2 
Hz), 3. 49 (s, 4H), 1.18 (t, 3H, 3JHH = 7.2 Hz) ppm. HRMS found m/z 418.1761, calculated 
m/z 418.1761 for [C24H23N3O4 + H]+.
Synthesis of L10
As for L1, but using Pro10 LG228 (318 mg, 0.76 mmol) and ammonium 
hexafluorophosphate (137 mg, 0.84 mmol). The product L10 was yielded as an orange 
solid (403 mg, 93 %). 1H NMR (500 MHz, Acetone) δH 9.87 (s, 1H), 8.93 (d, 1H, 3JHH = 8.5 
Hz), 8.72 (t, 2H, 3JHH = 7.9 Hz), 8.34 (d, 1H, 3JHH = 7.8 Hz), 8.10 (t, 1H, 3JHH = 7.4 Hz), 7.75 
(d, 2H, 3JHH = 7.8Hz), 7.64 (t, 2H, 3JHH = 7.5 Hz), 7.51 (t, 1H, 3JHH = 7.4 Hz), 5.22-5.08 (m, 
4H), 4.91 (s, 1H), 4.25 (q, 2H, 3JHH = 7.2 Hz), 1.29 (t, 3H, 3JHH = 7.1 Hz). 13C NMR (101 MHz, 
Acetone) δ 168.65, 163.76, 163.26, 157.16, 139.27, 137.00, 133.00, 132.00, 130.92, 
130.25, 129.86, 129.67, 128.92, 128.15, 126.02, 124.24, 123.62, 119.84, 62.06, 54.56, 
50.88, 42.05, 30.28, 30.09, 14.45. UV/Vis ((CH3)2CO) : λmax/nm (ε/ M-1 cm-1) = 432 (1080),  
345 (17760). HRMS found m/z 428.1607, calculated m/z 428.1605 for [C25H22N3O4]+, 
found m/z 445.1867, calculated m/z 445.1870 for [C25H22N3O4 + NH3]+. IR (solid. 
Vmax)/cm-1: 2978, 1753, 1705, 1659, 1633, 1589, 1404, 1379, 1323, 1275, 1215, 1180, 
829, 791, 760, 688, 665, 557, 497, 462, 457, 403.  
2.5.4 Complex Synthesis 
Ethoxyethanol 
Synthesis of [AuCl(L1)] 
L1 (81 mg, 0.15 mmol), KOtBu (17 mg, 0.15 mmol) and [AuCl(tht)] (49 mg, 0.15 mmol) 
were dissolved in CH3OH and then heated to reflux, under nitrogen, overnight in the 
absence of light. The solution was cooled, and then concentrated in vacuo, and then 
Et2O added dropwise to induce precipitation. [AuCl(L1)] was yielded as a grey coloured 
solid (yield: 76 mg, 81 %).  1H NMR (400 MHz, CDCl3): δH 8.68 – 8.59 (m, 2H), 8.25 (d, 1H, 
3JHH = 8.7 Hz), 7.83 (d, 2H, 3JHH = 7.8 Hz), 4.46 (q, 2H, 3JHH = 4.6 Hz), 4.04-3.81 (m, 5H), 
3.73 – 3.63 (m, 2H), 3.56 (s, 1H), 3.47 (q, 2H, 3JHH = 6.8 Hz)  1.42 (t, 2H, 3JHH = 7.3 Hz), 0.84 
(br. t, 3H). 13C{1H} NMR (126 MHz, CDCl3): δC 193.85, 163.89, 163.68, 132.27, 131.62, 
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129.05, 128.49, 128.00, 127.97, 126.22, 122.97, 72.38, 70.35, 70.00, 68.47, 66.76, 62.00, 
53.72, 48.66, 46.28, 39.86, 39.44, 15.29, 13.75. UV/Vis ((CH3)2CO): λmax / nm (ε / M-1cm-
1) 436 (1420), 351 (4620), 344 (4660). HRMS found m/z 636.0918, calcd m/z 636.0935 
for [C21H23AuClN3O4 + Na]+. IR (solid) ν / cm-1: 2899, 2666, 2360, 1695, 1653, 1582, 1537, 
1510, 1477, 1427, 1379, 1348, 1341, 1265, 1230, 1105, 1043, 835, 785, 737, 669, 600, 
581, 556, 455, 444, 436, 428, 420, 409.  
Synthesis of [AuCl(L2)] 
As for [AuCl(L1)], but using L2 (68 mg, 0.16 mmol), [AuCl(tht)] (51 mg, 0.16 mmol) and 
KOtBu (18 mg, 0.16 mmol). The product [AuCl(L2)]  was obtained as a grey solid (yield: 
88 mg, 84 %). 1H NMR (500 MHz, CD3CN): δH 8.66 – 8.59 (m, 2H), 8.01 (d, 1H, 3JHH = 7.9 
Hz), 7.94 (app. t, 1H, 3JHH = 7.9 Hz), 7.82 (d, 2H, 3JHH = 7.9 Hz), 7.53 (d, 2H, 3JHH = 7.8 Hz), 
7.43 (d, 2H, 3JHH = 7.6 Hz), 4.39 – 4.21 (m, 4H), 3.81 – 3.49 (overlapping m, 8H). 13C{1H} 
NMR (126 MHz, CDCl3): δC 192.74, 163.83, 163.63, 132.24, 131.47, 131.42, 129.73, 
128.95, 128.15, 128.07, 126.46, 123.38, 123.25, 116.48, 113.91, 72.42, 70.36, 70.01, 
68.48, 66.76, 66.00, 62.00, 53.70, 52.29, 52.24, 39.94, 15.41, 15.28. UV/Vis ((CH3)2CO): 
λmax / nm (ε / M-1cm-1)  433 (900), 349 (8700). HRMS found m/z 643.1608, calcd m/z
643.1614 for [C25H23AuN3O4 + NH3]+. IR (solid) ν / cm-1: 2990, 2880, 1705, 1659, 1593, 
1487, 1437, 1408, 1381, 1346, 1337, 1321, 1288, 1234, 1188, 1121, 1049, 887, 843, 789, 
756, 692, 559, 482, 451, 438, 426, 419, 405.  
Propyl 
Synthesis of [AuCl(L3)] 
As for [AuCl(L1)], but using L3 (80 mg, 0.17 mmol), KOtBu (19 mg, 0.17 mmol) and 
[AuCl(tht)] (53 mg, 0.17 mmol). The product [AuCl(L3)] was obtained as an off-white solid 
(yield: 40 mg, 45 %). 1H NMR (500 MHz, CDCl3): δH 8.55 (dd, 1H, JHH = 7.3, 1.0 Hz), 8.52 
(d, 1H, 3JHH = 7.7 Hz), 8.21 (d, 1H, 3JHH = 8.4 Hz), 7.76 (d, 1H, 3JHH = 7.7 Hz), 7.71 (t, 1H, 
3JHH = 7.3 Hz), 4.10 (m, 4H), 3.93 (t, 2H, 3JHH = 9.3 Hz), 3.83 (s, 2H), 1.76-1.67 (m, 2H), 1.29 
(t, 3H, 3JHH = 7.2 Hz), 0.96 (t, 3H, 3JHH = 7.4 Hz) ppm. 13C{1H} NMR (126 MHz, CDCl3): δC
193.48, 163.87, 163.40, 142.86, 131.92, 131.29, 129.37, 129.03, 128.44, 127.91, 126.27, 
123.52, 123.10, 53.78, 48.72, 46.22, 42.23, 21.50, 13.66, 11.66. UV/Vis ((CH3)2CO): λmax 
/ nm (ε / M-1cm-1) 439 (280), 351 (6900), 345 (6900). HRMS found m/z 602.0682, calcd 
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m/z 602.0682 for [C20H21N3O2AuCl + Cl]+. IR (solid) ν / cm-1: 2959, 2882, 2357, 1691, 
1651, 1585, 1520, 1470, 1423, 1383, 1362, 1344, 1333, 1267, 1234, 1190, 1065, 907, 
833, 789, 644, 557, 482, 405, 382, 359, 334, 324, 318, 312, 301, 293, 284, 276, 257, 231, 
220, 214. 
Synthesis of [AuCl(L4)] 
As for [AuCl(L1)], but using L4 (98 mg, 0.17 mmol), KOtBu (19 mg, 0.17 mmol) and 
[AuCl(tht)] (53 mg, 0.17 mmol). The product [AuCl(L4)] was obtained as a grey solid 
(yield: 86 mg, 85 %). 1H NMR (500 MHz, CDCl3): δH 8.56 (d, 1H, 3JHH = 7.3 Hz), 8.50 (d, 1H, 
3JHH = 7.7 Hz), 8.25 (d, 1H, 3JHH = 8.4 Hz), 7.83 (d, 1H, 3JHH = 7.7 Hz), 7.73 – 7.69 (m, 1H), 
7.65 (d, 2H, 3JHH = 7.2 Hz), 7.31 (m, 3H), 4.40 (br. t, 2H), 4.15 – 4.09 (m, 4H), 1.78-1.69 
(m, 2H), 0.98 (t, 3H, 3JHH =  7.4 Hz) ppm. 13C NMR (126 MHz, CDCl3): δC 192.25, 163.80, 
163.34, 142.56, 140.00, 131.80, 131.28, 129.60, 129.23, 128.81, 128.01, 127.93, 127.89, 
126.41, 123.51, 123.40, 123.22, 53.78, 52.49, 42.30, 21.53, 11.70. UV/Vis ((CH3)2CO): 
λmax / nm (ε / M-1cm-1) 352 (11760), 345 (11860). HRMS found m/z 597.1551, calcd m/z
597.1559 for [C24H21N3O2AuCl – HCl + NH4]+. IR (solid) ν / cm-1: 2967, 2955, 2873, 1703, 
1655, 1622, 1591, 1506, 1475, 1433, 1389, 1354, 1340, 1286, 1276, 1238, 1068, 1018, 
958, 908, 858, 785, 764, 754, 692, 673, 588, 546.  
Benzyl 
Synthesis of [AuCl(L6)]
As for [AuCl(L1)], but using L5 (62 mg, 0.16 mmol), [AuCl(tht)] (57 mg, 0.16 mmol) and 
KOtBu (17 mg, 0.16 mmol). The product [AuCl(L6)] was obtained as a grey solid. (yield: 
49 mg, 49 %). 1H NMR (400 MHz, CDCl3): δH 8.67 (d, 1H, 3JHH = 6.2 Hz,), 8.62 (d, 1H, 3JHH
= 7.7 Hz), 8.32 (d, 2H, 3JHH = 7.7 Hz), 7.91 (d, 1H, 3JHH = 7.8 Hz), 7.86 – 7.76 (m, 1H), 7.73 
(d, 2H, 3JHH = 8.0 Hz), 7.54 (d, 2H, 3JHH = 7.1 Hz), 7.47 – 7.30 (m, 5H), 5.42 (s, 2H), 4.48 (s, 
2H), 1.25 (s, 2H). 13C{1H} NMR (126 MHz, CDCl3): δC 192.51, 164.75, 164.16, 163.82, 
163.32, 149.44, 142.67, 139.94, 137.97, 137.19, 134.42, 132.20, 131.57, 131.54, 130.31, 
129.63, 128.99, 128.94, 128.64, 128.47, 128.05, 127.68, 127.37, 126.42, 125.09, 125.03, 
123.29, 122.67, 121.61, 120.90, 110.83, 104.00, 54.61, 54.52, 53.88, 53.83, 53.71, 52.32, 
50.12, 45.35, 43.89, 43.45, 40.19, 25.69. UV/Vis ((CH3)2CO): λmax / nm (ε / M-1cm-1) 436 
(700), 343 (1600). HRMS found m/z 645.1549, calcd m/z 645.1559 for [C28H20AuN3O2 +
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NH4]+. IR (solid) ν / cm-1: 2961, 2914, 2845, 1703, 1682, 1655, 1580, 1522, 1508, 1472, 
1454, 1425, 1402, 1383, 1312, 1260, 1236, 1177, 1136, 1069, 1016, 964, 845, 799, 785, 
737, 704, 692, 617, 594, 583, 557, 544, 500, 480, 459, 436, 428, 417. 
Octanyl 
Synthesis of [AuCl(L7)] 
As for [AuCl(L1)], but using L7 (86 mg, 0.16 mmol), KOtBu (18 mg, 0.16 mmol) and 
[AuCl(tht)] (50 mg, 0.16 mmol). The product [AuCl(L7)] was obtained as a grey solid 
(yield: 68 mg, 68 %). 1H NMR (400 MHz, (CD3)2CO): δH 9.39 (d, 2H, 3JHH = 7.5 Hz), 9.33 (d, 
1H, 3JHH = 7.6 Hz, 3H), 8.80 (d, 1H, 3JHH = 8.7 Hz), 8.71 (app. t, 1H, 3JHH = 7.5 Hz), 5.18 (br. 
s, 2H), 5.03 – 4.89 (m, 4H), 4.72 (dd, 2H, JHH = 13.8, 6.6 Hz), 2.57 – 2.47 (m, 2H), 2.16 (dd, 
13H, JHH = 27.8, 22.6 Hz), 1.66 (t, 3H, 3JHH = 5.6 Hz). 13C{1H} NMR (126 MHz, (CD3)2CO): δC
193.83, 164.27, 163.83, 144.41, 132.10, 131.65, 130.39, 130.00, 129.73, 128.50, 127.14, 
124.36, 123.68, 54.59, 49.52, 46.55, 40.87, 32.58, 30.24, 30.08, 28.71, 27.85, 23.31, 
14.35, 13.86. UV/Vis ((CH3)2CO): λmax / nm (ε / M-1cm-1) 439 (340), 351 (4360), 345 
(4360). HRMS found m/z 660.1678, calcd m/z 660.1663 for [C25H31AuClN3O2 + Na]+. IR 
(solid) ν / cm-1: 3341, 2920, 2854, 2110, 1703, 1657, 1585, 1531, 1470, 1429, 1391, 1350, 
1275, 1234, 1096, 856, 729, 478.
Synthesis of [AuCl(L8)]
As for [AuCl(L1)], but using L8 (70 mg, 0.16 mmol), [AuCl(tht)] (50 mg,0.16 mmol) and 
KOtBu (17 mg, 0.16 mmol). The product [AuCl(L8)] was obtained as a grey coloured solid 
(yield: 31 mg, 79 %). 1H NMR (500 MHz, CD3CN): δH 8.63 (d, 2H, 3JHH = 7.4 Hz,), 8.57 (d, 
1H, 3JHH = 8.6 Hz,), 8.00 (d, 1H, 3JHH = 7.2 Hz), 7.93 (app. t, 1H, 3JHH = 7.8 Hz), 7.82 (d, 2H, 
3JHH = 7.8 Hz), 7.52 (app. t, 2H, 3JHH = 7.4 Hz), 7.42 (app. t, 1H, 3JHH = 7.1 Hz), 4.45 (br. t, 
2H), 4.32 (br. t, 2H), 4.10 (t, 2H, 3JHH = 7.5 Hz), 2.81 (dd, 2H, JHH = 13.8, 6.8 Hz), 1.44 – 
1.22 (m, 10H), 0.88 (t, 3H, 3JHH = 6.0 Hz). 13C{1H} NMR (126 MHz, CDCl3): δC 192.80, 
163.80, 163.31, 142.42, 139.95, 131.98, 131.34, 129.71, 129.40, 128.62, 128.13, 128.11, 
128.04, 126.41, 123.68, 123.50, 123.25, 66.00, 53.70, 52.27, 40.86, 31.99, 29.51, 29.39, 
28.27, 27.33, 22.80, 15.42, 14.24. UV/Vis ((CH3)2CO): λmax / nm (ε / M-1cm-1) 441 (3380), 
351 (14160), 344 (14560). HRMS found m/z 650.2071, calcd m/z 650.2076 for 
[C29H31AuN3O2 - Cl]+. IR (solid) ν / cm-1: 3059, 2949, 2918, 2851, 1703, 1655, 1620, 1589, 
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1502, 1477, 1438, 1404, 1392, 1357, 1340, 1321, 1288, 1234, 1176, 1097, 1074, 1045, 
1024, 858, 785, 754, 692, 671, 651, 613, 584, 559, 543, 482, 410. 
Methoxyethylamine 
Synthesis of [AuCl(L9)] 
As for [AuCl(L1)], but using L9 LG217 (85 mg, 0.15 mmol), KOtBu (18 mg, 00.16 mmol), 
and LG216 (50 mg, 0.16 mmol). The product [AuCl(L9)] was yielded as a light grey solid 
(85 mg, 86 %). 1H NMR (500 MHz, Acetone-d6) δ 8.62 – 8.48 (m, 3H), 8.04 (d, 1H, 3JHH = 
7.7 Hz), 7.85 (d, 2H, 3JHH = 8.5 Hz), 7.78 (d, 1H, 3JHH = 7.4 Hz), 7.42 – 7.35 (m, 2H), 7.28 (d, 
1H, 3JHH = 7.3 Hz), 4.61-4.45 (br m, 4H), 4.25 (t, 2H, 3JHH = 6.4 Hz), 3.56 (t, 2H, 3JHH = 6.4 
Hz), 3.31 (s, 3H). 13C NMR (126 MHz, CDCl3) δ 198.63, 197.24, 193.10, 135.21, 132.25, 
131.55, 129.77, 129.55, 128.66, 128.19, 128.11, 126.42, 123.47, 123.17, 122.68, 69.72, 
66.00, 59.02, 58.94, 53.65, 52.18, 52.16, 39.68, 15.42. UV/Vis ((CH3)2CO) : λmax/nm (ε/ 
M-1 cm-1) 443 (2000), 350 (9400), 344 (9440). HRMS found m/z 654.0807, calculated m/z
654.0829 for [C24H21AuClN3O3 + Na]+. IR (solid. Vmax)/cm-1: 3310, 2957, 2870, 2198, 
2032, 1703, 1657, 1591, 1504, 1487, 1474, 1427, 1404, 1381, 1331, 1290, 1238, 1184, 
1115, 1059, 1018, 1001, 758, 765, 756, 739, 692, 671, 652, 590, 577, 536, 482, 428, 417, 
401. 
Glycine ethyl ester 
Synthesis of [AuCl(L10)] 
As for [AuCl(L1)], but using L10 LG238 (89 mg, 0.16 mmol), KOtBu (18 mg, 0.16 mmol) and 
LG36 (50 mg, 0.16 mmol). The product [AuCl(L10)] was yielded as a grey solid (82 mg, 
79%). 1H NMR (400 MHz, CDCl3) δ 8.59 (d, 1H, J = 7.2 Hz), 8.51 (d, 1H, J = 7.7 Hz,), 8.40 
(d, 1H, J = 8.5 Hz), 7.91 (d, 1H, J = 7.7 Hz), 7.74 – 7.69 (m, 1H), 7.69 – 7.64 (m, 2H), 7.35 
– 7.31 (m, 3H), 4.99 (s, 2H), 4.36 (br. s, 4H), 4.27 (q, 2H, J = 7.1 Hz), 1.32 (t, 3H, J = 7.1 
Hz). 13C NMR (126 MHz, CDCl3) δ 192.11, 168.12, 163.50, 163.00, 143.11, 139.94, 132.23, 
131.70, 129.58, 129.54, 129.35, 128.04, 128.00, 127.93, 126.47, 123.47, 122.88, 122.53, 
61.82, 53.83, 52.61, 41.73, 14.35. UV/Vis ((CH3)2CO) : λmax/nm (ε/ M-1 cm-1) 444 (240), 
351 (11800), 344 (11920). LRMS (ES+) found m/z 683.9; calculated 683.9 for 
[C25H21AuClN3O4 + Na]+. HRMS found m/z 641.1445, calculated m/z 641.1458 for 
84
[C25H21AuClN3O4 – HCl + NH4]+. IR (solid. Vmax)/cm-1: 2991, 2163, 2001, 1749, 1705, 
1659, 1591, 1506, 1476, 1427, 1404, 1386, 1348, 1329, 1287, 1238, 1213, 1182, 1163, 
1126, 1032, 980, 953, 787, 758, 691, 669, 650, 588, 563, 482, 455, 417, 409, 403.
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Chapter 3 - Fluorophore-Labelled 
Substituted Phosphinites and 
Aminophosphine Ligands and their 
Gold(I) Complexes: Syntheses, 
Photophysics and X-Ray Structure 
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3.1 Introduction 
3.1.1 Phosphines 
The chemistry of phosphorus has for some time been of invaluable importance due to 
its potential for use in an extreme breadth of applications, from consumer industry to 
biological and medicinal applications.1 For these reasons, it accounts for a major branch 
of chemistry in today’s society. The ground state valence electronic configuration of 
phosphorus is 3s2, 3px1, 3py1, 3pz1, which allows its involvement in ambivalent bonding 
(tri- and pentavalent), as well as access to a range of different bonding modes. The 
pyramidal geometry for trivalent phosphorus atoms is of particular significance. Stable 
trivalent tricoordinate compounds are formed with a variety of other elements, for 
example hydrogen, carbon, nitrogen, oxygen, sulphur and halogens and are a class of 
P(III) compounds related to the parent compound, PH3.1
P M P M
Figure 3.1: Orbital interactions and bonding of PR3 donors with d-block metals. Left: σ bonding. Right: π 
backbonding 
Primary, secondary and tertiary phosphines are classified according one (PH2R), two 
(PHR2) or three (PR3) R group substituents, respectively. Phosphines and their 
corresponding applications make up an extensive proportion of phosphorus chemistry, 
for example showing promising potential in semiconductor industries.2,3 In addition, 
their contribution to the development, understanding and utility of organometallic 
chemistry is of particular importance due to numerous catalytic applications.1
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Rh ClPh3P
PPh3
Ph3P
Ir CCl
PPh3
Ph3P
O
Figure 3.2: Wilkinson's catalyst (left) and Vaska's complex (right) 
In organometallic chemistry, phosphine ligands are classed as σ-donors, with relatively 
weak π-acceptor character, where the donating and accepting properties vary according 
to the nature of the substituents on the phosphorus atom (Figure 3.1).4,5 Phosphorus 
has been involved in many well documented organometallic literature examples, for 
example Wilkinson’s catalyst ([RhCl(PPh3)]), Vaska’s complex ([IrCl(CO)(PPh3)2]) (Figure 
3.2) and Kagan’s phosphine [Fe(CpPPh2){1,2-Cp(PPh2)(C∗HMe(NMe2))}].6,7 In more 
recent work, ferrocenyl ligands containing phosphine moieties have been utilised as 
homogenous enantioselective hydrogenation catalysts.8 In addition, water soluble 
phosphines have been shown to have biomedical applications, for example Katti et al. 
reported a wide range of phosphine ligands and complexes,9 which also found uses in 
asymmetric hydrogenation and hydrovinylation reactions.10,11
3.1.2 Aminophosphines 
Aminophosphines (also referred to as phosphanamines, phosphazanes or phosphinous 
amides) are classed as a tricoordinate P(III) centre bound to a tricoordinate N(III) centre.1
Michaelis discovered the first example of an aminophosphine in 1903.12 Due to the 
possibility of manipulation on both the phosphorus and the nitrogen atom, 
aminophosphines are hugely important in organometallic chemistry.13 However, there 
are currently no examples of aminophosphine metal complexes where both the nitrogen 
and the phosphorus coordinate to the metal. Structural variety of aminophosphines is 
also important, where cyclic, cage, polymeric and supramolecular P-N networks have 
been described.14–16 It is also worth noting that P-unsubstituted phosphinous amides 
H2PNR2 are extremely rare, with the exception of the documented compounds 
H2PN(SiMe3)217 and H2PN(CF3)2.18,19 In terms of their reactivity, the presence of a lone 
pair on the adjacent nitrogen atom increases the nucleophilicity of the phosphorus, but 
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the extent of this is not comparable to the alpha effect observed for N-N and N-O 
nucleophiles.20 It is thought that the increase in nucleophilicity is due to the repulsive 
interaction between the N and P lone pairs, thus raising the energy to cause higher levels 
of basicity and nucleophilicty.21
P
NR2
R
R
P
NR2
R
R2N
P
NR2
R2N
R2N
monoaminophosphine bisaminophosphine trisaminophosphine
R = alkyl or aryl group
Figure 3.3: Structural representation of aminophosphines 
Synthesis of aminophosphines involves the creation of one, two or three P-N bonds 
around a trivalent phosphorus centre, as shown in Figure 3.3. There are three main 
synthetic methods: condensation, scrambling and transamination, where the 
condensation route is the most widely used.1 This reaction usually involves a 
phosphorus(III) halide (most commonly phosphorus trichloride) and a primary or 
secondary amine.22–29 The synthesis is considered to be of relative ease for three main 
reasons: i) cost, availability and reactive nature of starting materials; ii) the common 
byproduct, amine hydrochloride, is relatively easy to separate from the product; and iii) 
suitable reaction conditions can be chosen in order to exert control over product 
formation. Reaction conditions that can be altered accordingly include temperature, 
time, solvent, mole ratio, mode of addition of the reagents and presence of a hydrogen 
chloride scavenger.1 Reaction temperatures have been found to range from -40 to 100 
°C, and aliphatic amino groups react more readily than aromatic and heteroaromatic 
moieties due to enhanced nucleophilicty.13 Information on the breadth of this synthetic 
method is shown in Figure 3.4, where Grignard reactions are typically used to form P-Ph 
bonds.1 A scrambling reaction between a tris(amino)phosphine and phosphorus 
trichloride is another synthetic possibility, and usually leads to the formation of 
amino(chloro)phosphines, (R2N)xPCl3-x (x= 1, 2).30,31 An additional variation of a 
scrambling reaction, known as transamination, is observed when a 
tris(amino)phosphine is treated with a primary or secondary amine. Although this 
synthetic method is reasonably well understood, desired products only form when the 
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product amine is a volatile compound. For this reason, transamination has been used 
for the synthesis of tris(dimethylamino)phosphine and tris(diethylamino)phosphine.32,33
Alternatively, aminophosphines can be prepared by exploiting the high affinity between 
silicon and halogen atoms. In this case, reactions between halophosphines and N-
(trimethylsilyl)anilines, N-(trimethylsilyl)amides or N-(trimethylsilyl)ureas and thioureas 
have been carried out, where the P-N bond and a halosilane are formed in situ.34–37
Despite being thermally stable, the majority of aminophosphines exhibit sensitivity to 
air oxidation; hence they require a dry and inert atmosphere for their preparation, 
handing and storage. This routinely requires the use of Schlenk techniques, inert 
atmosphere manipulations and vacuum line techniques for safe handling.38,39
31P NMR spectroscopy is an extremely important technique when identifying 
organophosphorus compounds, specifically aminophosphines, as reaction products.40
Here, the chemical shift values are dependent upon a number of characteristics 
associated with the central phosphorus atom: i) nature; ii) electronegativity; iii) sterics; 
iv) π-bonding effects or the phosphorus substituents and v) bond angles. For example, 
upon replacement of a chloro group with an amino group, the chemical shift values are 
shifted upfield due to shielding.1 With reference to NMR, it is also worth noting that low 
temperature 1H NMR (-65 °C) has detected hindered rotation around the P-N bond for 
tetrasubstituted phosphorus amides.41 In this work, different environments were 
observed for two Me3Si groups in the compound Ph2PN(SiMe3)2, where the activation 
energy for rotation was 10.2 kcal mol-1.42
Despite the sensitivity of P(III)-N bonds, aminophosphines are involved in a wide variety 
of applications, for example as essential materials for day-to-day life.1 In this vein, 
P(NMe2)3 has been found to catalyse the production of polyethers from the reaction 
between thiodiglycol and triethylene glycol, where shorter reaction times and improved 
product yields are observed in comparison to traditional methods. Aminophosphines 
have also found applications as both inorganic heterocycles43 and synthons.44 They have 
also been found to possess antimicrobial activity.45 In addition, gallium phosphide (GaP) 
thin film depositions using trimethyl gallium and P(NMe2)3 have been indicated to be 
suitable for use in optoelectronic materials.46
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RPCl2
RR'PCl RR'2(R''2N)P
PCl3
(R2N)3P (R2N)(R'2N)2P
R(R'2N)PCl R(R'2N)(R''2N)P
(R2N)PCl2 (R2N)(R'2N)PCl
R(R'2N)2P
R2PCl
R2(R'2N)P (R2N)(R'2N)(R''2N)P
RMgX
R'MgX
R''2NH
R''2NH
R''2NH
R'2NH
R2NH R'2NH
2 R'2NH
2 RMgX
R'2NH 3 R2NH 2 R'2NH
Figure 3.4: Condensation reactions for formation of aminophosphines1
In comparison to phosphines, the coordination chemistry of aminophosphines is under 
explored. However, it is commonly seen that upon the synthesis of a novel 
aminophosphine, the preparation of the corresponding metal complex is explored.47 In 
particular, a significant contribution to this developing area of research has been made 
by Woollins and coworkers, amongst others.48–51 This has given rise to a huge breadth 
of exploration of organometallic aminophosphine complexes. 
For monodentate aminophosphine ligands, the cone created by the phosphorus ligand 
is a significant factor when it comes to investigating the steric crowding around a central 
metal atom, and is referred to as the Tolman cone angle.52 Variation of this angle thus 
dictates the coordination number of the complex, and therefore is reflected in the 
potential catalytic activity of the final complex. For this reason, catalytic activity can be 
tuned depending on the nature of the substituent on the nitrogen atom of the 
aminophosphine. For bidentate ligands, the catalytic activity of a metal complex can be 
partly determined by the bite angle.53,54 As mentioned above, despite the possibility to 
exploit the donor capabilities of both the nitrogen and the phosphorus atom, there are 
to date no examples of metals being bound via the nitrogen centre. It is thought that 
this is due to the nitrogen lone pair’s involvement in negative hyperconjugation with 
phosphorus orbitals. In addition, most of the literature displays the soft nature of 
aminophosphine ligands where they coordinate with soft metal centres, for example 
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Cu(I), Mo(0), Ru(I), Ru(II), Ir(I) and Au(I). Work by Dixon et al. demonstrated that the 
electronic properties of a metal complex can be drastically altered when appropriate 
changes to the P substituent on an aminophosphine are made.55  A variety of 
[Ru(terpyridine)(bipyridine)L]2+ (L = aminophosphine, phosphine or phosphite) were 
prepared and their electronic properties investigated using cyclic voltammetry , UV-vis 
and luminescence spectroscopy, all of which demonstrated appreciable differences. In 
addition, these complexes showed luminescence at 77 K in an alcoholic matrix and 
lifetimes originating from 3MLCT states (3.5 – 5.5 μs).   
N N
H
N
H
Ph2P PPh2
Figure 3.5: N,N-bis(diphenylphosphino)-2,6-diaminopyridine (PNP) 
The most explored application of organometallic compounds containing an 
aminophosphine ligand is catalysis, particularly of organic reactions.13 For example, the 
ligand N,N-bis(diphenylphosphino)-2,6-diaminopyridine (PNP), shown in Figure 3.5, has 
been used in the preparation of complexes of the type [M(PNP)]Cl.L (M = Ni, L = H2O; M 
= Pd, L = EtOH, M = Pt) and mer-[M(NPN)(CO)3].2THF (M = Cr, Mo, W). These complexes 
have been used as catalysts in the hydrogenation of styrene to ethylbenzene.56 It is also 
well established that the oxidative addition step of the Suzuki-Miyaura reaction is 
accelerated by the use of electron rich phosphanes, making aminophosphines ideal 
candidates due to their strong σ-donor ligand ability.13 Chiral aminophosphines have 
also been found to be useful catalysts for enantioselective allylic alkylation reactions.57
In addition, Gilbertson et al.  developed a range of iridium complexes based on enantio-
enriched aminophosphine ligands, which were found to catalyse the asymmetric 
hydrogenation reactions of C=C and C=O bonds.58 Other reaction types include 
asymmetric 1,4-addition to enones59 and asymmetric hydrosilylation.60
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3.1.3 Fluorescent Phosphines 
In Chapter 2, new ligand architectures were developed that are able to impart 
fluorescence properties upon a coordination complex. Aminophosphines present a class 
of compounds that are extremely under-explored in this area. However Zhang and co-
workers reported a series of papers in the early 2000s that described the Au(I) 
coordination chemistry of anthracene-based aminophosphine ligands together with 
their fluorescence properties.61–63 In the most recent of these works, Zhang developed 
a range of novel gold(I) η2-arene complexes with arm-closing configurations and hence 
weak fluorescence emission (structured profile between 400 and 450 nm) attributed to 
charge transfer from the anthracene unit to the Au+ ion. When these complexes were 
reacted with one equivalent of triphenylphosphine in dichloromethane, an arm-opening 
configuration was formed and a stronger emission was observed.63 Research into 
fluorescent phosphine-based ligands is also relatively under-developed. One example 
comes from Higham, who developed a range of Bodipy-tagged systems with desirable 
photophysical properties common to the Bodipy scaffold (λem = 526 – 532)64, and have 
been successfully applied to cell imaging studies (Figure 3.6)65. In other work, it was seen 
that the Au(I) complexes of Bodipy-phosphine dyads have been investigated in gold-
catalysed alkyne transformations.66
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Figure 3.6: BODIPY derivatives for imaging of mitochondrial dysfunction in cancer and heart cells65
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In recent work, Gabbai has demonstrated that a fluorescein-functionalised tertiary 
phosphine can be used as a “sensor” for Au(III) ions by modulating photoinduced 
electron transfer between the phosphorus atom and fluorophore.67 Other examples of 
fluorophore-functionalised phosphines have attempted to manipulate the reactivity of 
phosphorus in the detection of reactive oxygen species (ROS).68–71  Similar approaches 
utilising aminophosphine architectures have not been widely reported.  
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Figure 3.7: Anti-bacterial aminophosphine Au(I) complexes72
Aminophosphine complexes of Au(I) and Ag(I) have also been reported, and have shown 
anti-bacterial activity against Gram-negative Salmonella enterica serovar typhimurium 
and Echerrichia coli and Gram-positive Listeria monocytogenes and Staphylococcus 
aureus (Figure 3.7).72 The bacterial assays showed effectiveness of all novel Au(I) 
compounds, comparable to reference antibiotics.  
3.1.4 Phosphinites  
In addition to aminophosphines, phosphinites (R2POR) comprise an important family of 
ligands for organometallic chemistry. Although transition metal complexes 
incorporating tertiary phosphines and phosphites have a more developed history, 
phosphinites and phosphonites (RP(OR)2) have recently received increased levels of 
attention.73 Phosphinites differ from phosphines, phosphonites and phosphites in the 
number of P-C and P-O bonds (Figure 3.8). Electronic and steric parameters rank 
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phosphinites between phosphines and phosphonites bearing the same substituents. 
The nature of these parameters can in part be measured by studying the Tolman cone 
angle,52 which decreases from 132° (phosphine) to 109° for R=Et, and from 118° to 107° 
for R=Me, with intermediate values predicted for the phosphinite and 
phosphonite.52,74,75 When compared to other organophosphorus ligands, additional 
benefits are observed due to the tunable nature of the donor-acceptor ability and ligand 
topology of phosphinites.76 For example, the π-acceptor ability of the ligands is 
predicted to decrease in the order P(OR)3 > RP(OR)2 > R2P(OR) > R3P, especially for small 
R groups where steric effects are negligible. The electronegativity of OR groups lowers 
the energy of the empty 3d orbitals of phosphorus, thus enhancing the π-acceptor 
properties. As OR groups stabilise the σ-donor orbitals, σ-bonding tendencies should 
reverse the order of the series, where R3P ligands are the best.73 However, when steric 
and metal-ligand combination effects are considered, a complex picture emerges and 
generalizations can become somewhat unreliable. For this reason, explicit consideration 
of the aforementioned factors and comparison of closely related compounds must be 
explored before planning applications, for example in homogenous catalysis.73
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Figure 3.8: Structures of some P-O containing compounds 
When compared to phosphine ligands, the synthesis of phosphinite ligands relatively 
simple, and most commonly involves mixing ROH and R’R’’PCl with a base such as Et3N 
or DMAP.76 This method was recently utilised by Diez-Gonzalez et al., who synthesised 
a range of phosphonites and phosphinite ligands for Cu(I) complexes suitable for Click 
azide-alkyne cycloaddition catalysis.77 The synthesis, structures and 31P NMR shifts are 
displayed in Figure 3.9. In addition, stronger bases such as NaH or n-BuLi can be required 
when a sterically crowded phosphorus centre is present. In a less common synthetic 
method, a Grignard reagent is reacted with methoxy chlorophosphines78 or substituted 
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aryls are lithiated and treated with aminodichlorophosphine in the first step, followed 
by methanolysis.79
ClPR2 
+    Ar-OH                                 (ArO)PR
2
NEt3, DMAP
THF, RT, 18 hr
R = Ph
Ar =
OMe SMe
OMe
110.4 ppm 117.4 ppm 111.8 ppm 112.6 ppm
Figure 3.9: Synthesis, structures and 31P NMR shifts of compounds by Diez-Gonzalez et al.77
The simplicity of synthesis of phosphinite ligands, as well as the low cost of starting 
materials means they have found application in transition metal catalysis, sometimes 
being used as attractive surrogates for previously investigated phosphines.76 For 
example, (t-Bu)2PO(n-Pr) was used to replace the more expensive but sterically similar 
phosphine ligand Ad2P(n-Bu) (Ad = 1-adamantyl) in the palladium catalysed reductive 
carbonylation of aryl bromides, where catalytic activity was not compromised.80 One of 
the earliest examples of phosphinite ligands in catalysis involved  the use of 
diphenylphosphinite derived from (S,S)-trans-1,2-cyclohexanediol in the Rh(I)-catalysed 
asymmetric hydrogenation of alkenes.81 Phosphinites have been found to be less 
susceptible to hydrolysis when compared to phosphites and phosphonites. However, π-
acceptor capability is still maintained, which leads to advantages for catalytic activity.76
For example, DuPont employed phosphites as supporting ligands for the nickel-
catalysed hydrocyanation of butadiene and 4-pentenenitrile, but other 
organophosphorus compounds were sought as alternatives due to their tendency to be 
hydrolysed by adventitious water.82 In relation to this, Pringle et al. discovered that 
phospha-adamantane-based phosphonites were very effective for the desired 
hydrocyanation reaction and stable to air and moisture.83 A large number of chiral 
phosphinite ligands have also been developed due to the ready availability of chiral 
alcohols, including carbohydrates.73,84–86 Optically active bidentate ligands with 
phosphine and phosphonate moieties have also been developed, but they require more 
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difficult synthetic protocols.87 In addition to this, aminophosphine phosphinites have 
been developed as chiral precatalysts and used in asymmetric catalysis.88
Phosphinites have also been used to construct catalytically active metallacyclic 
compounds of two discrete classes: monometallacyclic phosphinite complexes and 
phosphinite-based pincer complexes.76  One article describes the synthesis of a 
tetranuclear gold(I) metallacycle containing bridging thiolate ligands and a phosphinous 
acid/phosphinite ligand combination, the latter of which gives rise to additional bridging 
through strong hydrogen bonding.89 Organic transformations such as the Mitsunobu 
reacton and the Arbuzov reaction have also employed phosphinites.90,91 Notable metal 
catalysed transformations that have utilised phosphinite ligands include hydrogenation, 
transfer hydrogenation, Suzuki-Miyaura coupling, Mizoroki-Heck coupling, 
hydroformylation and allylation.76,92
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3.2 Aims 
This chapter describes the development of the synthesis of of a range of novel, 
fluorescent aminophosphine and phosphinite ligands and their corresponding Au(I) 
complexes. The desired compounds incorporate naphthyl (L1), pyrenyl (L2) and 
anthraquinone (L3 and L4) chromophores into their structures. It was thought that the 
ligands would react with [AuCl(tht)] (tht = tetrahydrothiophene) to give monometallic 
complexes of the form [AuCl(L)], as well as the possibility of a dimetallic complex 
[Au2Cl2(L)]. Another aim was to design a synthetic protocol for phosphinite compounds 
incorporating anthracene (L5) and pyrene (L6), and for their Au(I) chemistry to be 
investigated. Among other techniques, 31P NMR spectroscopy would be utilised to 
confirm formation of products. 
The difference in photophysical properties between ligands and complexes would also 
be important due to the presence of a range of fluorophores within the chapter. Solid 
state X-ray crystallographic data would also be obtained to consider the coordination 
geometry of the resulting Au(I) compounds, as well as to study interactions between 
different moieties comprising the complexes. In addition, supporting TD-DFT 
calculations would be computed to assist and inform the assignments of the electronic 
transitions noted from experimental observations. 
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3.3 Results and Discussion 
3.3.1 Synthesis of Ligands and Complexes 
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Figure 3.10: Structures of the isolated ligands
The aminophosphine ligands were synthesised in a single step from 
chlorodiphenylphosphine (Ph2PCl) and the relevant primary amine (1-
naphthalenemethylamine, 1-pyrenemethylamine, 1-aminoanthraquinone). The 
phosphine was added dropwise to a stirred degassed dichloromethane solution of the 
amine and triethylamine at 0 °C. L1 and L2 were isolated as colourless and yellow oils, 
respectively, while the anthraquinone derivative L3 was obtained as a dark orange solid 
and L4 as a dark pink solid. The formation of L3 is noteworthy as the aryl amine of 1-
aminoanthraquinone is far less basic than the other amines and is delocalised into the 
strongly electron withdrawing anthraquinone ring. As the only disubstituted ligand, L4
is also of particular interest as it gives rise to the potential of coordination to two Au(I) 
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atoms. All ligands were treated as air-sensitive materials and were stored under inert 
atmosphere. The corresponding gold(I) complexes were synthesised by stirring 
[AuCl(tht)] (where tht = tetrahydrothiophene) with the ligand in deoxygenated 
dichloromethane to yield monometallic complexes of the form [AuCl(L)], as well as a 
dimetallic complex [AuCl2(L4)2]. Due to the light sensitivity of Au(I) compounds, tin foil 
was used to eliminate any light during the reaction. 
The substituted phosphinites were also synthesised in a single step process from 
chlorodiphenylphosphine and the relevant methanol derivative (9-anthracenemethanol 
and 1-pyrenemethanol). The methanol derivative and 4-dimethylaminopyridine (DMAP) 
were dissolved in dry and degassed tetrahydrofuran (THF). Following this, triethylamine 
was added as well as chlorodiphenylphosphine. L5 and L6 were both isolated as pale 
yellow oils. Similarly to the aminophosphines, both ligands were treated as air-sensitive 
in their storage. Despite repeated attempts, the corresponding Au(I) complexes for 
these ligands were unable to be synthesised successfully. This was sopported by the 
observation of starting material and what is thought to be an oxidised ligand peak in the 
31P NMR. 
3.3.2 Spectroscopic Characterisation 
Multinuclear NMR spectroscopy was used to confirm the proposed structures of the 
ligands. In the first instance, 31P NMR data (Table 3.1) gave immediate indication of the 
formation of the target aminophosphine. For structurally related L1 and L2, which 
incorporate a methylamine unit, this value is approximately +42 ppm, which is 
comparable to reports on chemical shift values for monoaminophosphine type species 
(+40 to +70 ppm).93–96 For L3 and L4 the 31P chemical shift value appeared at a 
significantly upfield value +26.11 and +26.30 ppm suggesting that the phosphorus 
nucleus is more shielded in the aminoanthraquinone derivative. This value is consistent 
with the report of Woollins which describes the reactivity of an arylamine with Ph2PCl 
to give a corresponding aminophosphine with 31P NMR resonance at approximately +27 
ppm.97 In addition, the 31P NMR chemical shifts of L5 and L6 (+113.74 and +114.03, 
respectively) are comparable to a previously reported derivative, 
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benzyldiphenylphosphinite (118.1 ppm),98 as well as to other related analogues by Diez-
Gonzalez et al.77
Compound 31P NMR δ / ppm (δcomplex - δligand) / ppm
L1 +42.19
L2 +42.12
L3 +26.11
L4 +26.30
L5 +113.74
L6 +114.03
[AuCl(L1)] +64.58 +22.39
[AuCl(L2)] +64.72 +22.60
[AuCl(L3)] +55.77 +29.66
[Au2Cl2(L4)] +56.63 +30.33
Table 3.1: 31P NMR chemical shift values for the ligands and complexes 
In the 1H NMR spectra of L1 and L2, the NH resonance gave rise to a complex multiplet 
around 2.3 ppm due to both 3JHH and 2JHP coupling. The methylene resonances for L1 and 
L2 were observed at 4.44 and 4.67 ppm, respectively. In L3 the NH resonance appeared 
much further downfield at ca. 10.3 ppm, due to the strongly electron withdrawing 
anthraquinone unit, and is a doublet, which is attributed to H-P coupling (2JHP = 7.3 Hz).  
L4 displays a similar downfield peak at 11.13 ppm, which integrates to two protons in 
this case. These values are consistent with previous work on substituted 
aminoanthraquinones which often show such resonances at chemical shifts above 9 
ppm.99 In addition, the methylene resonances for L5 and L6 were observed at 5.68 and 
5.39 respectively, where each is a doublet due to 3J coupling to the phosphorus atom.  
For L3, the 13C NMR spectrum revealed the two carbonyl carbons at 186.38 and 183.52 
ppm due to the unsymmetrical nature of the anthraquinone moiety. In contrast, L4
shows a single carbonyl carbon resonance at 184.83 ppm due to its symmetrical nature. 
In L1 and L2, the methylene carbon resonance was a doublet (2JCP ~ 16 Hz) ca. 48 ppm, 
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again consistent with the formation of the aminophosphine. High resolution mass 
spectrometry (HRMS) was obtained for each ligand, where [M+H]+ or [M]+ was observed 
in each case, thus confirming the proposed formulation.  IR spectra of the ligands 
allowed identification of ν(N-H) and in the case of L3 and L4, ν(C=O) stretching 
frequencies. In the cases of L5 and L6, ν(C-O) stretching frequencies were observed. 
Figure 3.11:1H NMR spectrum of [AuCl(L1)] 
The Au(I) complexes were similarly characterised by an array of techniques. Firstly, 31P 
NMR spectra (Table 3.1) revealed significant downfield shifts (up to around +30 ppm) 
for each of the complexes relative to the free ligands consistent with coordination to 
Au(I). As with the corresponding ligands, the phosphorus resonances for [AuCl(L1)] and 
[AuCl(L2)] are very similar (ca. +65 ppm), while [AuCl(L3)] appeared at +55.77 ppm and 
[Au2Cl2(L4)] at +56.63. 1H NMR spectra show retention of the fluorophore labelled 
aminophosphine in each case (with the appropriate number of aromatic resonances), 
and for [AuCl(L1)] (Figure 3.11) and [AuCl(L2)] the methylene resonances were shifted 
downfield by around +0.2 ppm upon formation of the complexes. These spectra also 
show the NH resonance again confirming the integrity of the aminophosphine upon 
coordination to Au(I). For [AuCl(L3)] and [Au2Cl2(L4)], the 13C NMR spectrum showed a 
subtle shift in the carbonyl carbon resonances of the anthraquinone unit (two for 
[AuCl(L3)] and one for [Au2Cl2(L4)]), while for [AuCl(L1)] and [AuCl(L2)] the methylene 
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carbon was again around 48 ppm. HRMS data showed [M-H]- or [M-Cl]+ for each of the 
complexes supporting their successful formation. An example for [AuCl(L2)] is shown in 
Figure 3.12.  
3.3.3 X-ray Crystallography 
In addition to solution state characterisation, confirmation of the solid-state structures 
was provided through X-ray crystallographic studies on one complex, [AuCl(L3)]. Crystals 
suitable for X-ray diffraction were obtained by room temperature vapour diffusion of 
diethyl ether into a concentrated acetonitrile solution of [AuCl(L3)]. Data collection, 
refinement and structure solution was conducted by Dr Peter Horton at the UK National 
Crystallography Service, Southampton. Data collection parameters are shown in Table 
3.2, together with selected bond length and bond angle data in Table 3.3. The resultant 
structures of [AuCl(L3)] are shown in Figure 3.13. 
Figure 3.12: HRMS of [AuCl(L2)]
N
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The X-ray crystal structure for [AuCl(L3)] confirms the suggested formulation in the solid 
state (Figure 3.13). Within the structure there are two independent molecules within 
the asymmetric unit. The structure reveals the integrity of the anthraquinone 
functionalised aminophosphine and its coordination to Au(I). The complex adopts an 
approximately linear coordination geometry at Au(I) with ∠P-Au-Cl in the range 
176.75(2)-178.38(2). The Au-P and Au-Cl bond lengths are around 2.22 Å and 2.29 Å, 
respectively. The geometry around the nitrogen atom is approximately trigonal planar 
rather than pyramidal as noted in the X-ray structures of other aminophosphines.100 The 
P-N distances are ca. 1.67 Å. While these can be regarded as relatively short when 
compared to other aminophosphines,13 the distinction here is that the ligand is 
coordinated; Woollins has previously reported a Pt(II) complex of a bis-aminophosphine 
with a comparable reported P-N distance of 1.6843(19) Å.49 The structure also reveals 
an intramolecular hydrogen bonding interaction of 2.9 Å between the N-H and C=O 
Figure 3.13:Crystal structure of [AuCl(L3)]. Ellipsoid drawn at 50% probability
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groups of the anthraquinone. The influence of this, together with the relatively 
planarised nitrogen, is to orient the P-N bond in the plane of the anthraquinone. 
Figure 3.14: Packing diagram for [AuCl(L3)]
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Sample [AuCl(L3)]
Empirical formula C26H18AuClNO2P
Formula weight 639.80
Temperature 100(2) K
Wavelength 0.71073 Å
Crystal system Triclinic
Space group P−1
Unit cell dimensions 9.23605(10) Å α = 90.9323(9)°
14.82932(17) Å β = 101.3732(9)°
16.64944(19) Å γ = 94.2899(9)°
Volume 2228.21(4) Å3
Z 4
Density (calculated) 1.907 g / cm-3
Absorption coefficient 6.819 mm−1
Crystal Block; orange
Crystal size 0.167×0.059×0.050 mm3
θ range for data collection 2.497 − 27.483°
Reflections collected 60900
Independent reflections 10204 [Rint = 0.0335]
Absorption correction Semi−empirical from equivalents
Data / restraints / parameters 9595 / 0 / 577
Goodness-of-fit on F2 1.032
Final R indices [F2 > 2σ(F2)] R1 = 0.0176, wR2 = 0.0391
R indices (all data) R1 = 0.0197, wR2 = 0.0399
Largest diff. peak and hole 0.74 and −0.506 e Å−3
Table 3.2:Data collection parameters for the X-ray structures 
The packing arrangement displayed in Figure 3.14 revealed a number of intermolecular 
π-π interactions for [AuCl(L3)] that exist between phenyl rings of the anthraquinone 
unit, and the phenyl rings of the diphenylphosphine moiety. From the packing 
arrangements, the angles between the two planes involved in these interactions are 
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0.000, 0.664 and 3.656 °, the centroid-centroid distances are 3.559, 3.615, 3.702, 3.819, 
3.823 and 3.939 Å, and the shift distances are 0.961, 1.258, 1.484, 1.486 and 2.263 Å. 
The closest interactions are between the anthraquinone units of neighbouring complex 
units. There are no aurophilic interactions revealed by this structure, presumably due to 
the large steric requirements of the aminophosphine ligand. 
Selected bond lengths (Å)
Au(1)-Cl(1) 2.2874(5) Au(31)-Cl(31) 2.2900(6)
Au(1)-P(1) 2.2225(6) Au(31)-P(31) 2.2224(6)
P(1)-N(1) 1.6774(19) P(31)-N(31) 1.6851(19)
Selected bond angles (Å)
P(1)-Au(1)-Cl(1) 178.38(2) P(31)-Au(31)-Cl(31) 176.75(2)
N(1)-P(1)-Au(1) 116.88(7) N(31)-P(31)-Au(31) 117.38(7)
Table 3.3:Selected bond lengths and bond angles for [AuCl(L3)]
The steric properties of L3 have also been assessed from the crystal data by use of the 
SambVca 2 program101  for determination of buried volume (%Vbur) and the method of 
Mingos102  for deriving crystallographic cone angles. The %Vbur values for the two 
independent molecules in the unit cell are 32.0 and 32.9 respectively, with attendant 
cone angles of 163° and 169°. These relatively large values reflect the absence of any 
steric hindrance at the metal (as is typical for a linear L-Au-Cl complex) with the largest 
values being associated with the complex where both phenyl rings are orthogonal with 
M-P-C-C torsion angles of 13.3° and 9.9°. 
3.3.4 Photophysical Properties  
The photophysical properties of all the ligands and complexes were investigated via UV-
vis., steady state luminescence and luminescence lifetimes, measured in aerated 
solutions of acetonitrile in all cases, excluding L5 and L6 where measurements were 
carried out in aerated solutions of chloroform. For the complexes, quantum yields were 
also obtained. This was not carried out for any of the ligands due to instability in solution 
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for extended time periods. A summary of the photophysical properties are shown in 
Table 3.4. 
Figure 3.15: UV-vis spectra of L1-L4
The absorption spectra for the ligands are dominated by π→π* absorbances associated 
with the various aromatic units (Figures 3.15 and 3.16). The phenyl substitutents 
contribute at the higher energies (<260 nm), while the naphthyl, pyrenyl, anthracenyl 
and anthraquinone chromophores gave absorbances at progressively longer 
wavelengths. For L2 and L6, the spectra revealed a vibronically structured appearance 
at 300-375 nm, consistent with the various pyrene centred π→π* transitions. Similarly, 
L5 showed a vibronically structured appearance at 330-385 nm.  
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Figure 3.16: UV-vis spectra of L5 & L6 
Figure 3.17: UV-vis spectra of the complexes
In the case of the anthraquinone derivatives, L3 and L4, a lowest energy broad absorption 
band appeared at 470 nm (ε ~ 5000 M-1 cm-1) and 600 nm (ε ~ 5000 M-1 cm-1) respectively. 
Amine-substituted anthraquinone derivatives are known to possess N-to-quinone 
transitions that can be described as ICT103 due to the donor-acceptor character of the 
chromophore. The precise positioning of the ICT band can depend upon the nature and 
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position of the substitutent on the anthraquinone core. Therefore the 470 nm and 600 
nm bands are also ascribed to an ICT-type transition, but one that may involve 
participation from the bonded P atom in the donor component. 
For the Au(I) complexes the UV-vis. spectra were dominated by the ligand-centred 
transitions discussed above (Figure 3.17), with minor perturbations observed as a 
consequence of coordination to Au(I). The cases of [AuCl(L3)] and [Au2Cl2(L4)] are most 
noteworthy, both with a hypsochromic shift of the ICT visible band. The shift is 
consistent with a reduction in the donor ability of the nitrogen donor at anthraquinone, 
and rationalised by the attachment of the gold atom to the anthraquinone unit through 
the P-N bond.  
Compound λabs / nma λem / nm τobs / nsb φ c
L1 293, 282, 272, 262, 223 339 6.5 -d
L2 375, 344, 328, 314, 300, 276, 
266, 242, 235 sh 
398, 478 8.0 -d
L3 470, 309, 279, 269, 245, 228 sh 571 1.0 -d
L4 600, 555, 371, 255, 224 630 1.5 -d
L5 385, 365, 347, 330, 283 sh, 255 418, 442 1.5 -d
L6 376, 347, 331, 316, 302, 279, 
268, 257 
397 sh, 417 4.5 -d
[AuCl(L1)] 291, 282, 272, 223 339 3.9 8 %
[AuCl(L2)] 375, 343, 327, 313, 300, 276, 
266, 242, 233 
377, 397, 
417
14.9 17 %
[AuCl(L3)] 442, 298, 270, 241, 224 574 1.0 2 %
[Au2Cl2(L4)] 523, 325, 282, 254, 224 603 1.3 2%
Table 3.4:Absorption and emission data for the complexes a measurements obtained in MeCN solutions 
(with the exception of L5 and L6: CHCl3); b using λex 295 nm.; c for quantum yield measurements using 
[Ru(bpy)3](PF6)2 as reference of 0.016 in aerated MeCN;d not determined due to air-sensitivity in solution. 
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Figure 3.18: Emission profiles of L1-4 
Figure 3.19: Emission profiles of L5 and L6 
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Figure 3.20: Emission profiles for the complexes 
Each of the ligands was shown to be fluorescent in solution, with emission wavelengths 
(Table 3.4) and profiles (Figures 3.18 and 3.19) consistent with the presence of the 
fluorophore; the emission energy decreased across the series L1 (naphthyl) > L2
(pyrenyl) > L3 (anthraquinone) > L4 (anthraquinone). For L5 and L6, similar emission 
energies were observed, with emission intensity maxima at ca. 417 nm in both cases. In 
the case of L2, the emission profile was composed of both structured monomer-type 
(350-425 nm) and a broader feature at 475 nm which was attributed to excimer-type 
emission. For L3, the visible emission peak at ca. 575 nm was broad and structure-less 
in appearance which is consistent with an emitting state of ICT character localised on 
the aminoanthraquinone group. By comparison of L3 and L4, it can be seen that 
movement from a mono-substituted anthraquinone moiety to a disubstituted causes a 
bathochromic shift in the visible emission peak, which is consistent with literature 
examples.104,105
Time-resolved measurements (λex = 295 nm) revealed observed lifetimes that were 
consistent with fluorescence emission in all cases (Table 3.4). The corresponding 
measurements on the complexes, using excitation wavelengths that correlate with the 
ligand-based absorption bands, revealed that the characteristic ligand-based 
fluorescence was retained upon complexation to Au(I) (Figure 3.20). For [AuCl(L2)] the 
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appearance of the emission profile was highly structured with no evidence of excimer-
type emission. The emission spectra of L2 and [AuCl(L2)] were obtained using the same 
concentration solutions (2.5 × 10-5 M), and therefore suggests that the presence of the 
coordinated {AuCl} unit may inhibit π-π stacking (the excimer band in L2 may be due to 
intramolecular interactions between the pyrene and phenyl groups within the ligand). 
[AuCl(L3)] and [Au2Cl2(L4)] again showed visible region ICT-based fluorescence bands 
with small shifts attributed to metal-based perturbation upon Au(I) coordination. It is 
noteworthy that formation of the complexes led to variations in the recorded lifetimes, 
and in the case of [AuCl(L2)] an extension to ca. 15 ns. This may indicate that the 
quenching of the pyrene fluorophore is inhibited by coordination to Au(I). In all cases 
the observed lifetimes suggest a ligand-centred emission which is fluorescent in nature. 
Quantum yields were also obtained for the complexes using aerated solvent and 
determined to be 8%, 17%, 2% and 2% for [AuCl(L1-3)] and [Au2Cl2(L4)], respectively. 
3.3.5 Density Functional Theory Studies 
Supporting TD-DFT calculations of L3 and [AuCl(L3)] were computed to assist and inform 
the assignments of the electronic transitions noted from experimental observations. 
These calculations were performed by Dr Benjamin Ward. Long-range corrected 
functionals such as CAM-B3LYP106 are often required to give an adequate description of 
excited states with a significant charge-transfer component.107   In this case however, all 
the TD-DFT analyses (vide infra) gave excitation energies that were significantly higher 
in energy than those observed experimentally. After several functionals were screened, 
the M06 functional gave good agreement between experiment and theory,108  and was 
therefore used throughout.  The SDD basis set,109 along with associated effective core 
potentials, was used for the Au atom, as is common practice for heavy transition metals; 
Dunning’s correlation-consistent double-ζ basis set cc-pVDZ gave good results with 
reasonable computational cost,110 although the cc-pV(D+d)Z basis set was used for the 
third period elements, since this gives improved d-polarization compared to the original 
formulations,111  and is likely to be beneficial in coordination complexes bearing P and 
Cl donors. 
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Figure 3.21:Calculated structure of [AuCl(L3)] [M06 – SDD/cc-pV(D+d)Z/cc-pVDZ]112
The calculated structure of [AuCl(L3)] is shown in Figure 3.21, and is in good agreement 
with that obtained from X-ray data.  The Au-donor distances (see Table 3.3) are slightly 
overestimated in the calculated structure (Au–Cl: calculated = 2.356 Å, experimental = 
2.2874(5) Å and 2.2900(6) Å; Au–P: calculated = 2.296 Å, experimental = 2.2225(6) Å and 
2.2224(6) Å), whilst those within the ligand manifold are more accurately reproduced 
(e.g. P–N: calculated = 1.698 Å, experimental = 1.6774(19) Å and 1.6851(19) Å).  The 
trigonal planar (sp2-hybridized) amine is well replicated by the calculations (sum of 
angles subtended at N: calculated = 358.2°, experimental = 360.0° for both independent 
molecules in the asymmetric unit).  The modest differences in bond distance are not 
thought to be significant in light of crystal packing forces and temperature effects (X-ray 
data were collected at 100 K), and other properties pertaining to this complex were well-
reproduced (vide infra). 
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The 31P NMR shielding tensors were calculated to validate the observed experimental 
values; this is especially relevant since there are few literature examples of this 
molecular fragment to give a reliable expected chemical shift range.  As noted by 
Pellegrinet,113,114 the accuracy of such calculations can be improved by ensuring that a 
suitable reference molecule is chosen and calculated at the same level of theory. Given 
the structure of L3 (i.e. bearing two phenyl groups), PPh3 was used, and for which the 
experimental chemical shift is well established (–6 ppm).  These calculations allowed the 
31P NMR chemical shifts (Table 3.1) of L3 and [AuCl(L3)] to be estimated as +26.8 and 
+49.9 ppm respectively, in good agreement with the experimental values of +26.1 and 
+55.8 ppm. 
Figure 3.22:Simulated UV-vis absorption spectra of L3 and [AuCl(L3)] [M06 – SDD/cc-
pV(D+d)Z/cc-pVDZ]112
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The underlying electronic basis of the observed differences in the absorption spectra for 
L3 and its Au(I) complex was also investigated.  Simulated spectra, derived from the TD-
DFT data, are shown in Figure 3.22, and represent a good agreement with those 
obtained experimentally.  The principal area of interest is the low energy band between 
400 and 500 nm, which undergoes a significant blue-shift upon coordination to the Au(I) 
centre, as observed in the experimental data.  As expected, the low energy bands 
correspond primarily to HOMO-LUMO transitions in both L3 and [AuCl(L3)] (Figure 3.22), 
and are dominated by significant π-π* character within the substituted anthraquinone.  
In addition, the HOMO of L3 contains appreciable orbital coefficients based upon the 
phosphorus and nitrogen atoms, effectively the P and N lone pairs, which gives the low 
energy transition a combination of π-π*, n(P)-π*, and n(N)-π* character.  The nitrogen 
orbital component is retained in the HOMO of [AuCl(L3)], but the phosphorus orbital 
character is somewhat altered, as expected, due to coordination of the phosphorus 
atom to the Au(I) centre; in [AuCl(L3)] this component is encompassed in the Au-P σ-
bond and thus σAu-P-π* character may also contribute to the HOMO-LUMO transition 
Figure 3.23:Top: Calculated a) HOMO and b) LUMO of L3 [M06 – SDD/cc-pV(D+d)Z/cc-pVDZ]. Bottom: Calculated 
a) HOMO and b) LUMO of [AuCl(L3)] [M06 – SDD/cc-pV(D+d)Z/cc-pVDZ]112
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(Figure 3.23).  Considering the energies of the orbitals involved, the energy of the LUMO 
is lowered very slightly upon Au coordination, from –2.83 eV in L3 to –2.98 eV in 
[AuCl(L3)], whereas the corresponding effect on the HOMO is much more pronounced, 
reducing the energy from –6.29 eV to –6.80 eV.  Thus, in effect, the observed blue shift 
in the absorption spectra is predicted upon lowering of the HOMO upon coordination of 
the Au(I) ion. 
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3.4 Conclusions 
This chapter has described the synthetic development and spectroscopic analysis of a 
series of aminophosphines and phosphinite fluorophores, generating six new ligands, 
where L1-4 were utilised for Au(I) coordination chemistry.  
Two fluorescent, functionalised phosphinites (L5 and L6) have been synthesised from a 
corresponding methanol-functionalised fluorophore and chlorodiphenylphosphine, 
where fluorophores include anthracene and pyrene. In addition, four aminophosphines 
(L1-4) have been synthesised straightforwardly using an appropriate amino-derived 
fluorophore and chlorodiphenylphosphine. Examples in this chapter show that 
naphthyl, anthracenyl or anthraquinone fluorophores can be incorporated into 
aminophospine ligand structures in this way. The ligands L1-L4 react with [AuCl(tht)] to 
give the expected Au(I) complexes via coordination through the phosphorus donor.  
The resultant 31P NMR spectra of the complexes show significant downfield shifts (+22 
to +31 ppm) for the coordinated aminophosphines. An X-ray structure for the 
anthraquinone derivative, [AuCl(L3)], showed the expected linear coordination 
geometry at Au(I) and significant intermolecular packing interactions between 
neighbouring anthraquinone units. The complexes are luminescent with ligand-based 
emission dominating. In the series, [AuCl(L3)] shows visible emission at 574 nm which is 
attributed to ICT-type emitting state localised on the phosphino-amino-anthraquinone 
unit and is relatively similar to the free ligand. In contrast, the dimetallic complex, 
[Au2Cl2(L4)], displays a hypsochromically shifted emission wavelength when compared 
to the free ligand (630 nm and 603 nm, respectively).
Supporting TD-DFT calculations reliably reproduced the structural features of [AuCl(L3)] 
and support the notion that the emission is ICT in nature with coordination to Au(I) 
diminishing the phosphorus contribution to the HOMO. The adopted TD-DFT 
approaches can also reliably reproduce the excitation energies for the anthraquinone 
derivative and provide further validation via calculated 31P NMR chemical shifts. Future 
work will explore and expand the coordination chemistry of fluorescent 
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aminophosphine and phosphinite ligands and investigate their viability in bioimaging 
and catalytic applications.
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3.5 Experimental  
3.5.1 General Experimental Considerations 
All reagents and solvents were commercially available and were used without further 
purification if not stated otherwise. For the measurement of 1H, 31P, and 13C NMR 
spectra a Bruker Fourier300 (300 MHz), Bruker AVANCE HD III equipped with a BFFO 
SmartProbeTM (400 MHz) or Bruker AVANCE III HD with BBO Prodigy CryoProbe 
(500 MHz) was used. The obtained chemical shifts δ are reported in ppm and are 
referenced to the residual solvent signal. Spin-spin coupling constants J are given in Hz.   
Low-resolution mass spectra were obtained by the staff at Cardiff University. High-
resolution mass spectra were carried out at the EPSRC National Mass Spectrometry 
Facility at Swansea University. High resolution mass spectral (HRMS) data were obtained 
on a Waters MALDI-TOF mx at Cardiff University or on a Thermo Scientific LTQ Orbitrap 
XL by the EPSRC UK National Mass Spectrometry Facility at Swansea University. IR 
spectra were obtained from a Shimadzu IR-Affinity-1S FTIR. UV-Vis studies were 
performed on a Shimadzu UV-1800 spectrophotometer as MeCN solutions (2.5 or 5 × 
10-5 M) or CHCl3 solutions (2.5 or 5 × 10-5 M). Photophysical data were obtained on a 
JobinYvon–Horiba Fluorolog spectrometer fitted with a JY TBX picosecond 
photodetection module as MeCN/CHCl3 solutions. Emission spectra were uncorrected. 
The pulsed source was a Nano-LED configured for 459 nm output operating at 1 MHz. 
Luminescence lifetime profiles were obtained using the JobinYvon–Horiba FluoroHub 
single photon counting module and the data fits yielded the lifetime values using the 
provided DAS6 deconvolution software. Quantum yield measurements were obtained 
on aerated MeCN solutions of the complexes using [Ru(bpy)3](PF6)2 in aerated MeCN as 
a standard (Φ = 0.016).115
3.5.2 X-ray Diffraction  
Single orange block-shaped crystals of [AuCl(L3)] were submitted. A suitable crystal 
(0.167 × 0.059×0.050) mm3 was selected and mounted on a MITIGEN holder in 
perfluoroether oil on a Rigaku FRE+ equipped with HF Varimax confocal mirrors and an 
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AFC12 goniometer and HG Saturn 724+ detector diffractometer. The crystal was kept at 
T = 100(2) K during data collection. Using Olex2116, the structure was solved with the 
Superflip117 structure solution program, using the Charge Flipping solution method. The 
model was refined with version 2014/7 of ShelXL118 using Least Squares minimisation. 
All non-hydrogen atoms were refined anisotropically. Hydrogen atom positions were 
calculated geometrically and refined using the riding model. The value of Z' is 2. This 
means that there are two independent molecules in the asymmetric unit. 
3.5.3 Preparation of Aminophosphine Ligands and Complexes 
Preparation of aminophosphine ligands  
Synthesis of L1 
1-Naphthalenemethylamine (0.17 ml, 1.4 mmol) and triethylamine (0.19 ml, 1.4 
mmol) were dissolved in deaerated dichloromethane (10 ml) under a nitrogen 
atmosphere. Diphenylchlorophosphine (0.21 ml, 1.4 mmol) in dicloromethane 
(10ml) was added dropwise at 0 °C over 10 minutes. The resulting solution was 
stirred at room temperature for 2 hours. The solution was then washed with 
deaerated water (20 ml), dried over MgSO4 and the solvent removed in vacuo to 
give L1 as a colourless oil (463 mg, 97 %).  1H NMR (400 MHz, CDCl3): δH 7.91 – 
7.87 (m, 1H), 7.77 (dd, JHH = 6.8, 2.8 Hz, 1H), 7.67 (d, 3JHH = 7.8 Hz, 1H), 7.43-7.34 
(m, 7H), 7.34 – 7.24 (m, 7H), 4.44 (app. t, 3JHH = 6.7 Hz, 2H, CH2), 2.25 – 2.16 (m, 
1H, NH) ppm. 13C{1H} NMR (101 MHz, CDCl3): δC 141.20 (d, JCP = 12.5 Hz), 137.08 
(d, JCP = 8.1 Hz), 133.95, 132.33, 132.23, 131.68, 131.48, 128.98, 128.84, 128.79, 
128.73, 128.45, 128.96, 128.39, 127.99, 126.20, 125.82, 125.75, 125.70, 125.57, 
123.89, 123.32, 48.12 (d, JCP = 16.3 Hz) ppm. 31P{1H} NMR (162 MHz, CDCl3): δP
+42.19 ppm. HRMS found m/z 342.1400, calcd m/z 342.1412 for [C23H20NP]+. UV-
vis. (MeCN) λmax (ε / dm3mol-1cm-1): 293 (8520), 282 (12520), 272 (12360), 262, 
(11280), 223 (86480) nm. IR (solid) ν / cm-1: 3399, 3243, 3049, 1595, 1581, 1508, 
1477, 1431, 1390, 1321, 1311, 1261, 1167, 1094, 1082, 1061, 1026, 997, 970, 910, 
883, 858, 839, 794, 769, 740, 711, 634, 617, 594, 552, 521, 507, 488, 469, 444, 
420, 413. 
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Synthesis of L2 
As with L1, but using, 1-pyrenemethylamine (487 mg, 2.1 mmol), triethylamine 
(0.33 ml, 2.5 mmol), diphenylchlorophosphine (0.38 ml, 2.1 mmol) and 
dichloromethane (20 ml) to give L2 as a yellow oil (808 mg, 93 %). 1H NMR (400 
MHz, CDCl3): δH 8.14 – 8.06 (m, 2H), 8.02 – 7.83 (m, 7H), 7.69 (dd, JHH = 11.1, 7.6 
Hz, 1H), 7.50 (app. t, JHH = 7.9 Hz, 1H), 7.45 – 7.39 (m, 5H), 7.28 (d, 3JHH = 5.1 Hz, 
2H), 7.18 – 7.13 (m, 1H), 4.67 (app. t, 3JHH = 6.6 Hz, 2H, CH2), 2.34 – 2.26 (m, 1H, 
NH) ppm. 13C{1H} NMR (101 MHz, CDCl3): δC 141.18 (d, JCP = 12.5 Hz), 135.54 (d, 
JCP = 7.1 Hz), 135.34 (d, JCP = 7.1 Hz), 134.87 (d, JCP = 8.0 Hz), 131.71, 131.52, 
131.41, 130.89 (d, J = 7.9 Hz), 129.74, 128.98, 128.78, 128.75, 128.67, 128.59, 
128.57, 128.44 (d, J = 6.2 Hz), 127.72, 127.56, 127.25, 126.69, 126.02, 125.24, 
125.18, 125.13, 124.95, 124.87, 123.36, 48.26 (d, JCP = 15.8 Hz) ppm. 31P{1H} NMR 
(202 MHz, CHCl3): δP +42.12 ppm. HRMS found m/z 415.1484, calcd m/z 415.1490 
for [C29H22NP]+. UV-vis: (MeCN) λmax (ε / dm3mol-1cm-1): 375 (920), 344 (34480), 
328 (23800), 314 (10800), 300 (6040), 276 (39680), 266 (27120), 242 (56960), 235 
sh (46440) nm. IR (solid) ν / cm-1: 3044, 2963, 2857, 1601, 1585, 1477, 1431, 1414, 
1391, 1342, 1306, 1261, 1179, 1173, 1159, 1088, 1067, 1026, 997, 968, 912, 893, 
841, 816, 739, 719, 692, 617,586, 555, 513, 419, 409, 401. 
Synthesis of L3 
As for L1, but using 1-aminoanthraquinone (1 g, 4.6 mmol), triethylamine (0.74 
ml, 5.5 mmol), diphenylchlorophosphine (0.85 mmol, 4.6 mmol) and 
dichloromethane (30 ml) to give L3 as a dark orange solid (583 mg, 64 %). 1H NMR 
(500 MHz, CDCl3): δH 10.36 (d, 2JHP = 7.3 Hz, 1H, NH), 8.17 – 8.08 (m, 2H), 7.87 – 
7.80 (m, 1H), 7.67 – 7.57 (m, 5H), 7.47-7.39 (m, 6H), 7.29-7.26 (m, 2H), 7.12 (s, 
1H) ppm. 13C{1H} NMR (126 MHz, CDCl3): δC 186.38 (C=O), 183.52 (C=O), 152.47, 
152.33, 139.00, 138.92, 135.26, 135.24, 134.74, 134.61, 134.17, 133.62, 133.14, 
131.47 (d, JCP = 21.3 Hz), 129.65, 128.90 (d, JCP = 7.1 Hz), 127.04 (d, JCP = 16.9 Hz), 
126.93, 123.27, 122.78, 122.55, 118.50, 117.40, 116.09, 116.07 ppm. 31P{1H} NMR 
(162 MHz, CHCl3): δP +26.11 ppm. UV-vis. (MeCN) λmax (ε / dm3mol-1cm-1): 470 
(4880), 309 (7880), 279 (16160), 269 (18120), 245 (36720), 228 sh (32720) nm. 
HRMS found m/z 408.1167, calcd m/z 408.1153 for [C26H19N2OP]+.  IR (solid) ν / 
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cm-1:  3167, 3051, 1668, 1630, 1593, 1570, 1431, 1396, 1346, 1300, 1253, 1231, 
1169, 1092, 1070, 1040, 1018, 997, 912, 893, 831, 806, 775, 748, 735, 704, 692, 
602, 546, 513, 476, 436, 420.  
Synthesis of L4 
As for L1, but using 1,4-diaminoanthraquinone (250 mg, 1.05 mmol), 
triethylamine (0.33 ml, 2.5 mmol) and diphenylchlorophosphine (0.38 ml, 2.1 
mmol) and dichloromethane (15 ml) to give L4 as a dark pink solid (408 mg, 64 %). 
1H NMR (400 MHz, CDCl3) δ 11.13 (d, 2JHP = 6.0 Hz, 2H, NH), 8.23 – 8.14 (m, 2H), 
7.96 – 7.91 (m, 2H), 7.62 – 7.55 (m, 4H), 7.48 – 7.37 (m, 14H), 7.15 (d, JHH = 2.9 Hz, 
2H). 13C{1H} NMR (101 MHz, CDCl3) δ 184.83 (C=O), 147.18, 147.00, 145.98, 
139.27, 139.18, 139.10, 134.35, 134.25, 132.94, 132.88, 132.61, 131.40 (d, JCP = 
21.0 Hz), 131.32, 129.41, 128.70 (d, JCP = 7.1 Hz), 128.46, 128.22, 126.55. 31P{1H} 
NMR (162 MHz, CHCl3): δP +26.30 ppm. HRMS found m/z 607.1702, calcd m/z
607.1704 for [C38H29N2P2O2]+.  UV-vis: (MeCN) λmax (ε / dm3mol-1cm-1): 600 (4400), 
555 (5520), 371 (2800), 255 (31520), 224 (34440). IR (solid) ν / cm-1:  3053, 1614, 
1582, 1560, 1533, 1464, 1433, 1395, 1367, 1335, 1287, 1240, 1161, 1123, 1109, 
1096, 1024, 972, 907, 883, 822, 797, 729, 691, 529, 509, 461, 419, 411.  
Preparation of aminophosphine complexes  
Synthesis of [AuCl(L1)] 
L1 (111 mg, 0.32 mmol) and tetrahydrothiophenegold chloride (94 mg, 0.29 
mmol) were added to degassed dichloromethane (20 ml) and the solution stirred 
at room temperature under nitrogen for 1.5 hours. The solvent was reduced in 
vacuo and hexane added dropwise. The mother liquor was decanted to leave 
[AuCl(L1)] as a grey solid (35 mg, 21 %). 1H NMR (400 MHz, CDCl3): δH 7.96 (d, 3JHH
= 7.9 Hz, 1H), 7.87 (d, 3JHH = 8.4 Hz, 1H), 7.79 (d, 3JHH = 8.2 Hz, 1H), 7.67 (d, 3JHH = 
7.5 Hz, 2H), 7.64 (d, 3JHH = 7.4 Hz, 2H), 7.54-7.48 (m, 4H), 7.48-7.42 (m, 5H), 7.42 
– 7.36 (m, 1H), 4.71 – 4.64 (m, 2H), 2.71-2.63 (m, 1H, NH) ppm. 13C{1H} NMR (101 
MHz, CDCl3): δC 134.06, 132.70, 132.55, 132.38, 132.35, 131.80, 131.17, 129.30, 
129.18, 129.09, 129.06, 126.84, 126.70, 126.21, 125.54, 123.41, 47.89 ppm. 
31P{1H} NMR (162 MHz, CDCl3): δP +64.58 ppm. UV-vis. (MeCN) λmax (ε / dm3mol-
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1cm-1): 291 (9080), 282 (13160), 272 (12920), 223 (97680) nm. HRMS found m/z
572.0629, calcd m/z 572.0609 for [C23H19AuClNP]-. IR (solid) ν / cm-1: 3248, 3207, 
3049, 2359, 1595, 1576, 1555, 1508, 1499, 1476, 1460, 1435, 1395, 1379, 1306, 
1265, 1248, 1180, 1167, 1105, 1063, 1041, 1026, 995, 962, 881, 854, 800, 789, 
770, 745, 714, 691, 619.  
Synthesis of [AuCl(L2)] 
L2 (267 mg, 0.64 mmol) and tetrahydrothiophenegold chloride (187 mg, 0. 58 
mmol) were added to degassed dichloromethane (20 ml) and the solution stirred 
at room temperature under nitrogen for 2 hours. The solvent was reduced in 
vacuo and diethyl ether added dropwise. The resultant precipitate was filtered 
and dried to yield [AuCl(L2)] as a pale yellow solid (50 mg, 13 %). 1H NMR (500 
MHz, CDCl3): δH 8.15 – 8.10 (m, 3H), 8.05 (d, 3JHH = 9.2 Hz, 1H), 7.99 (d, 3JHH = 8.9 
Hz, 1H), 7.95 (s, 1H), 7.87 (d, 3JHH = 7.7 Hz, 1H), 7.74 (dd, JHH = 13.9, 7.1 Hz, 2H), 
7.62 – 7.56 (m, 4H), 7.41 – 7.37 (dd, JHH = 7.4, 1.8 Hz, 1H), 7.36 – 7.31 (m, 3H), 7.23 
(app. t, JHH = 7.2 Hz, 2H), 4.83 (dd, JHH = 8.8, 6.4 Hz, 1H), 2.75 (br. s, 1H, NH) ppm. 
13C{1H} NMR (101 MHz, CDCl3): δC 134.25, 133.14, 132.69, 132.54, 132.33, 132.27, 
131.41, 131.38, 130.83, 129.41, 129.29, 129.17, 128.89, 128.56, 128.03, 127.91, 
127.87, 127.48, 127.15, 126.34, 125.74, 125.62, 124.97, 124.84, 124.80, 122.78, 
122.66, 119.82, 48.21 ppm. 31P{1H} NMR (202 MHz, CDCl3): δP +64.72 ppm. UV-
vis. (MeCN) λmax (ε / dm3mol-1cm-1): 375 (200), 343 (25280), 327 (18120), 313 
(8640), 300 (5080), 276 (32480), 266 (21240), 242 (51680), 233 (42280) nm. HRMS 
found m/z 612.1143, calcd m/z 612.1150 for [C29H22AuNP]+. IR (solid) ν / cm-1: 
3379, 3036, 2363, 1605, 1587, 1553, 1504, 1499, 1477, 1435, 1418, 1395, 1375, 
1304, 1240, 1180, 1169, 1130, 1101, 1067, 1049, 1022, 995, 961, 920, 903, 878, 
843, 825, 820, 808, 746, 723, 710, 692, 619.  
Synthesis of [AuCl(L3)] 
L3 (130 mg, 0.32 mmol) and tetrahydrothiophenegold chloride (93 mg, 0.29 
mmol) were added to degassed dichloromethane (15 ml) and the solution stirred 
at room temperature under nitrogen for 2 hours. The solvent was reduced in 
vacuo and diethyl ether added dropwise. The resultant precipitate was filtered 
and dried to give a crude solid. This was then purified by column chromatography 
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(silica) and eluted as the first fraction from 9:1 DCM:MeOH, to give [AuCl(L3)] as 
an orange solid (13 mg, 19 %). 1H NMR (500 MHz, CDCl3): δH 10.92 (d, 2JHP = 6.1 
Hz, 1H, NH), 8.31 – 8.24 (m, 2H), 7.95 (d, 3JHH = 7.4 Hz, 1H), 7.89 – 7.83 (m, 4H), 
7.80 (dd, JHH = 5.9, 2.1 Hz, 2H), 7.67 (d, JHH = 8.0 Hz, 1H), 7.64 – 7.60 (m, 3H), 7.60 
– 7.55 (m, 4H) ppm. 13C{1H} NMR (126 MHz, CDCl3): δC 187.47, 182.67, 146.60, 
135.88, 134.70, 134.55, 134.45, 134.09, 133.20, 133.18, 133.16, 132.71, 132.65 
(d, J = 16.1 Hz) 130.29, 129.83 (d, J = 12.7 Hz), 127.34, 122.84 (d, J = 13.8 Hz), 
120.96, 117.96, 117.92 ppm. 31P{1H} NMR (162 MHz, CDCl3): δP +55.77 ppm. HRMS 
found m/z 604.0791, calcd m/z 604.0735 for [C26H18AuNO2P]+. UV-vis. (MeCN) 
λmax (ε / dm3mol-1cm-1): 442 (3720), 298 (6040), 270 (16560), 241 (30240), 224 
(33760) nm. IR (solid) ν / cm-1: 3410, 3306, 3042, 2976, 2587, 2496, 2374, 1165, 
1632, 1585, 1543, 1472, 1460, 1435, 1396, 1344,1265, 1298, 1233, 1171, 1159, 
1105, 1042, 1022, 997, 829, 802, 777, 748, 735, 695, 640, 606.   
Synthesis of [Au2Cl2(L4)]
L4 (50 mg, 008 mmol) and tetrahydrothiophenegold chloride (48 mg, 0.15 mmol) 
were added to degassed dichloromethane (8 ml) and the solution stirred at room 
temperature under nitrogen for 2 hours. The solvent was reduced in vacuo and 
diethyl ether added dropwise. The resultant precipitate was filtered and dried to 
give [Au2Cl2(L4)] as a purple solid (31 mg, 35 %). 1H NMR (500 MHz, CDCl3) δ 11.24 
(d, J = 6.1 Hz, 2H), 8.27 – 8.25 (m, 2H), 7.84 – 7.78 (m, 8H), 7.62 – 7.62-7.59 (m, 
4H), 7.59 – 7.54 (m, 10H), 7.53 (s, 2H). 13C{1H} NMR (126 MHz, CDCl3) δ 186.54 
(C=O), 142.13, 135.41, 135.30, 134.54, 133.51, 133.34, 133.32, 132.67, 132.60 (d,
JCP = 16.1 Hz), 132.52, 130.70, 130.15, 129.91 (d, JCP = 12.7 Hz), 129.78, 129.68, 
127.26, 126.29, 126.18, 119.70.  31P{1H} NMR (202 MHz, CDCl3) δ + 56.63. HRMS 
found m/z 1035.0640, calcd m/z 1035.0640 for [C38H28Au2N2P2Cl]+.  UV-vis. 
(MeCN) λmax (ε / dm3mol-1cm-1): 523 (4240), 325 (4620), 282 (15640), 254 (31560), 
224 (34440). IR (solid) ν / cm-1: 3402, 2363, 2347, 1620, 1587, 1574, 1537, 1472, 
1435, 1364, 1342, 1294, 1242, 1177, 1126, 1105, 1030, 984, 901, 880, 827, 797, 
748, 729, 691, 528, 511, 438, 403.  
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3.5.4 Preparation of Substituted Phosphinite Ligands 
Synthesis of L5 
9-Anthracenemethanol ( 500 mg, 2.4 mmol) and 4-dimethylaminopyridine (DMAP) (59 
mg, 0.48 mmol) were dissolved in dry & degassed THF (30 ml). Triethylamine was added 
(2.9 mmol, 0.40 ml) followed by diphenylchlorophosphine (2.6 mmol, 0.48 ml). The 
resulting solution was stirred at room temperature for two hours under a nitrogen 
atmosphere. The solvent was reduced in vacuo and 9:1 hexane:ethyl acetate (50 ml) was 
added. The resulting mixture was filtered through celite and alumina and the solvent 
removed in vacuo to give LG334 as a yellow oil. (866 mg, 92%). 1H NMR (500 MHz, CDCl3) 
δ 8.31 (s, 1H), 8.21 (d, J = 8.7 Hz, 1H), 8.16 (d, J = 8.7 Hz, 1H), 7.85 (d, J = 8.1 Hz, 2H), 7.69 
– 7.60 (m, 1H), 7.41 – 7.30 (m, 8H), 7.25 – 7.13 (m, 5H), 5.68 (d, J = 8.0 Hz, 2H). 13C{1H} 
NMR (126 MHz, CDCl3) δ 141.90, 141.76, 132.23, 132.20, 131.84, 131.76, 131.52, 131.41, 
131.00, 130.90, 130.72, 130.55, 130.41, 129.38, 129.07, 129.05, 128.78, 128.53, 128.43, 
128.35, 128.30, 126.74, 126.32, 125.15, 125.05, 124.52, 124.02. 31P{1H} NMR (202 MHz, 
CDCl3) δ 113.74, 32.22 (minor oxidised product impurity). HRMS found m/z 393.1415, 
calculated m/z 393.1408 for [C27H22OP]+. λmax {ε/dm3 mol-1 cm-1}: 385 {7080), 365 {7880}, 
347 {5440}, 330 {3920}, 283 (s) (9720}, 255 {111320}. IR (solid. Vmax)/cm-1: 3051, 1720, 
1665, 1655, 1624, 1602, 1582, 1526, 1472, 1435, 1371, 1341, 1308, 1259, 1180, 1157, 
1128, 1111, 1093, 1053, 1026, 968, 887, 868, 845, 804, 770, 727, 690, 626, 602, 579, 
554, 515. 
Synthesis of L6 
As for L5, but using 1-pyrenemethanol (250 mg, 1.1 mmol), DMAP (26 mg, 0.22 mmol), 
dry & degassed THF (20 ml), triethylamine (0.17 ml, 1.3 mmol) and 
diphenylchlorophosphine (0.22 ml, 1.2 mmol) to give LG335 as a pale yellow oil (407 mg, 
91%). 1H NMR (400 MHz, CDCl3) δ 8.09 (d, J = 9.2 Hz, 1H), 7.96 (d, J = 7.6 Hz, 10H), 7.70 
– 7.61 (m, 1H), 7.47 (dd, J = 7.9, 6.9 Hz, 1H), 7.43 – 7.35 (m, 4H), 7.23-7.16 (m, 2H), 5.39 
(d, J = 8.9 Hz, 2H). 13C{1H} NMR (101 MHz, CDCl3) δ 140.69, 140.51, 134.38, 134.31, 
134.18, 134.11, 130.64, 130.24, 130.08, 129.62, 129.57, 129.36, 128.53, 128.25, 127.91, 
127.46, 127.24, 127.18, 126.59, 126.32, 126.27, 125.69, 124.77, 124.48, 124.12, 123.70, 
132
123.55, 123.42, 122.21. 31P{1H} NMR (162 MHz, CDCl3) δ 114.03. HRMS found m/z
416.1335, calculated m/z 416.1330 for [C29H21OP]+. λmax {ε/dm3 mol-1 cm-1}: 376 {1360}, 
347 {41400}, 331 {29160}, 316 {13520}, 302 {7920}, 279 {50200}, 268 {33520}, 257 
{23340}. IR (solid. Vmax)/cm-1: 3042, 1600, 1587, 1510, 1481, 1454, 1435, 1416, 1375, 
1371, 1306, 1223, 1182, 1126, 1094, 1063, 1026, 991, 980, 843, 816, 739, 691, 610. 
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Chapter 4 - Rapid, Machine-Assisted 
Syntheses of Substituted Iridium(III)-
Pyrazolate Complexes with Tuneable 
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4.1 Introduction
4.1.1 Synthesis and Applications of Pyrazole and Pyrazolate
The synthesis of heterocyclic compounds is an extremely important area of research. 
In an already established field, the diversity, simplicity of scale up and sustainability of 
the synthetic protocol represent key factors in the future progress of the field.1
Pyrazoles are characterized as five-membered heterocycles featuring two adjacent 
nitrogen atoms, with applications in materials, agrochemicals and pharmaceuticals, for 
example celecoxib, crizotinib, sildenafil and pyrazoxyfen (Figure 4.1).2
Figure 4.1: Structures of celecoxib, crizotinib, sildenafil and pyrazoxyfen2
Cyclo-condensation of hydrazines with 1,3-dicarbonyl compounds is the most common 
preparatory method for pyrazoles and pyrazolates at scale. This can either be carried 
out via cyclo-condensation with simple hydrazine followed by a non-selective alkylation 
of a tautomeric mixture, or by specific substitution of hydrazine followed by an 
electronically controlled regioselective cyclo-condensation. The latter of these synthetic 
methods is usually a more selective process and hence is more commonly used. 
However, because methods are associated with the preparation and storage of 
hydrazines on a large scale, there is a significant safety risk.1
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Palladium-catalysed cross-coupling methods have been utilised for the synthesis of 
substituted hydrazines, where the scope for this technique has been recently increased 
by the development of specific ligands that assist a difficult reductive elimination step.3
Due to this problematic step, a continuous flow approach has also been explored.4 In 
addition, amine-redox chemistry has been employed and allows access to a wide range 
of substituted hydrazine centres. This synthetic technique involves oxidation through 
diazotization, followed by reduction of the N-N triple bond, usually with tin(II) chloride. 
An example of this is provided by Widlicka et al, who reported N-aryl pyrazoles prepared 
from anilines in a three-step telescoped approach, where a continuous flow set up was 
used to minimise accumulation of the highly energetic and potentially explosive 
diazonium salt and hydrazine intermediates to enable safe scale up.5
Due to the increased importance of green chemistry, there has recently been advances 
in the use of more sustainable reductants that can be washed away from the product 
through simple aqueous extraction. In this vein, methods utilising ascorbic acid or 
sodium sulfite acting as a reductant have been described.6 In addition, a selection of di-
, tri- and tetrasubstituted pyrazoles have been synthesised from α,β-unsaturated 
aldehydes and ketones via I2-mediated oxidative C-N bond formation (Figure 4.2).7
Figure 4.2: Oxidative bond formation with I27
Recent work describes the first example of an end-to-end, metal-free, multistep 
continuous flow process.1 The process begins with an amine-redox cycle followed by 
hydrolysis of the hydrazine surrogate resulting in cyclo-condensation. The method 
involves by low levels of diazonium salt and hydrazine at all times, as well as the use of
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vitamin C as the reductant. The authors demonstrated that the conditions and 
parameters were applicable to a broad range of amine and 1,3-dicarbonyl substituents.
4.1.2 Pyrazole and Pyrazolate as Ligands
Heterocyclic compounds with bidentate and tridentate ligand capabilities have been 
extensively reviewed. For example, compounds containing six membered rings such as 
2,2’-bipyridine (bipy) and 1,10-phenanthroline (phen) have been the basis of many 
studies.8 The vacant low-lying π* orbitals in the nucleus makes them excellent π-
acceptors and hence they act as soft ligands for metal coordination. In contrast, the π-
excessive five-membered nitrogen heterocycle, pyrazole, is a better π-donor and thus 
acts as a hard donor site. Anionic tripodal ligands, poly(pyrazolyl)borates, have found a 
range of applications in bioinorganic and organometallic chemistry since their discovery 
in 1966.9 In more recent years, a wider range of pyrazole/pyrazolate-based chelating 
ligands have been utilised to create a range of coordination complexes, providing 
varying coordination geometry and nuclearity.8 These ligands have a huge potential in 
terms of their coordination chemistry as they can range from mono- through to tetra-
dentate, although in this chapter only bidentate applications will be discussed. In 
addition, the ease of synthesis is a beneficial factor in the design of new ligands, and 
allows electronic and steric control of the properties of the metal complexes.
Figure 4.3: 3-(2-pyridyl)pyrazole and 3-(2-phenyl)pyrazole
Estevan et al. conducted research that explored the versatility and ability of stabilizing 
pyrazole and pyrazolate ligands. In this work, novel palladium(II) and (III) compounds 
were synthesized and structurally characterized, where one compound was the first 
paddlewheel dinuclear palladium(II) compound with pyrazolato bridging ligands 
described in the literature.10
143
4.1.3 Pyrazole and Pyrazolates as Ligands for Iridium(III)
Pyrazoles and pyrazolates have been utilized as ligands for Ir(III). An example of this is 
provided by Costa et al., who incorporated a 3,5-dimethyl-1-phenylpyrazole ligand into 
an ionic iridium complex [Ir(dmppz)2(pbpy)][PF6] (Hdmppz = 3,5-dimethyl-1-
phenylpyrazole; pbpy = 6-phenyl-2,2’-bipyridine).11 This ligand was used to exploit the 
wider band gap of phenylpyrazole based ligands when compared to their 2-
phenylpyridine (ppy) based equivalents.12,13 The complex was used to form a 
supramolecular cage, upon which a new light emitting electrochemical cell (LEEC) was 
based which showed extremely high stability of around 2000 h. Rh(I) and Ir(I) complexes 
incorporating bidentate chelate groups through one pyrazole nitrogen and a pyridine 
nitrogen atom have also been described, where the Ir(I) compounds act as modest 
catalysts for the hydrosilyation of phenylcetylene with triethylsilane at 60 °C.14 In 
addition, Han et al. described DFT studies and photophysical properties of three novel 
heteroleptic iridium(III) complexes bearing two cyclometalated 2’,6’-difluoro-2,3’-
bipyridyl (dfpypy) chelates and one pyridyl pyrazolate ligand (Figure 4.4).15 It was shown
that the lowest energy absorption wavelength calculated is in agreement with the 
experimental value, where the lowest energy emissions are localised between 454 and 
821 nm. A range of iridium(III) complexes with similar designs and photophysical 
properties have also been reported for use as highly efficient phosphorescent organic 
light emitting diodes (OLEDs) (Figure 4.4).16
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Figure 4.4: Examples of Ir(III) complexes containing pyrazole ligands15,16
As well as this, three multifunctional cationic Ir(III) complexes with aggregation-induced 
emission and piezochomic luminescence characteristics have been designed and 
synthesized.17 Complexes contain cyclometalated dfppz (dfppz = 1-(2,4-
difluorophenyl)1H-pyrazole) and varying ancillary ligands which are used to tune the 
photophysical properties. Absorption spectra exhibited spin allowed π-π* transitions, as 
well as triplet metal to ligand charge transfer (3MLCT) and ligand-to-ligand charge 
transfer (1LLCT). In addition, solution state emission spectra displayed a broad, 
featureless peak at 497 nm in MeCN. Finally, Davies et al. used 3-substituted 
phenylpyrazoles ligands to demonstrate that cyclometalated phenyls with substituents 
para to the iridium have a larger impact on the redox potentials and emission of 
complexes [Ir(R-ppz)2(bipy)]PF6 than those at the meta position.18 In this case, emission 
wavelengths ranged from 504-615 nm depending on the nature of the substituent. 
4.1.4 Luminescent, Cyclometalated Iridium(III) Complexes and their Applications
Currently, luminescent iridium(III) complexes are at the forefront of scientific interest in 
coordination complexes due to a number of specific properties: kinetic inertness, large 
Stokes’ shifts, long luminescence lifetimes and high photostability.19 The inherent 
stability of iridium(III) through kinetic inertness is due to its low-spin, d6 configuration.
This configuration means iridium(III) has a strong preference to cyclometalate and thus 
has the ability to form a number of complexes with a range of mono-, bi- or tri-dentate 
ligands.20 In turn, emission profiles are representative of 3MLCT21, triplet intraligand 
charge transfer (3ILCT)22, triplet ligand to ligand charge transfer (3LLCT)23 and sigma bond 
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to ligand charge transfer (3SBLCT).24 As well as long lifetimes, the luminescent properties
of iridium(III) often show high phosphorescence quantum yields, with tunable and 
environment sensitive emission properties.25
The highly efficient emission properties described exist for several reasons. Firstly, a 
large Δ is caused due to the presence of strong field cyclometalating ligands, such as 
ppy. In addition, the high oxidation state and the presence of 5d electrons gives rise to 
a large Δ, giving rise to efficient heavy atom assisted spin-orbit coupling (SOC).26 As a 
consequence, long-lived triplet states are accessible via efficient intersystem crossing 
(ISC). 27 Singlet and triplet state mixing then allows Larporte forbidden phosphorescence
relaxation. For example, Ir(III) complexes with phenylimidazo-phenanthroline ligands 
show strong orange-yellow phosphorescence (Ԏ = 0.2-100 μs, Φ = 1-50 %) centered 
between 540-600 nm. The excited states of the complexes possess a significant degree 
of charge transfer nature and hence have large Stokes’ shifts (ca. 210nm) associated 
with a reduction in self-quenching.25,26,28 In addition, synthesis and purification of the 
complexes with yields approaching theoretical can be performed with ease.26a
For the reasons outlined above, iridium(III) complexes are being employed for a range 
of varied applications, including sensing techniques, OLEDs29, light-emitting 
electrochemical cells (OLECs)30, photosensitisers in catalysis (including redox)31, 
photocatalysts for water splitting,32 cellular bioimaging33, piezochromics34, and as 
responsive materials for data recording35 (for some examples, see Figure 4.5).
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Figure 4.5: Examples of Ir(III) complexes for water splitting,32 OLEC,30 piezochromics34 and OLED29
applications
Cyclometalated iridium(III) complexes most widely investigated application is as OLEDs. 
An early example is provided by Lamansky et al. who reported complexes containing a 
range of CˆN ligands. By variation of the nature of the ligand, green to red 
phosphorescence and lifetimes less than 10 μs were observed, resulting in high 
performance OLEDs operating from the green to the red.36 In a similar study, 
cyclometalated iridium(III) complexes based on CˆN ligands were shown to be suitable 
for use as red-emissive materials in OLEDs. Specifically, the OLED devices doped with 
Ir(piq)3 (piq = 1-phenylisoquinoline) exhibited very high electroluminescence as well as 
distinctly saturated red emission, which was found to originate predominantly from 
3MLCT excited states with high quantum yields.37 Another example is provided by Wong 
et al,38 who demonstrated for the first time the synthesis of iridium phosphor complexes 
based on a diphenylaminofluorene framework for OLED applications. The complexes 
were shown to emit very strongly in the yellow to orange region, and had the potential 
for further structural modification for application variation. In addition, recent work has 
shown a yellow-emitting homoleptic iridium(III) complex constructed from a 
multifunctional spiro ligand.39 The compound was applied as a highly efficient 
phosphorescent OLED, and almost equal energy levels when compared to the 
commercial phosphor iridium(III) bis(4-phenylthieno[3,2-c]pyridinato-
N,C2’)acetylacetonate (PO-01). As well as this, another commercially available complex, 
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bis[2-(4,6-difluorophenyl)pyridinato-C2,N](picolinato)iridium(III) (FIrpic), has been 
shown to be effective as an addition to host materials to improve the efficiencies of blue 
phosphorescent OLEDs.40 Four carbazolylphosphines and carbazolylphosphine oxide 
compounds were synthesised which, when incorporated with FIrpic, proved to be 
among the best performing FIrpic-based blue phosphorescent OLEDs without using any 
light extraction methods.41
Figure 4.6: Examples of commercially available Ir(III) phosphors
In a similar vein, applications of iridium(III) as LEECs has been established and are now 
extensive. An LEEC is a solid-state device that has most of the advantages of OLEDs, as 
well as a few further benefits. An example of this is provided by Slinker et al., who 
reported single layer devices incorporating [Ir(ppy)2-(dtb-bpy)]+(PF6)- (ppy: 2-
phenylpyridine, dtb-bpy: 4,4’-di-tert-butyl-2,2’-dipyridyl).42 The devices exhibited 
yellow electroluminescence with brightness that exceeds 300 cd/m2 and a luminous 
power efficiency that exceeds 10 lm/W at just 3 V. In addition, cyclometalated 
iridium(III) complexes with methoxy- and methyl- substituted 2,3’-bipy and 4,4’-di-tert-
butyl-2,2’-bipy were shown to exhibit blue-green emission with onsets around 450 nm 
and quantum yields above 40%.43 When compared to previously published devices 
containing fluorine emitters the overall performance of these complexes was similar, 
with maximum luminescence above 1000 cd/m2 and efficacy of 9.74 cd/A. Similarly, 
Fernandez-Hernandez et al reported blue emitting electrochemical cells containing 
triazole-based luminophores (Figure 4.7).44
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Figure 4.7: LEECs containing triazole-based lumophores44 
There have been recent developments of Ir(III) diamine complexes as luminescent labels 
for biological applications.45,46 A specific example comes from Lo et al. where a positively 
charged [Ir(ppy)2(dppz)]+ complex has been synthesised and proven to show 
luminescence and avid DNA binding.47 As well as this, a highly selective chemosensor 
for homocysteine with emission enhancement based on the phosphorescent complex 
Ir(pba)2(acac) (Hpba = 4-(2-pyridyl)-benzaldehyde; acac = acetylacetone) that contains 
an aldehyde group has been presented.48 Surface charge analysis and electrochemical 
measurement shows that a photoinduced electron transfer process for [Ir(pba)2(acac)]-
Cysteine might be responsible for the high specificity of Ir(pba)2(acac) toward 
homocysteine over cysteine. [Ir(phq)2(H2O)2)] (phq = 2-phenylquinoline) is a cell 
permeable cyclometalated complex that preferentially stains the cytoplasm of both live 
and dead cells with a bright luminescence, and hence has been developed as a 
phosphorescent probe (Figure 4.8).49 Results indicate that the complex exhibits a high 
degree of selectivity for histidine over other amino acids, and the emission maximum
falls on the boundary of the near-infrared optical window. In similar work 
[Ir(ppy)2(DMSO)2]+ has been used as a luminescent agent for imaging live cell nuclei.50
In recent work, Qui et al. reported two iridium(III) complexes with aggregation enhanced 
1O2 generation and bright phosphorescence for mitochondria-targeted two photon 
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photodynamic therapy (PDT) in monolayer cells and multicellular tumour spheroids 
(MCTSs).51
Figure 4.8: A chemosensor for homocysteine48 and a cytoplasmic stain49
There have also been several reports of water soluble iridium complexes.52,53,54 For 
example triazoles have been utilised by Zanarini et al. who synthesised a cationic 
iridium(III) complex comprising two ppy ligands and a neutral bidentate triazole-pyridine 
ligand, where the high solubility in water makes them highly advantageous in 
electrochemiluminescence.55
As well as the biological applications discussed, Ir(III) complexes can be used as ion 
probes. Complexes can be exploited as pH sensors when they contain an acidic or basic 
substituent, for example iridium(III) bis-terpyridine complexes reported by Licini and 
Williams.56 Another example comes from Chi et al. where free nitrogen atoms cause a 
vast change in emission when in the presence of specific cations due to increased 3MLCT 
character.57 Anion sensors also exist and can be used to monitor by a specific colour 
change the cyanide anion, due to the cyanide anion breaking the conjugation in the 
molecule.58
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Figure 4.9: Complex used for data encryption and decryption35
In addition, smart luminescent materials that are responsive to external stimuli have 
received considerable interest, and are seen as promising candidates for data recording 
and security protection. Sun et al. reported iridium(III) complexes that simultaneously 
delivered mechanochromic, vapochromic and electrochomic phosphorescence (Figure 
4.9).35 Anionic counterion variation caused a change in emission colours from yellow to 
green due to hydrogen bond formation with an N-H moiety in the ligand. A data-
recording device was constructed and data encryption and decryption via fluorescence 
lifetime imaging and time-gated luminescence imaging techniques were 
demonstrated.35
4.1.5 Machine-Assisted Synthesis
In recent years, an increase in the use of machine-assisted practice in the synthesis 
laboratory has begun to streamline the discovery and scale-up of organic molecules with 
biological activity, such as pharmaceuticals, agrochemicals, flavours and fragrances.59
For example, a compact, reconfigurable manufacturing platform has been developed for 
the continuous flow synthesis and formulation of active pharmaceutical ingredients
(Figure 4.10).60 The system has the capacity to produce hundreds to thousands of oral 
or topical liquid doses of diphenhydramine hydrochloride, lidocaine hydrochloride, 
diazepam and fluoxetine hydrochloride, all of which met US Pharmacopeia standards.
In addition, inductively heated mesofluidic devices have shown high performance in an 
array of reactions, including heterocyclic condensations, transfer hydrogenations, 
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pericyclic reactions, cross-couplings and oxidations, as well as for the preparation of 
pharmaceutical compounds.61
Figure 4.10: Examples of compounds synthesised using a machine-assisted approach60
The use of robotic microwaves with touchscreen user interfaces and continuous flow 
apparatus has led to systems that can operate unmanned in a 24/7 regime and deliver 
results and data to human operators. The recent addition of computer control, inline 
analytics62 and optimising algorithms63 has already afforded early examples of machines 
capable of the unassisted optimisation of chemical reactions. Further, the addition of 
automated biological assays into the machine-assisted discovery loop has now led to a 
closed-loop machine platform that is capable of optimising compound potency through 
iterative synthesis, characterisation and screening cycles.64 Clearly these methods have 
the potential to be extremely powerful and greatly assist in the pursuit of new or 
improved material properties. However, the approach is highly multidisciplinary and 
requires significant proof-of-concept and machine testing studies to fully understand 
and develop the true capabilities of the method. To date, there have been few 
applications of these techniques to the area of inorganic synthesis including the 
preparation of metal complexes.18, 65
During the course of the work described in this chapter, Stephenson and co-workers
reported a significant reduction in the reaction times for complex formation using a 
microwave method for the two-step synthesis of cyclometalated Ir(III) complexes in 
ethylene glycol.66 In addition, Davies and co-workers have described microwave reaction 
conditions using iPrOH as solvent, which successfully gave cyclometalated Ir(III) dimer 
species.18
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4.2 Aims
This chapter describes initial efforts towards a machine–assisted discovery platform, for
the delivery of a series of pyrazolate-iridium complexes with tunable luminescent 
properties. Due to advances in the efficient, rapid and cost-effective synthesis of such 
species being rarely employed in the literature but highly desirable, a proof of concept 
model has been developed (Figure 4.11). 
Figure 4.11: This work: proof of concept, chemistry model validation and development of synthesis 
machines 1 and 2
As well as the current state-of the art process for materials optimisation, it is thought 
that machine-assistance would consist of real-time characterisation of material 
properties with direct input of this data into a computer. The computer would offer 
multiple purposes, such as reaction or property optimisation through statistical analysis, 
data storage, and management and direction of the synthetic steps. For the computer 
to be able to interface with the synthetic reaction steps of the process, the reactions 
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should be carried out by a technique that can readily interface with computer control. 
This first-generation approach towards this goal consists of the demonstration of a 
modular flow/microwave hybrid approach to the synthesis of a novel series of ligands, 
demonstration of a microwave approach to the assembly of the complexes, and 
identification of suitable model chemical system with which to explore this concept.
This chapter extends the concepts discussed to synthesise a range of iridium complexes 
based on substituted 3,5-dimethyl-1-phenylpyrazole ligands. The characterisation and 
photophysical properties of the novel ligands and complexes would be investigated. In 
addition, theoretical studies have been conducted in order to support spectral data, 
along with electrochemistry investigations.
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4.3 Results and Discussion
4.3.1 Synthesis of Ligands and Complexes
Please note: all ligand synthesis was carried out by Christiane Schotten.
Phenyl-pyrazoles were targeted as ligands with electron withdrawing, fluorine-
containing phenyl substituents that would firstly permit facile C-H 
insertion/cyclometalation following initial coordination of the pyrazole nitrogen to an 
iridium centre. Secondly, the ligand should induce a strong element of electronic tuning 
to the iridium colour centre. A family of such fluorinated pyrazole-iridium complexes 
have not been reported. Enhancing the electron withdrawing capability of the 
coordinating phenyl unit is known to blue shift the emission wavelength of luminescent 
Ir(III) complexes.67 The synthetic protocol is outlined in Scheme 4.1 and features the 
input of the appropriately fluorinated aniline(s) into the continuous flow apparatus for 
the ligand synthesis phase. This was followed by a two-step iridium ligation process in 
which both batch and microwave approaches were compared.
Scheme 4.1. Preparation of fluorinated pyrazole ligands using a continuous flow-microwave hybrid 
approach.
The substituted pyrazoles (ppz-1 to ppz-6) were synthesised from a selected aniline (4-
(trifluoromethoxy)aniline, 3-(trifluoromethyl)aniline, 4-(trifluoromethyl)aniline, 4-
(pentafluorothio)aniline, 3-(pentafluorothio)aniline, 4-fluoroaniline),  which was firstly 
diazotised in the flow reactor (outlined in Scheme 4.2) by combination with a stream of 
HCl and isoamylnitrite, before combination with a further stream that delivered the 
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ascorbic acid for reduction to the oxamayl-hydrazide derivative. The formed hydrazine 
surrogate was then collected in a microwave vial before combining with acetylacetone 
and irradiation at 140 °C for 30 minutes.
Scheme 4.2. Summary of the synthetic routes to the ligands and complexes.
The resultant product was purified by aqueous extraction and silica chromatography to 
furnish the fluorous substituted 3,5-dimethyl pyrazoles (ppz-X) in good-to-excellent 
yield. The utilised ‘flow + microwave’ setup is shown schematically in Scheme 4.2. It 
should be noted that whilst this chapter concerns the design and development of 
automatable machines, this chemistry can also be conducted more conventionally 
(batch) in a round-bottom-flask. For the latter approach, where unknown diazonium 
entities are being generated, small scale reactions are advisable due to potential for 
diazoniums to undergo uncontrollable energy release. Thus, the flow process for the 
generation and consumption of diazonium salts affords safety benefits as well as 
versatility and the potential for automation.
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Figure 4.12: Structures and comparison of preparative yields of the ligands
These fluorinated pyrazoles were then successfully utilised as cyclometalating ligands 
with Ir(III), thus delivering six new complexes of the general form [Ir(ppz)2(bipy)]BF4. 
Firstly, the complexes were synthesised by applying well-known batch chemistry 
conditions68 for the dimeric precursors [(ppz)2Ir(µ-Cl)2Ir(ppz)], where the reaction 
duration is 48 hours. Each [(ppz)2Ir(µ-Cl)2Ir(ppz)2] compound was then reacted with 
AgBF4 in MeCN (2 hrs) to give the corresponding bis-acetonitrile adduct 
[Ir(ppz)2(MeCN)2]BF4 (Scheme 4.2), and subsequent reaction with 2,2-bipyridine gave 
conversion (24 hrs) to the mixed-ligand target complexes [Ir(ppz)2(bipy)]BF4. The six 
complexes were isolated as pale green-brown powders. It is worth noting that, following 
formation of the [(ppz)2Ir(µ-Cl)2Ir(ppz)2], the remaining experimental procedure
described differs from traditional methods used for Ir(III) complex synthesis,69 but has 
been shown to produce complexes in higher yields and without the need for purification 
via column chromatography in the majority of cases.
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Following the regular batch chemistry, the usefulness of the machine-assisted approach 
for the iridium chemistry was assessed. Here the microwave approach was applied to 
each of the three steps: (i) [(ppz)2Ir(µ-Cl)2Ir(ppz)2] from IrCl3 in 2-methoxyethanol for 
15 min at 180 °C; (ii) dimer cleavage to cis-[Ir(ppz)2(MeCN)2]BF4 achieved in acetonitrile 
for 10 min at 120 °C; (iii) conversion to [Ir(ppz)2(bipy)]BF4 in chloroform for 15 min at 
130 °C. Using this microwave-assisted approach, the target [Ir(ppz)2(bipy)]BF4
complexes were much more rapidly isolated with total reaction times of < 1 hr. The 
yields of the target complexes are respectable and directly comparable to conventional 
methods, where 74 hrs are required to isolate these species. However, the complexes
are now obtainable within a day, including work-up procedures and purification via 
column chromatography (if required).
158
Figure 4.13:Structures, total reaction times and comparative yields (final step) of the complexes
4.3.2 Characterisation of the Ir(III) Complexes
The Ir(III) complexes were sufficiently soluble in a range of common organic solvents 
allowing characterization in the solution state using 1H, 13C{1H}, high resolution mass 
spectrometry, UV-vis., time-resolved transient absorption, luminescence spectroscopies 
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and cyclic voltammetry, as well as IR in the solid state. Supporting TD-DFT calculations 
were also used to assist and inform the assignments of the electronic transitions noted 
from experimental observations. Confirmation of the solid-state structures were 
provided through X-ray crystallographic studies on two examples.
As well as the protons associated with the pyrazole ligand, the 1H NMR spectra of the 
complexes show additional peaks in the aromatic region corresponding to the additional 
2,2’-bipyridine ligand. By comparison of ppz-5 and [Ir(ppz-5)2(bipy)]BF4, it can be seen 
that complex formation affects the shifts and multiplicities of the peaks associated with 
the ppz-5 ligand. The characteristic methyl groups (2.26 and 2.28 ppm in the ligand) have 
shifted to 2.85 and 1.57 ppm respectively in the complex, possibly due to the proximity 
to the cyclometalating nitrogen. In addition, the cyclometalating carbon means there is 
one less phenyl proton per pyrazole ligand observed for the complex and hence a 
doublet at 8.18 ppm is observed (Figure 4.15). 
Figure 4.14: 1H NMR spectrum of [Ir(ppz-5)2(bipy)]BF4
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Figure 4.15:1H NMR spectrum of ppz-5 (top) and [Ir(ppz-5)2(bipy)]BF4 (bottom)
Slight differences are observed when comparing ppz-2 and [Ir(ppz-2)2(bipy)]BF4. As 
previously seen, the additional aromatic protons associated with the cyclometalating 
ligand are observed. The characteristic methyl groups (2.34 and 2.30 ppm in ppz-2) have 
again shifted to 2.98 and 1.63 ppm respectively. In this case, however, the three proton 
multiplet (7.68 – 7.53 ppm) observed in ppz-2 becomes two doublets, each integrating 
to two protons at 7.14 and 6.59 ppm. In addition, the aromatic singlet (7.74 ppm) 
observed for ppz-2 remains a singlet at 7.82 ppm (Figure 4.17). 
 
Figure 4.16: 1H NMR spectrum of [Ir(ppz-2)2(bipy)]BF4
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Figure 4.17:1H NMR spectrum of ppz-2 (top) and [Ir(ppz-2)2(bipy)]BF4 (bottom)
Similar trends in the 1H NMR spectra are seen for the remaining complexes. In all cases, 
the proposed molecular formula was supported by HMRS (ES+), each showing the [M+ -
C2H6] peak with a representative Ir(III) isotope pattern (Figure 4.18). IR studies of ligands 
and their corresponding complexes show the addition of several peaks within the 
fingerprint region of the spectrum, presumably attributed to the cyclometallation and 
additional bipy ligand associated with the complexes.
Figure 4.18: HMRS of [Ir(ppz-5)2(bipy)]BF4
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4.3.3 X-ray Crystallographic Structural Studies
As well as solution state characterization, single crystal structure determinations were
obtained for [Ir(ppz-3)2(bipy)]BF4 and [Ir(ppz-6)2(bipy)]BF4 in order to further confirm 
the structure of the complexes (Figure 4.19). Crystals suitable for X-ray diffraction were 
obtained by room temperature vapour diffusion of diethyl ether into concentrated 
MeCN solutions of the aforementioned complexes. Data collection, refinement and 
structure solution was conducted by Dr. Peter Horton at the UK National Crystallography 
Service, Southampton. Data collection parameters are shown in Table 4.1, together with 
supporting bond length (Table 4.2) and bond angle data (Table 4.3). 
These structures revealed the anticipated formulations for both complexes and 
demonstrate retention of the different pyrazolato substituents, as well as the addition 
of bipy. In both cases the cyclometalating units are arranged with the coordinated C 
atoms in a cis arrangement. Bond lengths for the pyrazole ligands in both complexes 
range between Ir-N = 2.034-2.036 Å and Ir-C = 2.006(5)-2.016(4) Å, both ranges which 
are in agreement with similar literature examples.16 In addition, the Ir-N bond angles  in 
the bipy ligand (2.128(4)-2.135(4) Å) show correlation with reported values and 
ranges.70 The bond angles show a distorted octahedral geometry at Ir(III) in both cases, 
which is again in agreement with previous literature examples.29
163
Compound [Ir(ppz-3)2(bipy)]BF4 [Ir(ppz-6)2(bipy)]BF4
Formula C34H28F6IrN6, BF4, 
½(C2H3N)
C32H28F10IrN6S2, 2/3(C4H10O), BF4,  
1/3(H2O), 1/3(C2H3N)
Dcalc./ g cm-3 1.652 1.790
μ/mm-1 3.639 3.481
Formula Weight 934.16 1098.84
Colour Yellow yellow
Shape Plate cut needle
Size/mm3 0.120×0.080×0.030 0.150×0.035×0.015
T/K 100(2) 100(2)
Crystal System Monoclinic triclinic
Space Group P21/n P-1 
a/Å 10.71171(18) 14.25526(20)
b/Å 20.5811(3) 19.1140(4)
c/Å 17.8555(3) 23.8726(3)
α/° 90 70.9389(16)
β/° 107.3999(18) 84.0222(11)
γ/° 90 88.0894(14)
V/Å3 3756.27(11) 6114.61(18)
Z 4 6
Z' 1 3
Wavelength/Å 0.71073 0.71073
Radiation type MoKα MoKα
ϴmin/° 2.225 1.825
ϴmax/° 27.482 27.484
Measured Refl. 48865 107412
Independent Refl. 8604 28021
Reflections Used 7659 23235
Rint 0.0299 0.0413
Parameters 522 1643
Restraints 531 1707
Largest Peak 1.836 2.455
Deepest Hole -1.134 -2.187
GooF 1.055 1.047
wR2 (all data) 0.1120 0.0953
wR2 0.1080 0.0901
R1 (all data) 0.0446 0.0576
R1 0.0386 0.0433
Table 4.1: X-ray data collection parameters for the complexes
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[Ir(ppz-3)2(bipy)]BF4 [Ir(ppz-6)2(bipy)]BF4
Atom Atom Length/Å Atom Atom Length/Å
Ir1 N1 2.036(4) Ir1 N1 2.035(4)
Ir1 N21 2.034(4) Ir1 N21 2.036(4)
Ir1 N41 2.135(4) Ir1 N41 2.134(4)
Ir1 N42 2.130(4) Ir1 N42 2.128(4)
Ir1 C1 2.016(4) Ir1 C1 2.006(4)
Ir1 C21 2.006(5) Ir1 C21 2.015(5)
Ir2 N51 2.041(4)
Ir2 N71 2.037(4)
Ir2 N91 2.140(4)
Ir2 N92 2.124(4)
Ir2 C51 2.003(5)
Ir2 C71 2.011(4)
Table 4.2: Bond lengths for the complexes
[Ir(ppz-3)2(bipy)]BF4 [Ir(ppz-6)2(bipy)]BF4
Atom Atom Atom Angle/° Atom Atom Atom Angle/°
N1 Ir1 N41 101.43(15) N1 Ir1 N21 171.40(16)
N1 Ir1 N42 84.63(16) N1 Ir1 N41 100.41(16)
N21 Ir1 N1 170.33(15) N1 Ir1 N42 86.98(15)
N21 Ir1 N41 86.92(15) N21 Ir1 N41 86.71(16)
N21 Ir1 N42 102.15(16) N21 Ir1 N42 99.45(15)
N42 Ir1 N41 77.14(16) N42 Ir1 N41 76.58(16)
C1 Ir1 N1 79.31(18) C1 Ir1 N1 79.44(17)
C1 Ir1 N21 92.90(17) C1 Ir1 N21 94.04(17)
C1 Ir1 N41 174.00(17) C1 Ir1 N41 173.52(17)
C1 Ir1 N42 97.06(17) C1 Ir1 N42 96.95(16)
C21 Ir1 N1 94.38(19) C1 Ir1 C21 86.66(18)
C21 Ir1 N21 79.79(19) C21 Ir1 N1 94.18(17)
C21 Ir1 N41 95.86(17) C21 Ir1 N21 79.75(17)
C21 Ir1 N42 172.55(17) C21 Ir1 N41 99.81(18)
C21 Ir1 C1 90.00(18) C21 Ir1 N42 176.36(17)
N51 Ir2 N91 102.70(17)
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[Ir(ppz-3)2(bipy)]BF4 [Ir(ppz-6)2(bipy)]BF4
Atom Atom Atom Angle/° Atom Atom Atom Angle/°
N51 Ir2 N92 88.43(16)
N71 Ir2 N51 170.24(15)
N71 Ir2 N91 84.54(16)
N71 Ir2 N92 99.65(16)
N92 Ir2 N91 77.29(15)
C51 Ir2 N51 79.57(19)
C51 Ir2 N71 94.14(18)
C51 Ir2 N91 172.09(16)
C51 Ir2 N92 95.29(16)
C51 Ir2 C71 89.89(17)
C71 Ir2 N51 93.05(18)
C71 Ir2 N71 79.39(17)
C71 Ir2 N91 97.51(16)
C71 Ir2 N92 174.78(16)
N71 Ir2 N91 84.54(16)
N71 Ir2 N92 99.65(16)
Table 4.3: Bond angles for the complexes
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Figure 4.19:Molecular structures of the iridium complexes (top: [Ir(ppz-3)2(bipy)]BF4; bottom: [Ir(ppz-
6)2(bipy)]BF4). Thermal ellipsoids drawn at the 30% probability level. Hydrogen atoms, anions and 
solvent molecules are omitted for clarity
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4.3.4 Density functional theory (DFT) studies
Please note that all density functional theory studies were carried out by Dr. Jamie 
Platts.
Frontier molecular orbital data for the six Ir(III) complexes, calculated after full geometry 
optimisation, are reported in Table 4.4. They show a consistent HOMO-LUMO gap of 
around 3 eV with minor changes due to the nature and position of the fluorinated 
substituents on the cyclometalated ligand fragments. This is in broad agreement with 
the electrochemical data discussed later (Table 4.6), but with a slight overestimation. In 
all cases, the HOMO has mixed iridium 5d (12.5 to 21.9%) and pyrazolate -character, 
with the –SF5 substituents increasing the Ir contribution, while the LUMO is wholly 
located on the ancillary bipyridine ligand, as shown in Figure 4.20. 
 
Complex EHOMO / eV ELUMO / eV EBandgap / eV % 5d (HOMO)
[Ir(ppz-1)2(bipy)]BF4 -8.31 -5.39 2.92 17.3
[Ir(ppz-2)2(bipy)]BF4 -8.46 -5.47 2.99 12.5
[Ir(ppz-3)2(bipy)]BF4 -8.40 -5.42 2.98 14.7
[Ir(ppz-4)2(bipy)]BF4 -8.68 -5.59 3.09 21.9
[Ir(ppz-5)2(bipy)]BF4 -8.15 -5.33 2.82 13.5
[Ir(ppz-6)2(bipy)]BF4 -8.61 -5.54 3.07 21.8
Table 4.4:Calculated HOMO and LUMO energies and % 5d orbital character of the HOMO for each 
complex
To probe the spectroscopy of these complexes in more detail, TD-DFT calculations were 
carried out on [Ir(ppz-5)2(bipy)]+, using the CAM-B3LYP functional. Strong singlet 
transitions were predicted to lie in the range of 270 to 300 nm, the most intense of 
which at 272 nm is dominated by a -* transition within the bipyridine ligand. Lower 
energy triplet absorption bands are also predicted at 422 and 388 nm: at the scalar 
relativistic level used for these calculations, such bands are formally forbidden with an 
intensity of exactly zero. The orbital make-up of the 422 nm band is complex, with MOs 
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as low as HOMO-16 (metal 5d / bipy ) contributing, but it is interesting to note that the 
predicted dominant contribution is HOMO-6  LUMO, which is also a -* transition 
within bipyridine. This data therefore suggests that the shoulder seen in absorption 
spectra could comprise a 3ILbipy transition, which is presumably weakly allowed due to 
spin-orbit coupling that stems from smaller contributions from a 3MLCT transition. TD-
DFT was also used to examine emission from the geometry optimised lowest triplet 
excited state of [Ir(ppz-5)2(bipy)]+. Once again, such bands are formally forbidden so no 
information on intensity is available, but this approach predicts emission at 510 nm, 
again in qualitative agreement with the experimental data. However, as with the triplet 
absorption, this band is dominated by intra-ligand transitions within the bipyridine with 
smaller 3MLCT type contributions also noted, the latter a much more likely assignment 
to the broad featureless emission observed in the experiments.
Figure 4.20:Isosurface plots for HOMO (left) and LUMO (right) of [Ir(ppz-5)2(bipy)]+, displayed at 0.04 au.
4.3.5 Photophysical Properties of the Complexes
The photophysical properties of the complexes were measured in aerated acetonitrile 
solutions. The UV-vis absorption spectra of the complexes (Figure 4.21) show several 
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common features between 250 and 450 nm. Ligand-centred (1-*) transitions 
dominate, with high molar absorption coefficients, <320 nm. A much weaker feature, 
present as a shoulder between 400 and 450 nm is tentatively assigned as a 1MLCT 
transition with the possibility of a spin forbidden 3MLCT also contributing. The position 
of the MLCT band(s) appear to be relatively insensitive to the variations in substituent 
(nature and position) that are present on the cyclometalated pyrazole ligand. Previous 
related iridium-pyrazole complexes by Chen et al. are comparable, and show ligand 
centred transitions between 271 and 378 nm, as well as a lower energy shoulder 
attributed to MLCT transitions.16 Similar absorption values have been observed for Ir(III) 
complexes containing bipy ligands.43, 69
Complex em /
nm [a,b]
τ /
ns [a,c]
Φem [a]
kr / s-1 
106
knr / s-1 
106
[Ir(ppz-1)2(bipy)]BF4 543 (484) 92 (107) 0.10 1.09 9.78
[Ir(ppz-2)2(bipy)]BF4 528 (488) 109 (113) 0.15 1.37 7.80
[Ir(ppz-3)2(bipy)]BF4 537 (484) 101 (103) 0.11 1.09 8.81
[Ir(ppz-4)2(bipy)]BF4 516 (484) 123 (133) 0.19 1.54 6.59
[Ir(ppz-5)2(bipy)]BF4 557 (497) 77 (90) 0.05 0.65 12.34
[Ir(ppz-6)2(bipy)]BF4 520 (485) 112 (127) 0.15 1.34 7.59
Table 4.5: Photophysical properties of the [Ir(ppz)2(bipy)]BF4 complexes. a recorded at RT in aerated 
MeCN (ex = 405 nm); b values in parentheses were obtained at 77K (1:1 MeOH/EtOH glass); c values in 
parentheses are the lifetimes obtained from time-resolved transient absorption measurements.
Luminescence spectra were also obtained on aerated acetonitrile solutions (Table 4.5). 
Using an excitation wavelength of 380 nm the complexes revealed a broad featureless 
emission peak that ranged between 510 and 560 nm (Figure 4.22) depending upon the 
nature of the pyrazole ligand. For comparison, [Ir(ppy)2(bipy)]PF6 (ppy = 2-
phenylpyridine) emits at 602 nm from a mixed 3MLCT/3LLCT excited state;71 the more 
closely related [Ir(ppz)2(bipy)]PF6 (ppz = 2-phenylpyrazole) emits at 563 nm in MeCN.13
In this work, the most red-shifted emission was induced by para-fluorination of the 
cyclometalating ligand in [Ir(ppz-5)2(bipy)]BF4, whilst the blue-shifted variants were the 
pentafluorosulfanyl derivatives [Ir(ppz-4)2(bipy)]BF4 and [Ir(ppz-6)2(bipy)]BF4 (meta
substitution induced the highest energy emission). It is noteworthy that 
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pentafluorosulfanyl-substituted [Ir(ppy)2(bipy)]+ species have recently been shown to 
possess blue-shifted emission properties.72 In addition, other closely related complexes 
of [Ir(R-ppz)2(bipy)][PF6] (R = H, Me, CF3) exhibit emission wavelengths ranging between 
504 and 587 nm.18
Figure 4.21:Comparison of the UV-vis. spectra for the complexes (in MeCN)
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Figure 4.22:Main: Normalised emission spectra of the complexes (MeCN, λex = 380 nm). 
Foreground: emission spectra at 77K (MeOH/EtOH glass, λex = 380 nm).
These em trends are supported by the EBandgap data from the TD-DFT calculations (Table 
4.4). Low temperature (77K) spectra revealed a general hyposchromic shift in the 
emission maxima together with stronger vibrational features in the peak appearance 
(Fig. 4.22 inset). The aerated, solution state quantum yields (5-19%) were also obtained 
together with the luminescence lifetimes (Table 4.5), which lie in the range 77-123 ns.
The lifetimes were indicative of phosphorescence in all cases, with data best fitting a 
single exponential decay, thus indicating single component emission. These data are 
consistent with related previously reported examples.16, 69 From these values, kr and knr
were determined for the different complexes (Table 4.5) and the resultant data shows 
a clear correlation between the energy of the emission maximum and knr (and thus in 
accordance with the energy gap law). Therefore, for these complexes the nature of the 
emitting state, which is attributed to a strong 3MLCT character, is likely to be closely 
comparable across the series. The data suggests that in these complexes the electron 
withdrawing capacity of -SF5 is greater than -CF3, -OCF3 and -F.
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4.3.6 Transient Absorption Spectroscopy
Transient absorption (TA) spectroscopy, carried out by Dr Joseph Beames, was also 
conducted (using a pump wavelength of 266 nm) on the complexes under the same 
solvent conditions as described above for the UV-vis. and luminescence measurements. 
The spectral appearance of all six samples is very similar and contains a bleach (or 
reduction) in optical density (OD) at λ ~ 310 nm and three positive features at λ ~ 380, 
490 and 760 nm (Figure 4.24). Closer inspection of the individual peaks shows very little 
variation in wavelength position across the six complexes. Time-resolved analysis of the 
transient features at λ = 380 nm give lifetimes that compare well, both in magnitude and 
trend, to those obtained in the luminescence studies.
Figure 4.23:Transient absorption spectra and data. Left: a 3D time-resolved plot for [Ir(ppz-3)2(bipy)]BF4. 
Right: fitted (red trace) lifetime profiles for the different Ir(III) complexes. The lowest panel shows, as an 
example, the recovery of the spectral feature assigned as a bleach at λ=310 nm for [Ir(ppz-3)2(bipy)]BF4. 
The recovery of the bleach occurs on a timescale similar to the decay of the absorption features at longer 
wavelengths.
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Analysis of the time-resolved decay of the peaks at λ = 760 nm for each sample revealed 
similar lifetimes, each of which correlates reasonably well with their respective lifetimes 
at λ = 380 nm. These TA spectral features could, therefore, originate from the same 
excitation and intersystem crossing processes that produce the emissive 3MLCT states 
and, based on the state lifetimes, suggest excited states for the series of complexes that 
are very similar in nature.73 Careful analysis of the features at λ = 760 nm suggest that 
this peak has two underlying components and is a doublet. The data are presented as a 
3D contour plot (Figure 4.23) for [Ir(ppz-3)2(bipy)]BF4.
Figure 4.24: Comparative early time transient absorption spectra of the six iridium complexes (top-to-
bottom: [Ir(ppz-1)(bipy)2]BF4 to [Ir(ppz-6)(bipy)2]BF4)
4.3.7 Electrochemistry
The electrochemical characteristics of the six [Ir(ppz)2(bipy)]BF4 complexes (Table 4.6) 
were studied in de-oxygenated dichloromethane. The cyclic voltammograms were 
measured using a platinum disc electrode (scan rate υ = 200 mV s-1, 1 × 10-3 M solutions, 
0.1 M [NBu4][PF6] as a supporting electrolyte) and each complex showed one non-fully 
or fully reversible oxidation (Table 4.6) at +1.47 to + 1.75 V ascribed to the Ir3+/4+ couple. 
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Each complex also showed one partially reversible or irreversible reduction wave, which 
was assigned to a ligand-centred process. The small differences in Eox are probably due 
to the nature of the substituent on the cyclometalating ligand that can influence the 
electron density at the iridium centre. This data is again in correspondance with previous 
related examples.18, 44
Figure 4.25: Example cyclic voltammogram of [Ir(ppz-3)2(bipy)]BF4 in MeCN solution, at 200mVs-1 with 
0.1M [NBu4][PF6] as the supporting electrolyte, calibrated with FeCp2
Complex Eox / V[a] Ered / V[a] HOMO / eV [d] LUMO / eV[f] Ebandgap / eV[e]
[Ir(ppz-1)2(bipy)]BF4 +1.62[b] -1.33[b] -5.96 -3.43 2.53
[Ir(ppz-2)2(bipy)]BF4 +1.66[b] -1.32[c] -6.00 -3.44 2.56
[Ir(ppz-3)2(bipy)]BF4 +1.60[c] -1.35[c] -5.94 -3.39 2.55
[Ir(ppz-4)2(bipy)]BF4 +1.74[b] -1.30[c] -6.08 -3.52 2.56
[Ir(ppz-5)2(bipy)]BF4 +1.47[c] -1.47[b] -5.81 -3.30 2.51
[Ir(ppz-6)2(bipy)]BF4 +1.75[b] -1.30[b] -6.09 -3.47 2.62
Table 4.6:Electrochemical properties of the [Ir(ppz)2(bipy)]BF4 complex. a oxidation potentials were 
measured as dichloromethane solutions at 200 mVs–1 with 0.1 M [NBu4][PF6] as supporting electrolyte 
calibrated with Fc/Fc+ at +0.46 V; b irreversible wave; c reversible wave; d the HOMO energy level was 
calculated using the equation –EHOMO (eV) = Eox – EFc/Fc+ + 4.8; e Ebandgap was determined from the 
absorption edge of the iridium complexes; f the LUMO energy level was calculated using the equation 
ELUMO (eV) = EHOMO + Ebandgap
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For example, [Ir(ppz-5)2(bipy)]BF4 showed the lowest Eox value in the series, suggesting 
that para-fluorination of the pyrazole ligands renders the Ir3+ more easily oxidisable. The 
pentafluorosulfanyl derived complexes gave the highest oxidation potentials. Using the 
oxidation (Ir3+/4+) potential gave the HOMO energy levels (EHOMO), from which ELUMO was 
also determined. The calculated Ebandgap values again revealed a lowest value for [Ir(ppz-
5)2(bipy)]BF4, with both [Ir(ppz-4)2(bipy)]BF4 and [Ir(ppz-6)2(bipy)]BF4 at the largest 
values, which was supported by TD-DFT.
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4.4 Conclusions
In conclusion, this chapter reports the comparative syntheses of six new phenyl-1H-
pyrazoles and their corresponding cyclometalated iridium(III) complexes using both 
batch and, successfully applied, flow-microwave methodologies. The machine-assisted 
technology approach clearly delivers improvements on safety, versatility and time.
Specifically, microwave-assisted syntheses for the Ir(III) complexes allows isolation of 
spectroscopically pure species in less than 1 hour of reaction time from IrCl3. All new 
complexes were explored photophysically (including nanosecond time-resolved 
transient absorption spectroscopy), electrochemically and by TD-DFT studies which 
show that the complexes possess ligand-dependent, and thus, tuneable green-yellow 
luminescence (500-560 nm), with quantum yields in the range 5-15 %. This 
photophysical evaluation of the complexes show that varying the position and nature of 
the fluorine-containing substituents on the cyclometalated phenyl-1H-pyrazolate can 
easily tune the emission wavelength of the iridium-based phosphors across the green-
yellow part of the visible spectrum. 
Future improvements could emanate from connecting the two production phases 
(ligand and complex) into one machine (which would likely require an automated 
purification phase at the connecting junction) and include the ability to automatically 
screen the luminescent properties of the formed products. A third-generation approach 
could then use feedback and optimisation algorithms to deliver a discovery platform for 
the rapid generation of new metal-ligand phosphors with tunable and targeted 
luminescence properties.
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4.5 Experimental Procedures
4.5.1 General Experimental Considerations
All reagents and solvents were commercially available and were used without further 
purification if not stated otherwise. Petroleum ether refers to the 40-60 °C fraction. For 
the measurement of 1H, 13C and 19F NMR spectra a Bruker Fourier300 (250, 300 MHz), 
400 UltraShieldTM (400 MHz) or AscendTM500 (500 MHz) was used. The obtained 
chemical shifts δ are reported in ppm and are referenced to the residual solvent signal. 
19F NMR signals are reported uncorrected. Spin-spin coupling constants J are given in 
Hz.
The flow setup consisted of perfluoroalkoxy (PFA) tubing of an 0.8 mm ID and two 
syringe and two Knauer pumps. The residence coils were made from the tubing by taking 
the appropriate length for the desired volume. The microwave used was a CEM Discover 
SP. Column chromatography was performed using 60 A (40-64 micron) silica and solvent 
mixtures of petroleum ether and ethyl acetate.
Low-resolution mass spectra were obtained by the staff at Cardiff University. High-
resolution mass spectra were carried out at the EPSRC National Mass Spectrometry 
Facility at Swansea University. High resolution mass spectral (HRMS) data were obtained 
on a Waters MALDI-TOF mx at Cardiff University or on a Thermo Scientific LTQ Orbitrap 
XL by the EPSRC UK National Mass Spectrometry Facility at Swansea University. IR 
spectra were obtained from a Shimadzu IR-Affinity-1S FTIR. UV-Vis studies were 
performed on a Jasco V-570 spectrophotometer as MeCN solutions (2.5 or 5 × 10-5 M). 
Photophysical data were obtained on a JobinYvon–Horiba Fluorolog spectrometer fitted 
with a JY TBX picosecond photodetection module as MeCN solutions. Emission spectra 
were uncorrected and excitation spectra were instrument corrected. The pulsed source 
was a Nano-LED configured for 459 nm output operating at 1 MHz. Luminescence 
lifetime profiles were obtained using the JobinYvon–Horiba FluoroHub single photon 
counting module and the data fits yielded the lifetime values using the provided DAS6 
deconvolution software. Quantum yield measurements were obtained on aerated 
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MeCN solutions of the complexes using [Ru(bpy)3](PF6)2 in aerated MeCN as a standard 
(Φ = 0.016). [23]
4.5.2 X-ray Diffraction
For both samples, a suitable crystal was selected and mounted on a MITIGEN holder in 
oil on a Rigaku FRE+ (45.0 kV, 55.0 mA) equipped with HF Varimax confocal mirrors 
(100µm focus) and an AFC12 goniometer and HG Saturn 724+ detector diffractometer. 
The crystals were kept at T = 100(2) K during data collection. Data were measured using 
profile data from ω-scans using MoKα radiation. Cell determination and data collection
were carried out using CrystalClear. With the data reduction, cell refinement and 
absorption correction using CrystalisPro. Using Olex2, the structures were solved with 
the ShelXT structure solution program and the models were refined with version 2014/7 
of ShelXL using Least Squares minimisation. All non-hydrogen atoms were refined 
anisotropically. Hydrogen atom positions were calculated geometrically and refined 
using the riding model.
For sample [Ir(ppz-3)2(bpy)]BF4, the BF4 anions are disordered over symmetry sites and 
each contributes half an ion to the asymmetric unit. Also one of the CF3 groups is 
disordered over two positions. As such various geometrical (SADI, SAME, BUMP) 
restraints and displacement (RIGU) restraints were employed, along with displacement 
constraints (EADP).
For sample [Ir(ppz-6)2(bpy)]BF4, a general displacement restraint (RIGU) has been 
employed due to the number of readily disordered moieties in the asymmetric unit. Also 
there is a molecule of MeCN for which displacement constraints (EADP) have been 
employed.
4.5.3 DFT calculations
The geometry of all complexes was fully optimised without symmetry constraint using 
the B3LYP functional and a basis set consisting of 6-31G(d) on light atoms with Stuttgart-
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Dresden core potential and basis set on Ir. Frontier orbital properties were calculated 
with the same functional and a 6-31+G(d,p) basis on light atoms. TD-DFT used the CAM-
B3LYP functional known to perform well for charge transfer transitions, with 6-
31+G(d,p) on light atoms and Stuttgart-Dresden potential/basis on Ir. All DFT 
calculations were performed using the Gaussian09 package.
4.5.4 Transient Absorption
Transient absorption (TA) UV-Vis spectra were collected at Cardiff University using an 
Edinburgh Instruments LP920 laser flash photolysis spectrometer. All spectra were 
generated by exciting the samples (prepared as for UV-Vis studies described above) at 
266 nm (4th harmonic of a Continuum Surelite II Nd:YAG laser, operated at 10 Hz) and 
collecting subsequent transient absorption spectra between 300 nm    800 nm (a 
Xenon lamp provides probe wavelengths). Wavelength dependent TA data was 
recorded in 5 nm steps using an in-built monochromator, with a bandwidth of 1 nm. 
Data presented in this manuscript show early time spectra (t < 1 s post excitation), 
however no additional TA features were observed over longer timescales (t < 10 ms). TA 
spectra are presented as ODXenon lamp, hereafter simply referred to as OD, constructed 
by averaging the first 50 ns of data after the pump laser pulse. Lifetime data was created 
by fitting the raw experimental data using the Origin 2015 software package. Each fit is 
created using a single exponential decay function, with no evidence for multiexponential 
components.
4.5.5 Electrochemistry
Electrochemical studies were carried out using a Parstat 2273 potentiostat in 
conjunction with a three-electrode cell. The auxiliary electrode was a platinum wire and 
the working electrode a platinum (1.0 mm diameter) disc. The reference was a silver 
wire separated from the test solution by a fine porosity frit and an agar bridge saturated 
with KCl. Solutions (10 ml CH2Cl2) were 1.0 × 10-3 mol dm-3 in the test compound and 0.1 
mol dm-3 in [NBun4][PF6] as the supporting electrolyte. Under these conditions, E0′ for 
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the one-electron oxidation of [Fe(η-C5H5)2], added to the test solutions as an internal 
calibrant, is +0.46 V. [36] Unless specified, all electrochemical values are at υ = 200 mV s-
1.
4.5.6 Synthesis
For details of ligand synthesis and characterisation, please refer to the associated 
published paper.74
Preparation of fluorinated pyrazole-Iridium complexes in batch
Synthesis of [Ir(ppz-1)2(bipy)]BF4
IrCl3.xH2O (180 mg, 0.6 mmol), ppz-1 (310 mg, 1.2 mmol) and H2O (2 mL) were heated 
at reflux in 2-methoxyethanol (6 mL) under argon for 48 hours. The solution was cooled 
and H2O added (~20 mL). The resulting grey precipitate was filtered and oven dried to 
give presumed chloro-bridged dimer [Ir(ppz-1)2(μ-Cl)2(ppz-1)2]. The dimer [Ir(ppz-1)2(μ-
Cl)2(ppz-1)2] (100 mg, 0.07 mmol) was split by stirring for 2 hours at reflux in the 
presence of AgBF4 (27 mg, 0.14 mmol) with MeCN (15 mL) as solvent. The solution was 
cooled, filtered through cotton wool and the solvent removed in vacuo. The crude 
complex was precipitated from minimal dichloromethane and hexane as a grey oil, 
[Ir(ppz-1)2(MeCN)2]BF4. The [Ir(ppz-1)2(MeCN)2]BF4 (140 mg, 0.16 mmol) and 2,2’-
bipyridine (26 mg, 0.16 mmol) were dissolved in CHCl3 (7 ml) and heated at reflux under 
argon for 24 hours. The solution was cooled and the solvent removed in vacuo. The 
crude solid was dissolved in minimal dichloromethane and added drop wise to stirring 
Et2O (15 mL) at 0°C. The resultant precipitate was filtered to give [Ir(ppz-1)2(bipy)]BF4 as 
a yellow solid (91 mg, 60%). 1H NMR (500 MHz, CDCl3, 25°C): δ= 8.86 (d, 3JHH = 8.2 Hz, 
2H), 8.17 (t, 3JHH = 7.8 Hz, 2H), 7.80 (d, 3JHH = 5.2 Hz, 2H), 7.41 – 7.36 (m, 4H), 6.86 (d, 
3JHH = 8.1 Hz, 2H), 6.00 (s, 2H), 5.96 (s, 2H), 2.73 (s, 6H), 1.39 (s, 6H) ppm; 13C{1H} NMR 
(100 MHz, CDCl3, 25°C): δ= 156.3, 150.2, 149.6, 146.1, 142.6, 141.5, 140.3, 135.0, 127.9, 
125.6, 124.9, 115.2, 113.2, 110.6, 14.2, 12.0 ppm; IR (solid):  bar = 2976, 2359, 1607, 
1574, 1558, 1472, 1445, 1248, 1217, 1186, 1155, 1053, 804, 768, 664, 588, 521, 449 cm-
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1; UV-vis (MeCN): λmax (ε) = 340 (6800) sh, 310 (18300) sh, 297 (24400), 252 nm (51000 
M-1cm-1); HRMS: m/z: 859.1786, calc. 859.1802 for [M – C2H6]+.
Synthesis of [Ir(ppz-2)2(bipy)]BF4
Following the general procedure (GP3), with IrCl3.xH2O (156 mg, 0.53 mmol) and ppz-2 
(252 mg, 1.05 mmol). [Ir(ppz-2)2(bipy)]BF4 was isolated as a light yellow solid (130 mg, 
84%). 1H NMR (400 MHz, [D6]acetone, 25°C): δ= 8.91 (d, 3JHH = 8.2 Hz, 2H), 8.37 (app. td, 
JHH = 8.0, 1.5 Hz, 2H), 8.19 (d, 3JHH = 4.5 Hz, 2H), 7.82 (s, 2H), 7.76 – 7.70 (m, 2H), 7.14 (d, 
3JHH = 8.1 Hz, 2H), 6.59 (d, 3JHH = 7.9 Hz, 2H), 6.40 (s, 2H), 2.98 (s, 6H), 1.63 (s, 6H) ppm;
13C{1H} NMR (100 MHz, [D6]acetone, 25°C): δ= 157.5, 152.1, 151.8, 146.0, 143.9, 141.1, 
140.5, 135.1, 129.7, 125.9, 122.8 (q, JCF = 3.6 Hz), 112.2, 110.1 (q, JCF = 4.1 Hz), 14.4, 12.4 
ppm; IR (solid):  bar = 2979, 2359, 1605, 1557, 1429, 1294,1327, 1159, 1119, 1082, 
1051, 1026, 829, 772, 702; UV-vis (MeCN): λmax (ε) = 339 sh (4600), 310 sh (17500), 276 
nm (30900 M-1cm-1); HRMS: m/z: 827.1887, calc. 827.1905 for [M – C2H6]+.
Synthesis of [Ir(ppz-3)2(bipy)]BF4
Following the general procedure (GP3) with IrCl3.xH2O (151 mg, 0.5 mmol) and ppz-3 
(243 mg, 1.0 mmol). [Ir(L3)2(bipy)]BF4 was isolated as a green/yellow solid (100 mg, 71 
%). 1H NMR (400 MHz, [D6]acetone, 25°C): δ= 8.76 (d, 3JHH = 8.2 Hz, 2H), 8.22 (td, 3JHH = 
8.0, 1.6 Hz, 2H), 8.03 (dd, JHH = 5.5, 0.8 Hz, 2H), 7.71 (d, 3JHH = 8.6 Hz, 2H), 7.59 (ddd, 
3JHH = 7.6, 5.5, 1.2 Hz, 2H), 7.28 (dd, JHH = 8.5, 1.4 Hz, 2H), 6.44 (d, 3JHH = 1.9 Hz, 2H), 
6.27 (s, 2H), 2.80 (s, 6H), 1.49 (s, 6H) ppm; 13C{1H} NMR (100 MHz, [D6]acetone, 25°C): 
δ= 157.5, 152.4, 151.7, 148.5, 144.4, 141.0, 134.6, 130.1 (q, JCF = 3.8 Hz), 127.3 (q, 1JCF = 
31.1 Hz), 125.9, 121.8 (q, JCF = 4.0 Hz), 114.2, 112.0, 14.5, 12.4 ppm; IR (solid):  bar = 
2976, 1604, 1557, 1472, 1400, 1323, 1267, 1078, 1055, 897, 816, 767, 702, 648 cm-1; 
UV-vis (MeCN): λmax (ε) = 341 sh (6600), 310 sh (18700), 297 sh (21500), 277 nm (32400 
M-1cm-1) HRMS: m/z: 827.1883, calc. 827.1905 for [M – C2H6]+.
Synthesis of [Ir(ppz-4)2(bipy)]BF4
Following the general procedure (GP3) with IrCl3.xH2O (122 mg, 0.4 mmol) and ppz-4 
(243 mg, 0.8 mmol). [Ir(ppz-4)2(bipy)]BF4 was isolated as an off-white solid (116 mg, 52 
%). 1H NMR (400 MHz, [D6]acetone, 25°C): δ= 8.92 (d, 3JHH = 8.0 Hz, 2H), 8.38 (td, 3JHH = 
182
8.0, 1.5 Hz, 2H), 8.23 (d, 3JHH = 4.7 Hz, 2H), 7.97 (d, 3JHH = 2.1 Hz, 2H), 7.78 – 7.69 (m, 
2H), 7.31 (dd, JHH = 8.4, 2.1 Hz, 2H), 6.59 (d, 3JHH = 8.3 Hz, 2H), 6.42 (s, 2H), 2.97 (s, 6H), 
1.64 (s, 6H) ppm; 13C{1H} NMR (150 MHz, CD3CN, 25°C): δ= 157.0, 152.4, 152.0, 145.5, 
144.2, 140.8, 140.5, 134.4, 129.4, 125.7, 123.1, 111.8, 111.6, 111.1, 14.4, 12.4 ppm; IR 
(solid):  bar = 2982, 1607, 1553, 1470, 1427, 1080, 1051, 1035, 854, 833, 795, 771, 723, 
656, 594, 567, 519 cm-1; UV-vis (MeCN): λmax (ε) = 342 sh (6300), 308 sh (21400), 297 sh 
(28300), 276 nm (36600 M-1cm-1); HRMS: m/z: 943.1254, calc. 943.1280 for [M – C2H6]+.
Synthesis of [Ir(ppz-5)2(bipy)]BF4
Following the general procedure (GP3) with IrCl3.xH2O (200 mg, 0.7 mmol) and ppz-5 
(256 mg, 1.3 mmol). [Ir(ppz-5)2(bipy)]BF4 was isolated as a yellow solid (121 mg, 56 %). 
1H NMR (400 MHz, [D6]acetone, 25°C): δ 8.87 (d, J = 8.1 Hz, 2H), 8.38 – 8.28 (m, 2H), 
8.18 (d, J = 4.7 Hz, 2H), 7.78 – 7.59 (m, 4H), 6.83 (td, J = 8.7, 2.8 Hz, 2H), 6.29 (s, 2H), 5.96 
(dd, J = 9.0, 2.9 Hz, 2H), 2.85 (s, 6H), 1.57 (s, 6H).; 13C{1H} NMR (100 MHz, CDCl3, 25°C): 
δ= 156.6, 150.0 (d, JCF = 13.7 Hz), 141.0, 140.6, 128.0, 125.9, 120.1, 119.9, 113.8, 113.7, 
110.7, 110.0, 109.7, 14.6, 12.4 ppm; IR (solid):  bar = 1603, 1574, 1553, 1472, 1441, 
1260, 1194, 1051, 868, 814, 768, 750, 737, 615 cm-1; UV-vis (MeCN): λmax (ε) = 341 sh 
(4300), 308 sh (21600), 272 nm (35700 M-1cm-1); HRMS: m/z: 727.1951, calc. 727.1967 
for [M – C2H6]+.
Synthesis of [Ir(ppz-6)2(bipy)]BF4
Following the general procedure (GP3) with IrCl3.xH2O (117 mg, 0.4 mmol) and ppz-6 
(234 mg, 0.8 mmol). [Ir(ppz-6)2(bipy)]BF4 was isolated as a yellow solid (161 mg, 78 %). 
1H NMR (400 MHz, [D6]acetone, 25°C): δ= 8.78 (d, 3JHH = 8.1 Hz, 2H), 8.27 – 8.20 (m, 
2H), 8.07 (ddd, 3JHH = 5.5, 1.5, 0.7 Hz, 2H), 7.72 (d, 3JHH = 8.9 Hz, 2H), 7.61 (ddd, 3JHH = 
7.6, 5.5, 1.2 Hz, 2H), 7.46 (dd, JHH = 9.0, 2.6 Hz, 2H), 6.46 (d, 3JHH = 2.6 Hz, 2H), 6.32 (s, 
2H), 2.80 (s, 6H), 1.51 (s, 6H) ppm; 13C{1H} NMR (100 MHz, [D6]acetone, 25°C): δ= 157.5, 
152.9, 151.8, 147.6, 144.9, 141.2, 140.2, 134.3, 130.2, 129.7, 126.0, 122.6, 114.1, 112.2, 
14.3, 12.3 ppm; IR (solid):  bar = 2971, 1470, 1439, 1421, 1396, 1371, 1105, 1063, 1028, 
839, 831, 787, 766, 725, 658, 592 cm-1; UV-vis (MeCN): λmax (ε) = 340 sh (6800), 310 sh 
(18300), 297 sh (24400), 272 nm (37100 M-1cm-1); HRMS: m/z: 943.1251, calc. 943.1280 
for [M – C2H6]+.
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Preparation of fluorinated pyrazole-Iridium complexes using microwave irradiation 
Synthesis of [Ir(ppz-1)2(bipy)]BF4
IrCl3.xH2O (180 mg, 0.6 mmol), ppz-1 (310 mg, 1.2 mmol), H2O (2 mL) and 
2-methoxyethanol (6 mL) were heated in a microwave for 15 min at 180 °C. The solution 
was cooled and H2O added (~20 mL). The resulting grey precipitate was filtered and oven 
dried to give chloro-bridged dimer [Ir(ppz-1)2(μ-Cl)2(ppz-1)2]. [Ir(ppz-1)2(μ-Cl)2(ppz-1)2] 
(270 mg, 0.19 mmol) was split using MeCN (5 mL) and AgBF4 (74 mg, 0.38 mmol) heating 
in the microwave at 120 °C for 10 min. The solution was cooled, filtered through cotton 
wool and the solvent removed in vacuo. The crude complex was precipitated from 
minimal dichloromethane and hexane as a grey oily solid, [Ir(ppz-1)2(MeCN)2]BF4. 
[Ir(ppz-1)2(MeCN)2]BF4 (260 mg, 0.31 mmol) and 2,2’-bipyridine (49 mg, 0.31 mmol) 
were dissolved in CHCl3 (7 mL) and heated in the microwave at 130 °C for 15 min. The 
solution was cooled and the solvent removed in vacuo. The crude solid was dissolved in 
minimal dichloromethane and added drop wise to stirring Et2O (15 mL) at 0°C. Further 
purification was achieved using column chromatography (silica) and eluting with 99:1 
DCM/MeOH. The resultant precipitate was filtered to give [Ir(ppz-1)2(bipy)]BF4 as a 
yellow solid (110 mg, 40%).
Synthesis of [Ir(ppz-2)2(bipy)]BF4
Following the general procedure (GP4) with [Ir(ppz-2)2(MeCN)2]BF4 (42 mg, 0.050 
mmol). [Ir(ppz-2)2(bipy)]BF4 was isolated as a light yellow solid (26 mg, 57%).
Synthesis of [Ir(ppz-3)2(bipy)]BF4
Following the general procedure (GP3) with [Ir(ppz-3)2(MeCN)2]BF4 (318 mg, 0.38 
mmol). Further purification was achieved using column chromatography (silica) and 
eluting with 99:1 DCM/MeOH. [Ir(ppz-3)2(bipy)]BF4 was isolated as a green/yellow solid 
(26 mg, 22%).
Synthesis of [Ir(ppz-4)2(bipy)]BF4
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Following the general procedure (GP3) with [Ir(ppz-4)2(MeCN)2]BF4 (111 mg, 0.116 
mmol). [Ir(ppz-4)2(bipy)]BF4 was isolated as an off-white solid (167 mg, 76%).
Synthesis of [Ir(ppz-5)2(bipy)]BF4
Following the general procedure (GP3) with [Ir(ppz-5)2(MeCN)2]BF4 (50 mg, 0.067 
mmol). [Ir(ppz-5)2(bipy)]BF4 was isolated as a yellow solid (29 mg, 53%).
Synthesis of [Ir(ppz-6)2(bipy)]BF4
Following the general procedure (GP3) with [Ir(ppz-6)2(MeCN)2]BF4 (85 mg, 0.089 
mmol). [Ir(ppz-6)2(bipy)]BF4 was isolated as a yellow solid (64 mg, 71%).
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Chapter 5 – Synthetic Development 
and Spectroscopic Analysis of 
Ferrocene 1,8-Naphthalimide 
Derivatives for Electrochemical 
Biosensors Applications 
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5.1 Introduction 
5.1.1 Electrochemical Biosensors 
Biosensors are used to determine specific analytes as well as investigate chemical 
interactions of biomolecules such as DNA. They represent a measuring instrument 
requiring no additional reagents, thus providing selective qualitative and/or quantitative 
analytical information using a biological recognition element which is retained in spatial 
contact with a transduction element.1 The application of the biosensor depends on 
selection of its building blocks, where construction is tailored for a specific purpose. In 
particular, detection involving biomacromolecules such as DNA requires a biosensor 
with a rational and complex construction. DNA-based electrochemical biosensors 
comprise a nucleic acid recognition layer, which is immobilized over an electrode as the 
transducer converts the DNA response into an electronic signal. This type of biosensor 
can be applied in a variety of diagnostics of serious diseases, whilst typically offering 
high sensitivity, acceptable selectivity, easy automation and easy portability; leading to 
low running and investment costs.1
5.1.2 Electrochemical Clostridium Difficile Detection 
Clostridium difficile (CDF) is a spore-forming, ubiquitous bacterium that is present in the 
human colon of 2-5% of the adult population.2 CDF has significant antibiotic resistance, 
and upon commencement of antibiotic therapy the natural equilibrium of the gut is 
disturbed. This allows CDF to opportunistically dominate the colon, aiding the CDF 
infection (CDI). The symptoms of this disease are diarrhoea and inflammation,3 and can 
range from mild disease to life-threatening pseudomembranous colitis. With an 8% 
mortality rate, CDI led to 0.8% of all hospital deaths in 2012.4
The current clinical method of diagnosis begins with a two-step algorithm: initial 
screening for glutamate dehydrogenase (detects the presence of the organism), 
followed by an enzyme immunoassay test for the presence of disease causing toxins.5
This diagnostic method is lacking in terms of time-to-result, sensitivity and specificity. A 
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proposal based on a GW4 collaboration involving groups in Cardiff, Bristol and Bath 
universities aims to develop a diagnostic bedside test able to give a definitive result 
within ten minutes, thus allowing appropriate treatment to be given in a shorter time 
frame.  
The methodology for this bedside test is shown in Figure 5.1. A capture strand of DNA is 
used that is immobilised on a gold electrode, where the single stranded DNA is made up 
of complimentary base pairs to selectively target the DNA of CDF. If CDF is present, 
hybridisation will occur with the capture strand and form a double helix. This will in turn 
trigger one or more of the electronically active probes to bind to the DNA duplex on the 
electrode. This brings the redox-active element into proximity of the gold electrode and 
creates a detectable electrochemical signal for electrochemical impedance 
spectroscopy. This will perturb the typical signal of the gold electrode therefore causing 
the probe to act as a sensitiser for electrochemical detection of the DNA strand. An 
example of a suitable redox-active element is ferrocene, due to the facile redox 
properties of the ferrocene/ferrocenium couple, as displayed in Figure 5.2. 
Figure 5.1:Schematic showing hypothesised detection method for CDF
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Figure 5.2: Ferrocene/ferrocenium redox couple 
5.1.3 Naphthalimide Derivatives with Specific DNA Sequence Selectivity 
Small molecules are able to be highly selective towards a specific DNA sequence through 
binding modes including intercalation, electrostatic and hydrogen bonding interactions. 
This characteristic is invaluable when developing new diagnostic and therapeutic 
agents.6 It is possible for naphthalimide derivatives to achieve DNA binding by joining 
known minor groove-binding agents. For example, DNA-directed alkylating agents have 
been established that link naphthalimide, nitrogen mustard and lexitropsin moieties.7
Lexitropsin is a known DNA binding ligand which is commonly used to admininster 
antibiotics.8,9 However in this research the most biologically active compound 
unexpectedly lacked the lexitropsin unit.    
In other research, the intercalation effect of a 1,8-naphthalimide chromophore was 
combined with the minor groove-binding characteristics of a range of pyrrole-imidazole 
polyamides.10 The binding affinity and specificity of naturally occurring DNA binding 
proteins is mimicked by the pyrrole-imidazole polyamides: 8 membered ring systems 
containing a three-letter amino acid code.11 Therefore, the naphthalimide moiety 
ensures the molecule intercalated tightly with DNA and the pyrrole-imidazole unit 
directed the molecule to specifically bind to the topoisomerase II gene promoter 
sequence. Figure 5.3 displays compounds 2 and 3 from the study, where the 
naphthalimide unit in compound 3 improved the sequence selectivity for the ICB2 site 
by simultaneous intercalation and minor-groove binding. Following this, other research 
has successfully developed 1,8-naphthalimide units linked to peptide chains to ensure 
selective DNA binding. 
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Figure 5.3: Pyrrole-imidazole polyamides by Lee et al.10 Copyright 2006 John Wiley & Sons 
5.1.4 Biological Applications of Ferrocene  
Metallocenes have found applications in a wide variety of biological applications. There 
are three main characteristics that make them suitable for these applications. Firstly, 
they are small, rigid, hydrophobic molecules that can easily diffuse across the 
phospholipid  bilayer of the cell membrane;12 a characteristic that is maintained when 
the metallocene is functionalised with polar substituents. There are a number of in vitro
and in vivo investigations available for this genre of compounds.12 Secondly, the top 
surface of a metallocene bears resemblance to an aromatic system and hence they are 
able to mimic the binding of small aromatic molecules. However, due to their increased 
thickness they block further enzymatic sites, thus inhibiting enzyme-catalysed 
processes.12 Finally, the inherent thermodynamic stability of metallocenes ensures that 
the metal centre cannot be displaced without destroying the structure. As a result, the 
metal centre can act as a tracer, especially when the metal is redox active, for example 
Fe(II)13 or radioactive 87Ru.  
In particular, ferrocene has been widely used as an organometallic scaffold for the 
synthesis of many functionalised derivatives which have synthetic and medicinal 
applications.14 Ferrocene’s employment for a vast number of fields is due to a number 
of reasons: it is aromatic and readily functionalised; it has an electron rich Fe(II) centre; 
good solubility and ease of undergoing iron oxidation. In relation to these properties, 
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areas in which ferrocene has found use are electrochemistry, biochemistry, drug design 
mediators of protein redox reactions,15,16 internal standards in electrochemistry17,18 and 
organic synthesis,19 as in the functionalisation of cyclopentadienyl ligands.20,21
Derivatives are generally stable aerobically, thermodynamically and photochemically 
and hence a wide range of chemical behaviour can be explored.22 Due to a positive 
combination of chemical and physical properties, ferrocene derivatives have also found 
applications as electronic materials, metallic coatings, high-octane additives to motor 
fuel and hematopoietic substances.23 In addition, ferrocene-based polymers have also 
been explored in the fields of biosensing,24,25 biomedical engineering,26 biophysics and 
surface science.  
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Figure 5.4: N-(ferrocenyl)naphthoyl derivatives investigated in terms of cytotoxicity towards H1299 
cells27
Biological applications of ferrocene include analgesic, antineoplastic, anticonvulsant, 
anti-HIV, antitumour, antimalarial, antioxidant, antimicrobial and DNA-cleaving 
activities.23 In particular, the applications of ferrocene derivatives as promising targets 
for cancer disease have been extensively reviewed.23 Known compounds that are 
excellent anticancer and antimalarial agents include ferrocifen, tamoxifen28 and 
ferroquine. For example, ferrocifens were the first anticancer agents to be active against 
both hormone-dependant and hormone-independent breast cancer.29  In more recent 
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work, the N-(ferrocenyl)naphthoyl derivatives shown in Figure 5.4 were investigated for 
their cytotoxic activity against the human lung carcinoma cell line, H1299. All derivatives 
were found to be more cytotoxic in vitro than the clinically used anticancer drug 
carboplatin.27
In recent years, the development of DNA-biosensors has played a significant role in 
diagnostics and biomedicine, as well as forensics.23 For example, electrochemical DNA 
biosensors have been used to predict drug-DNA interactions, where the techniques used 
are fast, high-throughput and low cost30 thus giving rise to the ability to speed up the 
drug screening process. Oxidation reactions that take place at an electrode show similar 
behaviour to those in the body, which is why it is possible for electrochemical and 
biological reactions to be compared. For the same reason, an electrochemical signal 
related to DNA-drug interaction can provide information on interaction mechanism, 
binding constant, binding bite size and the role of free radicals generated during the 
interaction.23
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Figure 5.5: F4ND hybridisation indicator31
One example of a ferrocene derivative being applied as an electrochemical gene 
detector is provided by Sato et al., who developed a new naphthalene diimide F4ND 
hybridisation indicator (Figure 5.5).31 Although the compound had bulky substituents, 
F4ND showed binding to double-stranded DNA with intercalation mode therefore 
distorting the duplex. Methylated and unmethylated sites on the target DNA caused 
differences in the rate of dissociation of the F4ND which allowed distinction between 
these sites. As a consequence, an electrode was perturbed allowing identification of 
sites through an electrochemical detection system.  
5.1.5 1,8-Naphthalimide Ferrocene Complexes  
Multi-state fluorimetric logic gates with redox-active ferrocene groups have been 
developed and offer dual mode chemical and electrochromic contrast agents.32,33 For 
example, Magri et al., utilised naphthalimide based ferrocene complexes as logic gates 
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that combine acid-base and redox equilibria allowing simultaneous monitoring of redox 
potential and the pH of a system (Figure 5.6).34 These derivatives were found to emit 
fluorescence upon oxidation of the ferrocene unit and protonation of the tertiary amine 
to an almost 13-fold enhancement. These compounds exhibited a reasonable sensitivity 
between pH 5.5 and pH 7.5, and demonstrated a highly favourable driving force of -
1.59eV during PeT from ferrocene to the excited state fluorophore.  
Fe
N
O
O
S
S
Figure 5.6: Compound by Magri et al.34
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5.2 Aims 
As discussed above, 1,8-naphthalimides intercalate selectively with DNA double helices 
and exhibit fluorescence, both attributes that facilitate the detection of CDF by 
eliminating the need for a covalently labelled analyte, thus making them suitable for this 
application. In addition to an intercalating fluorophore, the technique requires a redox-
active element to introduce electrochemical functionality to the probe. Ferrocene is a 
suitable derivative due to the facile redox properties of the ferrocene/ferrocenium 
couple. The aim of this work, therefore, was to create a synthetic protocol for a 
luminescent, water soluble, 1,8-naphthalimide derivative coupled to a ferrocene 
moiety, in turn developing a fluorescent biosensor with an additional redox element. 
Once synthesised, spectroscopic and analytical characterisation would be carried out to 
provide data indicating the synthesis of the novel compounds, where 1H NMR 
spectroscopy is of particular significance to confirm the structural integrity of both the 
naphthalimide and ferrocene units. Study of the electrochemical and photophysical 
properties is also imperative due to the potential electrochemical application. In 
addition, preliminary fluorescence microscopy investigations have been carried out.   
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5.3 Results and Discussion 
5.3.1 Synthetic Protocol Investigations 
The general hypothesis required a covalently linked ferrocene unit with a 
naphthalimide. A variety of experimental procedures were attempted before a viable 
protocol synthesised the desired target compounds. Presentations of the considerations 
of these abandoned synthetic routes provides context and a rationale for the final route 
that was devised. 
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Scheme 5.1: Synthesis of a 4-substituted-1,8-naphthalimide 
The first step in Scheme 5.1 followed adapted standard methodologies35 from 
commercially available 4-chloro-1,8-naphthalic anhydride, where a yield of 30% was 
obtained. The second step also followed literature examples, and involved the addition 
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of piperidine at the 4-position of the 1,8-naphthalimide via a SNAr mechanism.36 A yield 
of 42% was obtained.  
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Scheme 5.2: Reaction of a 1,8-naphthalimide with 2-chloroferrocenyl ethanone 
A SN2 reaction was attempted in two ways with the product of Scheme 5.1 and 2-
chloroferrocenyl ethanone (synthesised by Dr. Samuel Adams37), described in Scheme 
5.2. Initially, this was carried out in chloroform using triethylamine (NEt3) to deprotonate 
the ammonium cation intermediate resulting in a crude, brown oil. This was determined 
to be a mixture of starting materials through 1H NMR spectroscopic analysis. The 
reaction was repeated using THF as the solvent, along with the addition of a catalytic 
amount of sodium iodide (NaI), as iodide is a better leaving group than chloride.38
However,  the brown oil produced was found to be only starting material through TLC 
and 1H NMR spectroscopy.   
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Scheme 5.3: Reactions with ferrocene carboxaldehyde 
Following this, a more reactive alternative to 2-chloroferrocenyl ethanone was sought. 
Ferrocene carboxaldehyde was used as an alternative reagent, as shown in Scheme 5.3.  
Rather than adding the ferrocene unit in the final step, the synthesis was altered to build 
from the ferrocene starting material and adding the naphthalimide in subsequent steps.  
Firstly, ferrocene carboxaldehyde was reacted with piperazine using a one-pot reductive 
amination approach. DCE was used as a solvent and 1.5 equivalents of sodium 
triacetoxyborohydride (STAB) were added after 2 hours. STAB acts as the reducing agent 
to reduce the imine intermediate, leading to the amine product.39 This  reaction was 
also unsuccessful and no product formation was observed.  
The amine was changed from piperazine to mono-BOC-protected ethylene diamine in 
an attempt to eliminate the possibility that the reductive amination was ineffective 
because of the steric hindrance associated with piperazine. Three different reactions 
were attempted with varying conditions, described in Scheme 5.3. Firstly, analogous 
reaction conditions to those used with piperazine were attempted;39 this was 
unsuccessful. Alternative conditions were attempted in ethanol with the addition of a 
catalytic amount of glacial acetic acid.40 It was thought that the acetic acid would act as 
a catalyst by protonating the carbonyl oxygen, thus increasing the electrophilicity of the 
carbonyl carbon.41 Once again this led to only starting material. In addition, the reaction 
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was carried out in chloroform with STAB as the reducing agent. After 3 hours at reflux 
under N2, magnesium sulphate was added as a drying agent as water is formed as a by-
product of a reductive amination reaction. Again, starting materials were observed 
following the reaction attempt.  
A further attempt using an adaptation of research by Richards et al. was carried out.42
This involved the use of Dean-Stark apparatus along with molecular sieves; both 
designed to collect and remove water from the reaction medium. A proof of concept 
reaction using benzylamine was conducted using the exact reaction conditions depicted 
in the literature, as shown in Scheme 5.4.  
Fe
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Scheme 5.4: Reaction using Dean-Stark apparatus 
This reaction was successful, producing results that are comparable to the 
aforementioned literature.42 Identical reaction conditions were thus applied to an 
amino 1,8-naphthalimide derivative shown in Scheme 5.5. TLC analysis suggested that 
the imine formation was successful but no product was isolated following the reduction 
step.  
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Scheme 5.5: Further reaction using Dean-Stark apparatus 
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5.3.2 Final Experimental Procedure
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Scheme 5.6: Final experimental protocol for N1
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Ferrocene carboxylic acid was then used as an alternative starting material. Step 1 of 
Scheme 5.6 involves the carboxylic acid moiety undergoing a nucleophilic substitution 
reaction with oxalyl chloride,43 thus replacing the –OH group with a –Cl group to form a 
more reactive acyl chloride.38 In Step 2 the acid chloride reacted with 2,2I-
(ethylenedioxy)bisethylamine43 to form an amide bond. The mechanism of this reaction 
is shown in Figure 5.7. This step produced FC-PEG with a yield of 84%.  
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Figure 5.7: Mechanism of reaction between ferrocene acid chloride and 2,2-(ethylenedioxy)bisethylamine 
FC-PEG was then reacted with 4-chloro-1,8-naphthalic anhydride in Step 3 using 
analogous conditions to above,35 where an excess of triethylamine was used as a base. 
This condensation reaction at the imide position on the naphthalic anhydride produces 
FC-P1, with a yield of 92%. Further functionalization with ethanolamine at the 4-position 
of the naphthalimide was successful (Step 4 – Scheme 5.6), and aimed to introduce 
intramolecular charge transfer (ICT) and water solubility to N1. This step was initially 
carried out using DMSO and had a yield of 21%.   
Due to the water-soluble nature of N1, the typical DMSO aqueous work-up used in Step 
4 led to the low yield mentioned above. For this reason, ethanolamine was employed as 
both the nucleophile and the solvent in this reaction, thus eliminating the difficult 
extraction from DMSO.  This resulted in an improved yield for N1 of 55%.   
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Figure 5.8: Structures of final compounds isolated in this chapter: N1-N3 
For N2 and N3, the synthetic procedure was common for Steps 1-3. However, for N2, 2-
methoxyethanol was used to replace DMSO in Step 4. This is because ethylenediamine 
shows higher levels of acute toxicity when compared to ethanolamine, hence it should 
be used in as smaller quantity as possible. For N3, the final step of the reaction was 
carried out in DMSO due to the decreased water solubility of the final product.  
5.3.3 Spectroscopic Characterisation 
FC-P1 and N1-N3 were fully characterised using 1H NMR, 13C NMR, UV-Vis, IR and HRMS. 
1H NMR spectroscopy was obtained due to all of the compounds’ high solubility in 
chloroform, obtaining well resolved spectra with the expected peak multiplicities.  The 
1H NMR of FC-PEG was comparable to that seen in the literature.43
1H NMR was informative when confirming the formation of FC-P1 (Figure 5.9). The peaks 
residing in the aromatic region, between 8.6 - 7.7 ppm are characteristic of the five 
212 
protons associated with the 1,8-naphthalimide moiety, as shown in Figure 5.9. Three 
distinctive singlets present between 4.2 – 4.0 ppm corresponding to the ferrocene group 
and integrate as 2:2:5 protons. Since the naphthalimide and ferrocene environments are 
in a 1:1 ratio to one another, product formation is suggested. In addition, the broad 
triplet at 6.4 ppm is characteristic of a naphthalimide N-H resonance following formation 
of the amide bond (Figure 5.9).   
Figure 5.9: 1H NMR spectrum of aromatic region of FC-P1 
Comparison of the 1H NMR spectra for FC-P1 and N1 confirmed the substitution of 
chloride for ethanolamine at the 4-position. The aromatic peaks present for FC-P1 have 
shifted and the multiplet present at 7.77 ppm has separated due to the shielding effects 
of the amine compared to the chloride. This has the most significant effect on the proton 
in the β-position to the amine, which has been shifted to 6.6 ppm, as shown in Figure 
5.10. There is also an additional N-H resonance at 5.9 ppm that integrates to one proton, 
thus confirming that ethanolamine is present at the 4-position. There are also additional 
peaks in the aliphatic region at 4.03 and 3.27 ppm which correspond to ethanolamine. 
All of the changes in spectra mentioned above indicate the successful formation of N1. 
Similar trends in the 1H NMR spectra were observed for the formation of N2 and N3.  
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Figure 5.10: 1H NMR spectrum of the aromatic region of N1 
In all cases N1-N3, the proposed molecular formula for the target compounds was 
supported by HRMS (ES+), each showing the expected [M+H]+ peak. IR spectroscopy 
further illustrated the formation of N1-N3. Comparison of the IR spectra of FC-P1 and 
N1 (Figure 5.11) illustrates product formation due to the new broad O-H stretch at 3345 
cm-1 assigned to the terminal alcohol on ethanolamine.    
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5.3.4 Photophysical Properties 
The photophysical properties of N1-N3 were investigated via UV-vis., steady state 
luminescence, luminescence lifetimes and quantum yields, and were measured in 
aerated solutions of acetonitrile in all cases. A summary of the photophysical properties 
are shown in Table 5.1.  
Compound λmax / nma λem / nm τobs / nsb φ c
FC-P1 353 - - -
N1 430 524 9.7 13.9
N2 433 521 8.3 11.0
N3 395 524 3.9 8.0
Table 5.1: Absorption and emission data for the FC-P1 and N1-N3: a measurements obtained in MeCN 
solutions; b using λex= 295 nm.; c for quantum yield measurements using [Ru(bpy)3](PF6)2 as reference of 
0.016 in aerated MeCN 
Figure 5.11: IR spectra of FC-P1 (top) and N1 (bottom)
215 
The absorption profiles of FC-P1 and N1-N3 are displayed in Figure 5.12. In the case of 
FC-P1, the absorption spectra is dominated by π→π* absorbances associated with the 
naphthalimide unit. The two intense bands between 200-250 nm correlate to high 
energy transitions, and the weaker, vibronically structured absorption at 300-360 nm 
are additional π→π* transitions. When compared to N1-N3, the π→π* absorbances are 
hypsochromically shifted to appear between 200 and 300 nm. Upon substitution at the 
4-position of the naphthalimide, in N1-N3, intramolecular charge transfer (ICT) gives rise 
to an additional absorption 395-430 nm, as seen with other related systems.44 Of the 
three systems, N3 has the ICT band ar highest energy due to the presence of a 
morpholine derivative. It is also worth noting that the absorption profile of ferrocene 
contains peaks at ca 320 and 430 nm. However due to extremely low molar extinction 
coefficients they are not visible in this case.45,46
Figure 5.12: Absorption profiles of FC-P1 and N1-N3
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Figure 5.13: Emission profiles of N1-N3
Each of the compounds, N1-N3, was shown to be fluorescent in solution, with emission 
wavelengths between 520-525, indicating that the nature of the group at the 4-position 
has little effect on the emission wavelength (Figure 5.13). The data are very typical of 
previously reported naphthalimide fluorophores.47 Time-resolved measurements (λex = 
295 nm) revealed lifetimes that were consistent with fluorescence emission from the 
ICT excited state in all cases (Table 5.1). Quantum yields range from 8-14%. For N3, a 
shorter lifetime and lower quantum yield are observed, suggesting that efficiency of the 
emission of the compound is not as significant. This may be due to the presence of a 
morpholine moiety at the 4-position and its differing electronic properties. Overall, the 
photophysical data from this series of ferrocene coupled naphthalimides demonstrated 
that the presence of the ferrocene moiety did not appear to quench the luminescent 
properties that are commonly associated with the naphthalmide unit. 
5.3.5 Bioimaging Studies 
Confocal fluorescence microscopy was performed using MCF7 cells. MCF-7 cells were 
grown on circular glass coverslips for 5-7 days in RPMI-1640 medium, supplemented 
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with 5% foetal calf serum (heat inactivated) and 100 U/ml penicillin/streptomycin 
solution, until around 70-90% confluent. For experiments, culture medium was replaced 
with 1 ml fresh RPMI-1640 and cells were incubated with 100 ug/ml of compound N1. 
This compound was incubated with the cells for 30 minutes at 37 °C, then washed in 
warmed PBS before imaging using an excitation wavelength of 405 nm.  
Figure 5.14: CFM images of N1 with MCF-7 cells
This preliminary study found that uptake into the cells was very fast and very bright 
images were obtained (Figure 5.14). These studies therefore provide clear evidence of 
the biocompatibility of N1 towards cell imaging using confocal fluorescence microscopy. 
Further studies are required to investigate the precise localisation and cytotoxicity of 
N1. 
5.3.6 Electrochemical Properties 
Complex Component Eox / V Ered / V
N1 
Ferrocene +0.60 +0.55
Naphthalimide +1.19 -
N2 
Ferrocene +0.47 +0.37
Naphthalimide +1.16 -
N3 
Ferrocene +0.59 +0.51
Naphthalimide +1.26 -1.39
Table 5.2: Electrochemical data for N1-N3
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The electrochemical characteristics of N1-3 were studied in deoxygenated DCM (Table 
5.2). The cyclic voltammograms were measured using a platinum disc electrode; scan 
rate υ = 200 mV s-1, 1 x 10-3 M solutions, 0.1 M [NBu4][PF6] as a supporting electrode 
calibrated with Fc/Fc+ at +0.47 V. N1-N3 all demonstrated fully reversible one-electron 
oxidation at +0.47-0.60 V ascribed to the ferrocene/ferrocenium couple, this showed a 
reversible reduction wave at +0.37-0.55V attributed to the reformation of the ferrocene 
unit. For N1 and N3 the anodic and cathodic wave of the ferrocene unit is shifted to a 
higher potential than the reference ferrocene, suggesting that these compounds are 
harder to oxidise than ferrocene.48 For N2, the waves associated with ferrocene in N2 is 
superimposed with that of the reference ferrocene. This may be due to the ferrocene 
derivative on N2 being more electron deficient due to the electron withdrawing ability 
of the amide attached to the ferrocene group. The additional anodic wave residing 
between +1.16-1.26 V is thought to correspond with the oxidisation of 1,8-
naphthalimide present in N1-N3. This peak has no mirroring cathodic wave, implying this 
is an irreversible process. For N1 and N2, there are no anodic or cathodic waves present 
at a negative potential, suggesting neither the ferrocene nor the naphthalimide unit are 
reducible within the voltage range explored. This is not the case for N3, where a 
reductive wave is observed at -1.39 V and attributed to a naphthalimide localised 
process.   
Consequently, N1-N3 have illustrated distinguishable electrochemical properties 
suggesting it would be able to perturb a gold electrode signal as desired in the aim of 
this chapter. N1 has been sent to our collaborators Prof. Martin Cryan and Dr. Pedro 
Estrela at the Universities of Bristol and Bath, respectively, for further investigations into 
its suitability for electrochemical detection of CDF.  
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5.4 Conclusions  
This chapter has described the determination of a successful synthetic route to, and 
spectroscopic analysis of, a series of fluorescent biosensors that incorporate both a 
redox active ferrocene unit and a naphthalimide moiety. Three novel target compounds 
were generated, N1-N3, as well as a novel precursor, FC-P1.   
The effective synthetic protocol was as follows: ferrocene carboxylic acid reacted with 
oxalyl chloride in a nucleophilic substitution reaction; the resultant acid chloride reacted 
with 2,2’-(ethylenedioxy)bisethylamine to form an amide bond (FC-PEG); FC-PEG was 
reacted with 4-chloro-1,8-naphthalic anhydride to form a naphthalimide (FC-P1); FC-P1 
was reacted with an amine (ethanolamine, ethylenediamine or morpholine) in a 
nucleophilic aromatic substitution reaction to form N1-N3. This approach proved to be 
a superior route over a number of alternatives, including the use of a 4-subsituted-1,8-
naphthalimide, 2-chloroferrocenyl ethenone, as well as ferrocene carboxaldehyde, that 
did not yield the desired targets. 
The resultant 1H NMR spectra of each of the target compounds showed the correct 
number of peaks with anticipated multiplicities, including N-H resonances in the cases 
of N1 and N2.  Retention of both the ferrocene and naphthalimide units during the final 
step of the synthetic protocol were confirmed in each case. The dyad compounds show 
their luminescent behaviour with naphthalimide-based emission attributed to the ICT 
character observed between 520-525 nm. The electrochemical properties of N1-N3 
were also investigated and showed a fully reversible one-electron oxidation attributed 
to the ferrocene unit (Eox = +0.47-0.60 V), in addition to an irreversible oxidation of the 
1,8-naphthalimide moiety (Eox = +1.16-1.26 V). 
Future work will involve collaborating with Prof. Martin Cryan (University of Bristol) and 
Dr. Pedro Estrela (University of Bath) to investigate the viability of N1-3 for an 
electrochemical detection method for CDF. In addition, further bioimaging studies will 
be carried out to establish the organelle localisation of the compounds, as studied with 
related structures in Chapters 2 and 3. 
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5.5 Experimental 
5.5.1 General Experimental Considerations 
All reagents and solvents were commercially available and were used without further 
purification if not stated otherwise. For the measurement of 1H and 13C NMR spectra a 
Bruker Fourier300 (300 MHz), Bruker AVANCE HD III equipped with a BFFO SmartProbeTM
(400 MHz) or Bruker AVANCE III HD with BBO Prodigy CryoProbe (500 MHz) was used. 
The obtained chemical shifts δ are reported in ppm and are referenced to the residual 
solvent signal. Spin-spin coupling constants J are given in Hz.   
Low-resolution mass spectra were obtained by the staff at Cardiff University. High-
resolution mass spectra were carried out at the EPSRC National Mass Spectrometry 
Facility at Swansea University. High resolution mass spectral (HRMS) data were obtained 
on a Waters MALDI-TOF mx at Cardiff University or on a Thermo Scientific LTQ Orbitrap 
XL by the EPSRC UK National Mass Spectrometry Facility at Swansea University. IR 
spectra were obtained from a Shimadzu IR-Affinity-1S FTIR. UV-Vis studies were 
performed on a Shimadzu UV-1800 spectrophotometer as MeCN solutions (2.5 or 5 × 
10-5 M) or CHCl3 solutions (2.5 or 5 × 10-5 M). Photophysical data were obtained on a 
JobinYvon–Horiba Fluorolog spectrometer fitted with a JY TBX picosecond 
photodetection module as MeCN/CHCl3 solutions. Emission spectra were uncorrected. 
The pulsed source was a Nano-LED configured for 459 nm output operating at 1 MHz. 
Luminescence lifetime profiles were obtained using the JobinYvon–Horiba FluoroHub 
single photon counting module and the data fits yielded the lifetime values using the 
provided DAS6 deconvolution software. Quantum yield measurements were obtained 
on aerated MeCN solutions of the complexes using [Ru(bpy)3](PF6)2 in aerated MeCN as 
a standard (Φ = 0.016).49
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5.5.2 Synthesis 
Synthesis of FC-PEG  
Ferrocenecarboxylic acid (1 g, 1 eq, 4.36 mmol) was dissolved in anhydrous DCM (50 mL) 
and oxalyl chloride (0.896 mL, 2.4 eq, 10.46 mmol) was added at 0oC. The mixture was 
allowed to warm to room temperature and left to stir for 2 hours under nitrogen. The 
solvent was removed in vacuo to give a crude brown solid; this was redissolved into 
anhydrous DCM (25 mL) and added dropwise at 0oC to a solution of 2,2I-
(ethylenedioxy)bisethylamine (6.36 mL, 10 eq, 43.6 mmol) in anhydrous DCM (2 x 20 
mL) over 10 minutes. The resulting solution was warmed to room temperature and left 
to stir under nitrogen for 2 hours. The reaction was quenched with NaHCO3 (25 mL), 
extracted into DCM (30 mL) and washed with water (2 x 30 mL) and brine (30 mL). The 
solution was dried over magnesium sulphate and the solvent removed in vacuo to give 
FC-PEG as a brown solid (1.31 g, 84%). 1H NMR (400 MHz, Chloroform-d) δ 6.32 (br. s, N-
H, 1H), 4.69 (t, 3JHH = 4.0, 2H), 4.33 (t, 4.0, 2H), 4.20 (s, 5H), 3.65 (dd, 3JHH = 9.8, 3.2 Hz, 
6H), 3.63 – 3.56 (m, 2H), 3.53 (t, 3JHH = 5.2 Hz, 2H), 2.89 (t, 3JHH = 5.2 Hz, 2H).  
Synthesis of FC-P1 
FC-PEG (1.31 g, 2 eq, 3.64 mmol) was dissolved in EtOH (50 mL) and 4-chloro-1,8-
naphthalic anhydride (423 mg, 1 eq, 1.82 mmol) with triethylamine (1.79 mL, 7 eq, 12.74 
mmol) was added. The solution was heated at reflux under nitrogen overnight. The 
solution was left to cool and the EtOH was removed in vacuo. The crude solid was 
redissolved into DCM, (40 mL) washed with H2O (2 x 40 mL), washed with brine (2 x 40 
mL) and dried over magnesium sulphate. The solvent was removed in vacuo, to give FC-
P1 as a brown solid (961 mg, 92 %).  1H NMR (400 MHz, CDCl3) δ 8.57 (d, 3JHH = 7.1 Hz, 
1H), 8.51 (d, 3JHH = 8.4 Hz, 1H), 8.40 (d, 3JHH = 7.9 Hz, 1H), 7.77 (dd, 3JHH = 18.1, 7.7 Hz, 
2H), 6.39 (br. S, N-H, 1H), 4.65 (s, 2H), 4.41 (t, 3JHH = 5.9 Hz, 2H), 4.23 (s, 2H), 4.17 (s, 2H), 
4.10 (s, 5H), 3.84 (t, 3JHH = 5.9 Hz, 2H), 3.60 (d, 3JHH = 4.8 Hz, 2H), 3.54 (d, 3JHH = 4.9 Hz, 
2H), 3.46 (d, 3JHH = 4.9 Hz, 2H). 13C NMR (400 MHz, CDCl3) δ 170.2, 163.6, 163.4, 139.0, 
131.9, 131.0, 130.6, 129.1, 128.9, 127.8, 127.3, 122.8, 121.3, 76.1, 70.4, 70.3, 70.2, 70.0, 
69.8, 69.7, 69.7, 69.6, 68.2, 68.1, 67.9, 53.5, 39.2, 39.1, 30.9. HRMS found m/z 573.1108, 
calculated m/z 573.1083 for [C29H27ClFeN2O5]+. UV-Vis (MeCN): λmax {ε/dm3 mol-1 cm-1}: 
222 
353 {5260}, 340 {6660}, 265 (s) {3860}, 235 {23740}, 211.5 {28800}. IR (solid. Vmax)/cm-1: 
3325, 3086, 2866, 2237, 1701, 1659, 1634, 1589, 1574, 1531, 1404, 1371, 1342, 1296, 
1234, 1188, 1105, 1051, 1001, 910, 820, 779, 750, 725, 667, 646, 567, 482, 417, 403. 
Synthesis of N1 
FC-P1 (306.6 mg, 1 eq, 0.534 mmol) was dissolved in ethanolamine (3 mL) and heated 
at reflux under nitrogen overnight. The solution was allowed to cool and extracted into 
DCM (2 x 20 mL), washed with water (2 x 20 mL), dried over magnesium sulphate, and 
the solvent removed in vacuo to give N1 as a brown oil. (177 mg, 55%). 1H NMR (500 
MHz, CDCl3) δ 8.47 (d, 3JHH = 7.2 Hz, 1H), 8.38 (d, 3JHH = 8.4 Hz, 1H), 8.12 (d, 3JHH = 8.2 Hz, 
1H), 7.50 (t, 3JHH = 7.8 Hz, 1H), 6.66 (d, 3JHH = 8.4 Hz, 1H), 6.42 (br. s, N-H, 1H), 5.95 (br. 
s, N-H, 1H), 4.66 (d, 3JHH = 7.3 Hz, 2H), 4.46 (t, 3JHH = 5.8 Hz, 2H), 4.26 (s, 2H), 4.20 (s, 2H), 
4.13 (s, 5H), 3.89 (t, 3JHH = 5.8 Hz, 2H), 3.67 – 3.53 (m, 6H), 3.50 – 3.44 (m, 2H), 3.27 (q, 
3JHH = 5.2 Hz, 2H). 13C NMR (400 MHz CDCl3) δ 169.6, 163.8, 163.2, 148.9, 133.5, 130.1, 
128.7, 125.6, 123.5, 121.6, 119.4, 108.9, 103.4, 74.8, 69.5, 69.3, 69.2, 69.0, 68.8, 68.7, 
67.2, 67.1, 59.1, 52.4, 44.7, 39.9, 38.2, 37.9, 29.9. HRMS found m/z 600.1777, calculated 
m/z 600.1752 for [C31H34FeN3O6]+. UV-Vis (MeCN): λmax {ε/dm3 mol-1 cm-1} 430.5 {3840}, 
340.5 {860}, 324.5 {800}, 277.5 (s) {6940}, 261 {7720}, 227 (s) {9440}, 204 {25740}. IR 
(solid. Vmax)/cm-1: 3345, 3090, 2916, 2866, 2234, 1682, 1634, 1576, 1541, 1452, 1425, 
1366, 1341, 1296, 1246, 1190, 1105, 1055, 1022, 953, 910, 820, 772, 756, 727, 664, 644, 
581, 482, 411.  
Synthesis of N2 
FC-P1 (347 mg, 0.60 mmol) and ethylenediamine (0.16 ml, 2.4 mmol) were dissolved in 
2-methoxyethanol (7 ml) and heated at reflux under nitrogen overnight. The resulting 
solution was cooled and the solvent removed in vacuo. The crude solid was then 
dissolved in DCM (15 ml) and washed with water (2 x 15 ml). The organic layer was 
extracted and dried in vacuo. The crude solid was washed with hexane (15 ml) and dried 
in vacuo to yield N2 as an orange oil (221 mg, 61%). 1H NMR (400 MHz, CDCl3) δ 8.55 (d, 
J = 7.2 Hz, 1H), 8.43 (d, J = 8.4 Hz, 1H), 8.19 (d, J = 8.9 Hz, 1H), 7.60 (t, J = 7.8 Hz, 1H), 
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6.68 (d, J = 8.5 Hz, 1H), 6.63 (br. t, 1H, NH), 6.27 (br. t, 1H, NH), 4.73 (t, J = 1.9 Hz, 1H), 
4.67 (t, J = 1.9 Hz, 1H), 4.46 (t, J = 6.0 Hz, 2H), 4.33 – 4.32 (m, 1H), 4.28 – 4.26 (m, 2H), 
4.20 (s, 2H), 4.16 (s, 5H), 3.87 (t, J = 6.0 Hz, 2H), 3.74 – 3.70 (m, 2H), 3.65 – 3.53 (m, 6H), 
3.17 (t, 1H). 13C NMR (101 MHz, CDCl3) δ 169.38, 163.83, 163.19, 148.93, 133.59, 130.15, 
128.89, 125.62, 123.60, 121.80, 119.46, 108.84, 103.39, 69.44, 69.35, 69.28, 69.13, 
68.95, 68.77, 68.73, 68.68, 67.22, 67.19, 67.17, 52.44, 43.96, 40.72, 39.12, 38.26, 37.83, 
29.93. HRMS found m/z 599.1938, calculated m/z 599.1951 for [C31H35FeN4O5]+.  UV-Vis 
(MeCN): λmax {ε/dm3 mol-1 cm-1}: 433 {5680}, 341 {1860}, 326 {1940}, 283 {8080}, 261 
{10640}, 228 {16020}, 209 {35100}. IR (solid. Vmax)/cm-1: 3509, 3331, 3094, 2963, 2920, 
2868, 1676, 1632, 1576, 1539, 1449, 1425, 1364, 1342, 1296, 1188, 1096, 1059, 1037, 
999, 818, 773, 756, 662, 579, 527, 482, 459, 413. 
Synthesis of N3  
FC-P1 (234 mg, 0.41 mmol) and morpholine (0.14 ml, 1.63 mmol) were dissolved in 
DMSO and heated at 100 °C under nitrogen for 48 hours. The solution was cooled, water 
was added, and the solution neutralised using 1M HCl. The resultant solution was 
extracted into DCM, washed with water and dried with MgSO4. The solvent was 
removed in vacuo to yield N3 as a brown oil (92 mg, 37 %). 1H NMR (400 MHz, CDCl3) δ 
8.51 (d, J = 7.3 Hz, 1H), 8.45 (d, J = 8.7 Hz, 1H), 8.35 (d, J = 8.6 Hz, 1H), 7.63 (t, 1H), 7.15 
(d, J = 7.7 Hz, 1H), 6.38 (br. s, 1H, NH), 4.64 (br. t, 1H), 4.40 (t, J = 6.9 Hz, 2H), 4.21 (s, 
2H), 4.14 (s, 1H), 4.08 (s, 5H), 3.98 – 3.93 (m, 4H), 3.81 (t, J = 4.9 Hz, 2H), 3.70 – 3.54 (m, 
8H), 3.23 – 3.14 (m, 4H). 13C NMR (101 MHz, CDCl3) δ 169.42, 163.10, 154.77, 131.65, 
130.32, 130.26, 130.19, 129.26, 128.96, 128.94, 125.11, 124.85, 124.79, 122.14, 121.08, 
117.41, 115.91, 113.95, 75.08, 69.35, 69.28, 69.24, 68.90, 68.78, 68.66, 67.21, 67.08, 
65.93, 52.40, 39.92, 38.22, 37.98, 28.67. HRMS found m/z 626.1947, calculated m/z 
626.1948 for [C33H36FeN3O6]+.  UV-Vis (MeCN): λmax {ε/dm3 mol-1 cm-1} 395 {2060}, 375 
(s) {6980}, 341 {860}, 326 {780}, 260 {7680}, 205 {25400}. IR (solid. Vmax)/cm-1: 2961, 
2922, 2857, 1694, 1653, 1585, 1574, 1537, 1518, 1452, 1422, 1375, 1348, 1296, 1260, 
1236, 1188, 103, 1086, 1043, 1016, 868, 785, 758, 700, 669, 658, 590, 536, 503, 480, 
457, 401. 
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